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ABSTRACT
The Role of Diet, Erythrocyte Fatty Acid Concentration, and Alzheimer’s-Related
Genes in Systemic Inflammation
in the Cache County Memory Study
by
Rola A. Jalloun, Doctor of Philosophy
Utah State University, 2015
Major Professor: Dr. Ronald Munger
Department: Nutrition, Dietetics, and Food Sciences
This project examined the association between dietary patterns, erythrocyte
membrane fatty acids concentration, and Alzheimer’s-related genes in systemic
inflammation, as indicated by C-reactive protein (CRP) levels, in order to achieve
more comprehensive knowledge of how nutrition and genetics influence systemic
inflammation among the elderly residents of Cache County, Utah.
First, the associations between dietary patterns defined by Dietary Approaches
to Stop Hypertension (DASH) and Mediterranean dietary patterns (MED) and the risk
of having a high level of CRP were examined. This study showed that a healthy
dietary pattern score was associated with CRP levels; a higher score reflecting the
ideal DASH diet and MED diet was associated with a 26% and 27% reduction in the
risk of having high CRP levels respectively. This association appeared stronger
among overweight and obese individuals.
Second, the association between erythrocyte membrane fatty acids (EMFAs)
and elevated serum C-reactive protein (CRP) levels was examined. Those that had
high EMFAs composition of palmitoleic acid and nervonic acids, both
monounsaturated fatty acids (MUFAs), and dihomo-y-linolenic acid (DGLA),
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docosapentaenoic acid (DPA-6), docosahexaenoic acid (DHA), all polyunsaturated
fatty acids (PUFAs), had an increased risk of having CRP elevation. In contrast, risk
of CRP elevation was reduced in those that have highest levels of saturated fatty acids
(SFAs) of margaric acid, stearic acid, and arachidic acid. These associations were
generally observed to be stronger among women compared to men.
Lastly, the study examined whether AD-related genes identified in previous
genome-wide association studies are associated with elevated levels of inflammatory
CRP. Results revealed a strong association between APOE-epsilon genotypes and
CRP levels. Results also showed an association between major alleles of APOE
rs439401, TOMM40 rs157580, and minor alleles MMP8 rs1892886, CR1 rs6656401,
CR1 rs3818361, and CR1 rs4844609 that were associated with a risk of elevation of
CRP. These associations were stronger among men compared to women.
Reduction in the prevalence of AD could have tremendous importance; the
results of this dissertation may help identify factors important to AD etiology and, in
turn, provide valuable targets for prevention.
(177 pages)
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PUBLIC ABSTRACT
The Role of Diet, Erythrocyte Fatty Acid Concentration, and Alzheimer’s-Related
Genes in Systemic Inflammation in the Cache County Memory Study
Rola Jalloun
Alzheimer’s disease (AD) is the most common type of dementia in the elderly,
accounting for 60 to 80% of all dementia cases. It affects 5.2 million Americans and
44 million worldwide. This project examines the association between dietary patterns,
erythrocyte membrane fatty acids concentration, and AD-related genes in systemic
inflammation as indicated by serum C-reactive protein (CRP). All studies performed
in this project used the data collected in the Cache County Memory Study (CCMS).
Higher levels of accordance with the Dietary Approaches to Stop
Hypertension (DASH) and Mediterranean dietary (MED) patterns were associated
with consistently lower levels of CRP in elderly men and women. Interestingly, this
association appeared stronger among overweight and obese participants when
compared with normal weight participants. These results emphasize that the DASH
and Mediterranean diets may play an important role in reducing systemic
inflammation, which may lower AD risk, especially among overweight and obese
persons.
A high erythrocyte fatty acid concentration of palmitoleic acid, and nervonic
acids, both monounsaturated fatty acids (MUFAs), dihomo-y-linolenic acid (DGLA),
docosapentaenoic acid (DPA-6), docosahexaenoic acid (DHA), all polyunsaturated
fatty acids (PUFAs), were similarly associated with increased risk of CRP elevation.
Margaric acid, stearic acid, and arachidic acid, all saturated fatty acids (SFAs), were
associated with a reduced risk of elevated CRP. These associations was stronger
among women than men.
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Several AD-related genes were found to influence risk for having CRP
elevation. APOE-epsilon alleles were associated with CRP levels among elderly men
and women. A major alleles of APOE (C/C) rs439401 and TOMM40 (A/A) rs157580,
and minor alleles of MMP8 (T/T) rs1892886, CR1 (A/A) rs6656401, CR1 (A/A)
rs3818361, and CR1 (A/A) rs4844609 lowered the risk of elevated CRP among
elderly men. These results emphasize the need to consider gene-environment
interactions when searching for genes influencing AD risk.
With the increased prevalence of AD and the association of systemic
inflammation, the results of this dissertation may help identify factors important to
AD etiology and, in turn, provide valuable targets for preventive intervention to
improve people’s quality of life and nutritional well-being.
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CHAPTER 1
INTRODUCTION

Alzheimer's Disease (AD) is an irreversible, progressive brain disease that
slowly degrades the memory and thinking skills and ultimately eliminates the
capability to perform the simplest tasks [1]. AD is the most common form of
dementia. The Alzheimer’s Association documents that Alzheimer’s disease (AD) in
the U.S. is the sixth leading cause of death for people who are 65 years or older. In
2015, 5.3 million Americans of all ages had AD and 44 million worldwide [2].
Evidence for the role of inflammation in AD still cannot be definitively stated
whether inflammation is a cause, contributor, or secondary phenomenon in AD [3].
Biochemical and neuropathological evidence suggest that astrocytes and microglia are
the major immune cells in the brain. In AD brain, astrocytes and microglia activate
and release inflammatory mediators due to the presence of Aβ plaques and
neurofibrillary tangles [4]. Until now, emerging evidence suggests that inflammation
in AD is complex, and it involves interaction with multiple factors that challenge the
researcher to find ways to tune inflammation to delay, prevent, or treat AD.
Inflammation is the first step of a non-specific immune response that occurs in
reaction to any bodily injury [5]. Inflammation can be acute or chronic [5]. When it is
acute immediate and rapid response occurs to the site of tissue injury. Chronic
inflammation occurs as a result of the progression of the acute inflammation, which
may last for weeks or months, and in some instances, for years [6]. In the central
nervous system, inflammatory components are linked to AD neuroinflammation. The
production of a proinflammatory cytokines such as tumor necrosis factor α (TNF-α)
plays a role in brain communication [7]. During infection, extensive communication
between the immune system and the central nervous system, in which neural activity
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is altered quite extensively during a peripheral infection [8]. Chronic systemic
inflammation, as indicated by increases in inflammatory biomarkers were linked with
an increase in cognitive decline in Alzheimer disease patients [7, 9-12].
C-reactive protein (CRP) is the sensitive marker of acute-phase response to
most forms of inflammation, infection, and tissue damage. Many cytokine levels
including interleukin-1β (IL-1β), interluken-6 (IL-6), and tumor necrosis α (TNF-α)
enhances CRP expression in humans [13]. It has been proposed that CRP predicts the
incidence of many diseases including cancer [14], type 2 diabetes [15], coronary
artery disease, heart attack [16], inflammatory bowel disease [17], arthritis [18],
pelvic inflammatory disease [19], lupus [18], and AD [20].
Scientific knowledge is far from complete regarding the relationship between
peripheral blood inflammatory biomarkers and AD. However, scientific advances
recently have been noticeably changing the understanding of the role of high levels of
peripheral blood inflammatory biomarkers in AD patients [21]. Strong evidence
suggest that CRP levels represented a strong risk predictor of systemic inflammation
in 60 patients with Late Onset Alzheimer's Disease (LOAD), 35 patients with
(Vascular Disease) VD, 25 subjects affected by cognitive impairment no-dementia
(CIND), and 40 cognitively normal controls [22]. O'Bryant et al. observed the same
when he evaluated CRP levels and compared 192 patients with AD with 174 nondemented [23].
Diet may influence the risk of AD and through its effects on systemic
inflammation [24]. Dietary components are important factors that should be
considered in inflammatory processes [25]. The Dietary Approaches to Stop
Hypertension Diet (DASH) and the Mediterranean diet (MED) have been associated
with protection against cognitive decline [26] and reduced risk for inflammatory
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biomarkers and AD [27, 28]. In recent years, a rapidly increasing number of studies
reported that due to the components of both diets components, the DASH and
Mediterranean diets are considered to be anti-inflammatory [29, 30]. These findings
support the hypothesis that DASH diet and the Mediterranean diet may be associated
with inflammatory biomarkers level in several conditions such as myocardial
infarction [31], diabetes [32], elevated triglycerides, elevated systolic and diastolic
blood pressure, colorectal cancer, insulin resistance, HDL cholesterol [33, 34], and
AD [27].
The metabolic effects of some diets may be attributable to pro-inflammatory
and anti-inflammatory properties [35] and their dietary constituents including aspects
of the Western diet such as higher intake of the fats and processed meats [36]. Fatty
acid is a carboxylic acid with a long aliphatic tail (chain), which is either saturated or
unsaturated [37]. The two main essential fatty acids are linoleic acid (LA) omega-6
fatty acid, and α-linolenic acid (ALA) omega-3 fatty acid [38]. Both omega-6 and
omega-3 polyunsaturated fatty acids (PUFA) play important roles in the regulation of
inflammation by being precursors of potent lipid mediators [39] and altering gene
expression [40]. High intake of fatty fish or n-3 PUFA oil fish supplements may
improve anti-inflammatory profiles by changing the production of lipid mediators and
regulating immune responses [39]. Consuming refined vegetable oils rich in omega-6
fatty acids and foods containing a low level of long-chain omega-3 fatty acids has
been associated with an increase in inflammation levels [41] in some but not all
studies.
Genes associated with AD may influence AD risk via their effects on
inflammation.

It has been proposed that the overall chances of an individual

developing AD is strongly influenced by a "susceptibility profile" reflecting the joint
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effects of inheriting multiple high-risk alleles and environmental factors. In complex
inflammatory diseases, inflammation gene polymorphisms may alter gene expression
and function [42]. Gene polymorphisms in both acute and chronic inflammation
produce different types of inflammatory responses [43]. The risk of AD was
substantially affected by ten polymorphisms in many inflammatory biomarkers [44,
45].
Dissertation Hypotheses and Objectives
The purpose of this study is to determine the extent to which dietary factors,
erythrocyte membrane fatty acid, and genes, previously associated with C-reactive
protein (CRP) markers of systemic inflammation among participants in the Cache
County Memory Study. The specific objectives and hypotheses of this dissertation
are:

1. To determine whether healthy dietary patterns, defined by the DASH and
Mediterranean diets, are associated with a reduced level of systemic
inflammation as indicated by level of inflammatory CRP in plasma obtained
from participants in the Cache County Memory Study (CCMS).
2. To determine whether erythrocyte membrane fatty acids are associated with
elevated levels of inflammatory CRP in the Cache County Memory Study
(CCMS).
3. To determine whether AD-related genes, identified in previous genome-wide
association studies, are associated with elevated levels of inflammatory CRP
in the Cache County Memory Study (CCMS).
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Dissertation Structure
This dissertation is divided into six chapters. Chapter 1 provides an
introduction to the research along with outlines covering study objectives and
hypotheses. Chapter 2 is titled “The role of diet, erythrocyte membrane fatty acid, and
Alzheimer’s-related genes in systemic inflammation in the Cache County Memory
Study: A Review.” This chapter provides the literature review of each of these three
modifiers and evidence that they are related to the risk of systemic inflammation.
Chapter 3 is titled “The role of dietary approach to stop hypertension and
Mediterranean-style dietary patterns in systemic inflammation in the Cache County
Memory Study.” This chapter examines the association between the dietary approach
to stop hypertension and Mediterranean- style dietary patterns and CRP levels in the
CCMS. Chapter 4 is titled “Erythrocyte membrane fatty acid concentration and
systemic inflammation in the Cache County Memory Study.” This chapter examines
the association between the erythrocyte membrane fatty acid composition and CRP
levels in the CCMS. Chapter 5 is titled “The role of Alzheimer’s-related genes in
systemic inflammation in the Cache County Memory Study.” This chapter examines
the association between Alzheimer’s-related genes and CRP levels in the CCMS.
Chapter 6 wraps up with a discussion of the findings and provides conclusions and
recommendation for further research directions and practitioners. The references for
each chapter were listed at the end of each.
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CHAPTER 2

THE ROLE OF DIET, ERYTHROCYTE MEMBRANE FATTY ACID
CONCENTRATION, AND ALZHEIMER’S- RELATED GENES IN SYSTEMIC
INFLAMMATION IN THE CACHE COUNTY MEMORY STUDY: A REVIEW
ALZHEIMER’S DISEASE (AD)
Alzheimer's disease (AD) is an irreversible, progressive brain disease that
slowly degrades memory and thinking skills and ultimately destabilizes the capability
to perform the simplest tasks [1]. It is the most common type of dementia and
gradually worsens over time. It accounts for an estimated 60 to 80 percent of all
dementia cases. It affects memory, thinking, and behavior. Most often, AD is
diagnosed in people over 65 years of age, but the less-prevalent, early-onset of
Alzheimer's can occur at a much earlier age. In 2015, Alzheimer’s disease affected 5.3
million Americans and 44 million people worldwide. Alzheimer's prevalence is 1 in 9
older Americans. The Alzheimer’s is predicted to affect 1 in 85 people globally by
2050. It accounts for over 226 billion dollars in annual costs in the U.S. alone and this
is estimated to rise to 1.1 trillion by 2050 [2]. The National Center for Health
Statistics 2015 indicates that Alzheimer’s disease is the United States’ sixth-leading
cause of death for people who are 65 years or older [2]. The Alzheimer’s Association
reported that between 2000 and 2025, the number of people with AD in Alaska,
Colorado, Idaho, Nevada, Utah, and Wyoming is expected to double or more. In
2015, the Utah percentage of AD will increase from 45% to 127% by the year 2025
[2]. AD patients need help with daily activities such as bathing, dressing, using the
bathroom, and eating [1, 3]. Patients lose their ability to communicate with others;
they find it hard to recognize their loved ones, and they spend most of their time in
bed with constant caregiver supervision.
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The main features of AD include: memory loss, impaired judgment,
disorientation, confusion, behavioral changes, and difficulty speaking, swallowing
and walking [4]. The main early characteristics of Alzheimer's disease are the loss of
neurons and synapses in the hippocampus. These losses caused significant atrophy in
some affected areas [5, 6]. In 2009, Clifford and his colleague used magnetic
resonance imaging (MRI) to study 21 healthy cognitively normal subjects, 32 with
amnestic mild cognitive impairment, and 8 with Alzheimer's disease. In this study,
they found that the brain size in AD patients became smaller over the time starting
from the mild cognitive impairment stage and worsening until it developed into
Alzheimer’s disease [7].
There are two types of AD: early onset and late onset [8]. The symptoms for
early onset AD appear before age 60. Research has narrowed down the main genetic
causes for some early onset as mutations in the amyloid precursor protein (APP) gene
located on chromosome 21 and the presenilin gene (PSEN1& PSEN2) [8]. Having
any of these mutated early onset AD genes indicates that this person will likely
develop AD before the age of 60 and in some cases as early as age 30. This type of
AD is called “familial” Alzheimer’s disease [9]. Early onset people tend to have
shorter survival and these patients show more extensive functional and structural
neuroimaging changes than late onset [10, 11]. Late onset Alzheimer’s disease
(LOAD) is defined by the onset of symptoms after age 65. It has yearly incidence
rates rising from 1% at 65–70 years to 6–8% at 85 years and older [12]. Genes play an
important role in increasing AD risk, especially for LOAD [13].
Even now it’s still hard to identify the main causes of Alzheimer’s disease.
AD occurs as a result of many diverse risk factors rather than one single factor, and
because of that, it is considered a multifactorial chronic disease [14]. Recent data
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reports that genetic factors, physical activity, diet, social isolation, cardiovascular
disease, and diabetes have been related to AD pathology [15]. For example, a diet
high in vegetables, fruit, and fiber intake may lower neurodegenerative disorders risk
by affecting the pathological processes of these diseases [16].

Inflammation
The base word for inflammation is the Latin word “inflammare”, which means
“to ignite or set on fire.” Cornelius Celsus, a Roman encyclopaedist, was the first to
describe the symptoms of inflammation [17, 18]. Inflammation is a natural step of a
non-specific immune response that occurs in reaction to any bodily injury.
Inflammation can be acute or chronic [19]. When it is acute, an immediate and rapid
response occurs at the site of the injured tissue. The main characteristics of acute
inflammation are vascular and leukocyte responses, fluid accumulation, and
inflammatory mediators such as cytokines. Acute inflammation has many
macroscopic events that lead to rubor (redness), calor (heat), dolor (pain) and tumor
(swelling) [18, 20]. The transformation from acute to chronic inflammation is still not
completely understood. Excess proinflammatory mediators are a main characteristic
of chronic inflammation [21]. Chronic inflammation occurs as a result of
inflammatory progression in acute inflammation and may last for weeks or months,
and in some instances for years [22]. Chronic inflammation is mainly characterized by
tissue destruction and fibrosis combination due to the prolonged and repeated
inflammation. Chronic inflammation involves complex interactions between several
cell populations and their secreted mediators causing leukocyte activation and
excessive infiltration that leads to resultant tissue damage and loss of function [20].
Chronic low-level inflammation is considered to be below the threshold of pain and in
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some cases it is called “silent inflammation” [23].
Both acute and chronic systemic inflammations are characterized by increases in
inflammatory biomarker levels in blood such as C-reactive protein (CRP), cytokines,
and chemokines [24]. In the central nervous system, acute and chronic systemic
inflammatory responses may begin with the detection of either bacterial or viral
invasions. When the immune response detects bacteria, products are produced that
activate diverse innate immune responses such as nucleotide-binding oligomerizationdomain protein-like receptors (NLRs) and Toll-like receptors (TLRs) [25-27]. TLRs
are a set of single membrane-spanning noncatalytic receptors that recognize
structurally conserved molecules derived from microbes. Identification of bacterial
products by TLRs and NLRs cause direct cell activation leading to the expression of
many immune factors such as proinflammatory CRP, cytokines, and chemokines [28].
Mechanistic studies suggest that viral inflammation has many effects such as
damaging the infected cells [29], destroying the body's immune system, altering the
genetic material (DNA) of infected cells [30], or causing inflammation that can
damage an organ [31].
A large body of epidemiological evidence supports the hypothesis that
peripheral inflammatory markers predict disease progression and determine whether
therapies targeting these markers alter prognosis in patients with these diseases [32,
33]. Many animal and human studies provide conflicting evidence about whether
inflammatory markers are the direct causes of adverse events or if they simply are the
result of illness in older adults [34]. When peripheral inflammatory markers were
evaluated in elderly patients with Mild cognitive impairment (MCI), AD, and normal
elderly, it was found that this method helped to detect early progression of both MCI
and AD [35]. Another study concluded the same result when they measured tumor
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necrosis factor α (TNF-α) in AD patients [33].
For a long time, the evidence of inflammatory processes in the pathogenesis of
AD involvement has been acknowledged, however, the inflammation theory in AD
pathology has recently surged to the surface [36]. The fact that diseases with a chronic
systemic inflammatory component are risk factors for Alzheimer’s disease implies
that crosstalk occurs between systemic inflammation and microglia in the Central
nervous system (CNS) [37]. Microglial cells are considered the first line of defense in
the CNS. In a healthy brain, microglia is relatively inactive, but in AD patients
microglia are always switched on [38]. Neuroinflammation is recognized as a
downstream consequence of amyloid theories causing activation of microglia and
starting a pro-inflammatory cascade. These changes cause neurotoxic substances to
release cytokines, chemokines, reactive oxygen and nitrogen species, and various
proteolytic enzymes, inducing deteriorating changes in neurons [39]. It has also been
proposed that microglia activation may cause phosphorylation of tau and the
formation of neurofibrillary tangles (NFTs) [40, 41].
C-reactive protein (CRP)
C-reactive protein (CRP) is a nonspecific marker of an acute-phase response
to most forms of inflammation, infection, and tissue damages [42]. Interleukin-1β (IL1β), interluken-6 (IL-6), and TNF-α are strongly induced by the expression of CRP in
human [43] hepatocytes and hepatoma. Human atherosclerotic studies showed that
indirect deposit of CRP from circulating cells or direct production of CRP by cells in
the arterial wall [44, 45]. Additionally, human neuronal cells were found to produce
CRP in Alzheimer’s disease patients [46]. CRP has also been found in renal cortical
tubular epithelial cells, which can be a result of inflammatory stimuli [47].
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CRP has several immune-related functions including: detecting the invading
particle to the phagocyte, activation of classical complement binding, modulation of
polymorphonuclear function [48], inhibition of growth and/or metastases of tumor
cells and a few additional diverse activities [49]. Casas and his colleague reported that
the normal function of CRP continues [50]. However, many extensive research
projects reported that CRP has a beneficial role in both innate immunities against
infection, appropriate, safe handling, and disposal of damaged autologous cells and
lipids [50].
Although, in normal healthy subjects CRP is at trace levels in plasma, high
levels of CRP indicates that there is inflammation somewhere in the body [51]. The
plasma half-life of CRP in humans is about 19 hours which is the same in all
individuals regardless of circulating concentrations of CRP [50]. Despite many claims
and assertions in the literature, genetic factors may affect the variation in the levels of
CRP [52]. Factors including diet and smoking cessation remain critical tools for CRP
reduction, and body mass index (BMI) has been associated with inflammatory
mediators including CRP [53, 54].
Indeed, CRP is the most extensively studied systemic marker of inflammation
[55]. CRP levels have been used to predict the incidence of many diseases including
cancer [56], type 2 diabetes [57], coronary artery disease risk, damage from a heart
attack [58], inflammatory bowel disease [59], some forms of arthritis [60], pelvic
inflammatory disease [61], lupus [60], and AD [62].
Scientific advances have been noticeably changing over the last decades
regarding our understanding of the role of high levels of CRP in AD patients. Crosssectional studies of AD patients and controls found that there were small differences
in IL-6, but mean levels of CRP were significantly different between AD cases and
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controls [63, 64]. Among 99 cases and 99 controls in a cross-sectional study, the
results found high serum CRP levels among demented participants when they were
compared with the controls. The same study also compared 34 AD patients with 64
vascular dementia (VaD) patients by checking the CRP levels in both groups. The
results indicated that AD patients had higher CRP levels than VaD [65]. An Italian
population-based elderly cohort (n = 804, 53.2% women, mean age 74 years old),
examined the relationships of baseline plasma CRP, serum IL6, plasma alpha-1antichymotrypsin, and hyperhomocysteinemia with the risk of incident Alzheimer’s
disease (AD) and vascular dementia (VaD). The study found that CRP and IL-6 were
the only inflammatory biomarkers related to the risk of VaD, but not with the
prediction of AD risk [66]. O’Bryant et al., found the same result when they 192
patients with AD and 174 non-demented controls and their CRP levels were evaluated
[67].
Diet and Inflammation
Numerous research studies indicate that dietary patterns have been used over
the last few decades to analyze human health [68]. While many dietary patterns have
been used in human health studies, much evidence shows that Mediterranean Diet [69,
70] and Dietary Approaches to Stop Hypertension (DASH) are effective for a short

and long term. Both diets are helpful in fighting or preventing metabolic diseases and
are anti-inflammatory [71, 72].
Mediterranean Diet (MED)
The Mediterranean Diet (MED) is a traditional dietary pattern from different
countries bordering the Mediterranean Sea. MED is a boasting a modern nutritional
recommendation inspired by the time tested way of eating traditional foods and drinks
from these countries [73]. The Mediterranean Diet is rich in fruits, vegetables,
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legumes, and complex carbohydrates, with a moderate consumption of fish, while the
consumption of olive oil is the main source of fat, and with a low-to-moderate amount
of red wine during meals [74]. This diet was noted by American scientist Ancel Keys
stationed in Pioppi, Italy in 1945, but it didn’t gain national attention until the Seven
Countries Study reported in 1960 that a Mediterranean Diet is a healthy diet [75].
Many large epidemiologic studies in different cohorts showed that there is a
positive association between Mediterranean Diet adherence and a reduction in the risk
of mortality and the incidence of major chronic diseases [76, 77]. A systematic review
of 12 studies with a grand total of 1,574,299 subjects reported that a high adherence to
the Mediterranean Diet in southern Europe is associated with a 6% reduction in
cancer, a 9% reduction in total cardiovascular mortality, and a 13% reduction in
Parkinson’s and Alzheimer’s disease incidence [78]. Meta-analysis of a larger number
of subjects and studies confirmed that Mediterranean Diet adherence was associated
with a lower risk of major chronic degenerative occurrences [79]. Subsequently, these
findings were confirmed by Francesco and colleagues, who reported a significant
inverse relationship between higher adherences to Mediterranean Diet and a reduced
risk of AD [80-82].
Mediterranean diet (MED) and Inflammation
Human observational studies:
Strong evidence suggests that the Mediterranean Diet could serve as an antiinflammatory diet by reducing CRP concentrations in plasma that have a protective
effect against several diseases [83, 84]. Two longitudinal studies reported that a
significantly higher adherence to MED reduced CRP levels when a diet score was
used to assess MED adherence. The Attica epidemiologic study in Greece examined
the high adherence of MED in randomly enrolled 3,042 participants (1,514 men and
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1,528 women). They found a higher adherence to MED had on average, 20% lower
CRP levels when compared with lower adherence to MED [85]. Later, Panagiotakos
et al. found that high adherence to MED had a protective effect that reduces CRP
levels by 3.1% after controlling for age, gender, body mass index, physical activity,
smoking status, diabetes and medication intake in myocardial infarction (MI)
survivors. The study was performed in six European countries: Greece, Germany,
Spain, Finland, Italy, and Sweden, which included 200 post-MI survivors [86]. Only
one cohort study assessed the association between MED adherence, inflammatory and
metabolic biomarkers, and risk of Alzheimer’s disease. This intervention diet had
significantly reduced serum concentrations of hs-CRP, and 118 incident AD cases
were identified among the 1,219 non-demented elderly (age ≥ 65) after four-year
follow up [87]. The Nurses' Health Study conducted a study of 690 nurses and
concluded that participants who were in the highest quintile of the diet score had on
average 24% lower CRP levels as compared with those in the lowest quintiles [88].
Human experimental feeding studies:
Results from clinical trial studies have given contradicting findings. Six
studies assessed whether there were significant associations between the
Mediterranean Diet and sensitive markers of systemic inflammation for CRP.
Esposito et al. wanted to determine the effect of MED on endothelial function and
vascular inflammatory markers in 180 metabolic syndrome patients (99 men and 81
women). When comparing patients who consumed the intervention diet (cases) with
the control diet (control), better adherence to MED was associated with lower levels
of hs-CRP [89]. The PREDIMED (Prevención con Dieta Mediterránea) study
compared three dietary interventions: MED with supplemental virgin olive oil (VOO),
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MED with supplemental nuts, and a low-fat diet. Among 112 participants, the study
found that CRP levels decreased only in the MED group given virgin olive oil [90].
Other studies confirmed the association between CRP levels and adherence to
MED in individuals with metabolic syndrome. Estruch et al. demonstrated that the
Mediterranean Diet plays an important role in decreasing inflammation by reducing
lipid accumulation in atherosclerosis and diabetes patients. In the study, a low-fat diet
(n = 257) compared with a Mediterranean Diet with those that consumed either free
virgin olive oil, 1 liter per week (n = 257), or free nuts, 30 g/d (n = 258). The data
showed that participants who were allocated to the Mediterranean Diet plus olive oil
group were associated with a lower CRP concentration when compared with
participants with a low fat diet and the Mediterranean Diet with olive oil groups [91].
Consistently, Viscogliosi et al. examined the associations between adherence to MED
and the prevalence of metabolic syndrome. They found the MED score to be inversely
associated with hs-CRP among 120 subjects [92].
Studies reported no association between MED and inflammatory biomarkers:
Five studies found no association with high adherence to MED and lowered
risk of developing systemic inflammation by reducing CRP levels. The studies by
Michalsen [93] et al, Ambring et al [94], Dai et al [95], Salvadó [96], and Rallidis et
al [97] showed no strong or consistent association between the MED and
inflammatory markers. Two hospitals recruited 101 patients with established coronary
artery disease (CAD) as verified by coronary angiography after undergoing diagnostic
coronary angiography to consume the MED diet for 12 months. CRP, fibrinogen,
fasting insulin, homocysteine, serum lipids and plasma fatty acids were measured
before and after the intervention. The study found that following the MED diet had no
effect on inflammation and metabolic risk factors in CAD patients [93]. Healthy
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individuals consumed either the MED diet or an ordinary Swedish diet for four weeks.
While MED lowered the number of platelet and leukocytes and vascular endothelial
growth factor, it did not change CRP levels between the two diets [94]. Moreover, an
investigation of psychological, behavioral, and biological risk factors for subclinical
cardiovascular disease using twins in The Twins Heart Study (THS) found that a high
adherence to MED did not help reduce CRP after adjustment for total energy intake
and other nutritional factors. These results suggest that the association between MED
adherence and systemic inflammation is unlikely to be affected by shared genetic and
environmental factors [95]. A study of Spanish men and women with a high risk of
cardiovascular disease by Salvadó did not find any association between adherence to a
Spanish Mediterranean diet and reduced inflammatory markers. Concomitantly, they
did find an inverse association between the high Spanish MED and hs-CRP levels.
Also, hs-CRP ranked the lowest in those categories with the highest consumption of
olive oil and nuts and IL-6 with the consumption of fruits and cereals [96]. A Greek
study by Rallidis did not show any effect of MED on hs-CRP, but they found that
endothelial function such as flow-mediated vasodilatation and diastolic blood pressure
improved after consuming a Mediterranean Diet for two months [97].

Dietary Approaches to Stop Hypertension (DASH)
The Dietary Approaches to Stop Hypertension (DASH) diet is a dietary
pattern developed by the U.S.-based National Heart, Lung, and Blood Institute to
prevent and control hypertension [98]. DASH diet is characterized by a high
consumption of fruits, vegetables, whole grains, and low-fat dairy foods, meat, fish,
poultry, nuts and beans, and is limited in sugar-sweetened foods and beverages, red
meat, and added fats [99].
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Evidence gathered from studies conducted approximately a decade ago
indicated that the DASH diet helps lower the risk of several diseases [100]. In 1999, a
study of 459 adults found that a DASH diet may be an effective alternative to drug
therapy in hypertension. It may also prevent hypertension in African-Americans when
compared to Caucasians [101]. Obarzanek et al. demonstrated that the DASH diet
may help reduce coronary heart disease in 436 randomized controlled outpatients
[102]. Two case-control studies found significant associations between adherence to a
DASH diet and blood pressure levels among patients with and without hypertension
issues when comparing DASH with two other dietary patterns [103, 104]. A
randomized crossover study of 12 obese patients with high-normal to stage 1
hypertension and 12 lean normotensive volunteers found that following a DASH diet
for four weeks raised antioxidant capacity, lowered blood pressure, and reduced
oxidative stress [99]. Many studies have reported that a DASH diet may reduce the
risk of contracting some cancers such as postmenopausal breast cancer [105] and
colorectal cancer [71]; while the calcium in dairy products would help lower the risk
of osteoporosis [105]. Wengreen et al. conducted a study to determine the associations
between DASH and Mediterranean-style dietary patterns and age-related cognitive
change in a prospective, population-based study. The study found that a higher
adherence to DASH and MED was associated with higher levels of cognitive function
in elderly men and women over an 11-year follow-up period [82].

Dietary Approaches to Stop Hypertension and Inflammation
In recent years, a rapidly increasing number of studies reported that the DASH
diet contributes to a decrease of several risk factors such as triglycerides, systolic
blood pressure, diastolic blood pressure, colorectal cancer, reduced insulin resistance,
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and increase HDL cholesterol. All of these factors would support the role of the
DASH diet in decreasing inflammation [71, 72]. A DASH diet improved
neurocognitive function among 124 participants [106]. The DASH diet is considered
an anti-inflammatory diet for diabetes patients because it helps to reduce liver
aminotransferases and fibrinogen levels [107].
Human experimental feeding studies:
A randomized crossover intervention trial was done of two diets, a high-fiber
(30-g/d) DASH diet or fiber-supplemented diet (30 g/d) for three weeks. Among 35
participants (18 lean normotensive and 17 obese hypertensive individuals), adherence
to the DASH diet, including high fiber intake levels, helps to reduce CRP levels
[108]. Similar results reported by Saneei et al. investigated the effects of the DASH
diet on systemic inflammation markers in adolescents with metabolic syndrome. After
six weeks of follow up among 60 post pubescent girls, CRP levels were reduced by
the DASH diet among participants, but it had no effect on other inflammatory markers
[109].
Two crossover clinical trials by Azadbakht et al. provide evidence of the effect
of DASH on CRP levels. The first study was of 42 postmenopausal women with
metabolic syndrome. These women consumed either a DASH diet, soy nut diet, or soy
protein diet for 8 weeks. Red meat in the DASH diet (one serving/day) was replaced
by soy protein in the soy protein diet and by soy nut in the soy nut diet. The study
found that replacing red meat with soy protein and soy nut lowered CRP levels more
than consuming a regular DASH diet [110]. The second study was of 60 patients
diagnosed with type 2 diabetes at the Shaheed Motahari Hospital of Fooladshahr in
Isfahan, Iran. The participants received either a control diet that included a
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macronutrient composition of 50–60% carbohydrates, 15–20% protein, 30% total fat,
and a 5% energy intake from simple sugars and DASH which included fruits,
vegetables, whole grains, and low fat dairy products, or a diet low in saturated fat,
total fat, cholesterol, refined grains, and sweets. The data suggests a beneficial effect
of DASH adherence in these participants because the decrease in CRP plasma and
other inflammatory markers during the DASH diet period was greater than that of the
control diet [111].
Other observational studies have provided equally confusing results, with
some findings suggestive, while others had statistically insignificant effects for DASH
on CRP levels and others found no effects. A case-control study evaluated the
association between inflammation levels and a low-fat/reduced-cholesterol diet versus
the DASH diet. In this randomized study, 100 participants were assigned to receive
either the DASH diet or the control diet for two weeks. The study found that the
consumption of the DASH diet had no effect on CRP levels [112]. Similarly, Asemi et
al. reported that the consumption of the DASH diet for four weeks in randomized
controlled clinical trials of 32 pregnant women had no effect on CRP levels [113].
Another observational study by Shenoy et al. found no preventive effects from DASH
on CRP in 81 (22 men and 59 women) participants with metabolic syndrome after
consuming the DASH diet [114].
Fatty Acids
Fatty acids are carboxylic acids with short, medium, and long chains, which
are either saturated or unsaturated. Most naturally occurring fatty acids have an even
number of carbon atoms, from 4 to 28 [115]. The structured name for a fatty acid is
based on the number of double bonds and the number of carbons in the acyl chain
[116]. Saturated fats (SFA) have no double bonds in the fatty acid chain. In contrast,
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unsaturated fatty acids contain either one double-bound monounsaturated fat (MUFA)
or more than one in polyunsaturated fat (PUFA) [117, 118]. Essential fatty acids
foods are the main source [119] including for linoleic acid (LA) omega-6 (n-6) fatty
acid, and α-linolenic acid (ALA) omega-3 fatty acid (n-3) [120].
Docosahexaenoic acid (DHA) is one of the major fatty acids in the brain. It
plays an important role in the development of the human central nervous system
[121]. There is a strong relation between a higher consumption of essential PUFAs
and improved cognitive function [122]. Human studies found the high consumption of
DHA increased IL-6 and IL-1 receptor antagonists which decreased levels of proinflammatory markers [123, 124]. In 2009, The Academy of Nutrition and Dietetics
reported that adequate DHA/EPA fatty acids may delay the onset of Alzheimer’s
disease [125].
Fatty acids and Inflammation
Recent works highlight the importance of fatty acid consumption and
inflammation levels. A growing body of literature shows strong correlations between
SFA consumption and the inflammatory state of white adipose tissue [126]. It has
been reported that a low consumption of SFA reduces the risk of CHD [127], liver
disease [128], many metabolic disorders [129], all causes of death [130]. In 1965,
Keys and his colleagues reported that a high intake of SFA and a low intake of PUFA
increase deaths from coronary heart disease, cancer, and stroke. These findings lead to
recommending higher PUFA consumption to replace SFA. In 2009, the American
Heart Association (AHA) reported that a high intake of n-6 is safe and may be
beneficial when it replaces with SFA [131, 132].
Omega-3 FAs make up a family of PUFAs. Omega-3 metabolism starts with
α-alpha linolenic acid (ALA). ALA is the simplest member of this omega-3 and it
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converts to Eicosapentaenoic acid (EPA) which forms prostaglandin (PGE3) and
docosahexaenoic acid (DHA). Both PGE3 and DHA have anti-inflammatory effects.
Biochemical studies have suggested that AA competes with EPA for the same set of
enzymes to form the long chain of PUFA derivatives [123, 124]. Strong evidence
suggests that high intake of omega-3 fatty acids increases fatty acid levels in human
immune cells, which leads to an improved anti-inflammatory profile by changing
mediator production and regulating immune response [121]. Animal experiments and
clinical intervention studies show that EPA and DHA have varied anti-inflammatory
effects by managing inflammation and autoimmune disease [133], modulating the
types and the amount of eicosanoids and cytokines, as well as altering gene
expression [134]. These effects are based on dosage, time, and baseline characteristics
of the subjects. Also, epidemiological observations from case-control studies found
that fish oils help to reduce the activity of chronic inflammatory diseases and it
naturally mimics anti-inflammatory drugs [135-137].
Until now, we are still unsure if n-6 fatty acids are harmful, harmless, or
helpful. Omega-6 fatty acids is another family of PUFAs. In 1985, the National
Academy of Sciences, the National Academy of Engineering, and the Institute of
Medicine reported that fish consumption had dropped and vegetable oil consumption
increased considerably [138]. Even then, scientists continued to debate over whether
Americans and others on a typical Western diet are eating too much of n-6. Many
epidemiological studies reported the negative effect of n-6 consumption on health,
which causes increased risks of contracting several diseases [139-141]. Andoh
reported that a higher consumption of a diet rich in omega-6 promotes immune
responses by increasing the cytokine IL-6 level and limited mucosal damage [142].
Chapkin and his colleague used interleukin 10 (IL-10) knock-out mice to investigate
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the association between n-6 and inflammation. The study concluded that chronic
inflammation level was high in the group who consumed corn oil (n-6) than the other
group who consumed fish oil (n-3) [143]. In Japan, a case control study of 111
patients reported that high intakes of n-6 was associated with coronary heart disease
(CHD) incidence [144] because n-6 increases the production of ROS from
inflammatory cells [145]. Two cross sectional studies provide evidence of higher
consumption of n-6 that has pro-inflammatory effects among Nonalcoholic fatty liver
disease (NAFLD) patients. The first study was in 45 NAFLD patients (cases)
compared with a sample of 856 (controls), matched for sex and age. The results of
that study suggest that increased n-6 intake may contribute to neuroinflammation
[146]. The second study was in 349 volunteers from the Israeli National Health and
Nutrition Survey. Diet history assessed by food frequency questionnaires (FFQ)
demonstrated higher meat intake and a tendency of having a lower intake of fish rich
in omega-3 in NAFLD patients [147].
Recently, researchers challenged the dogma of omega-6 as pro-inflammatory,
because they report that omega-6 fatty acids have both anti-inflammatory properties
and pro-inflammatory properties [131, 148, 149].

Relevant cell culture studies

reported that omega-6 fatty acids have anti-inflammatory properties by inhibiting the
production of interleukins, chemokines which reduces atherosclerosis progression
[150]. Omega-6 has an anti-inflammatory effect on regulating PGE2 production from
macrophages, which inhibits TNF-α synthesis [7] and lipoxins formation [9].
Likewise, two studies found that PPAR-alpha (PPARα) expression in pretreated
cultured human endothelial cells and human aortic smooth-muscle cells were
significantly expressing the anti-inflammatory effects of both n-6 (AA) and n-3 by
suppressing nuclear factor-kB (NF-kB) signaling [151, 152]. PUFAs, both n-6 (AA)
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and n-3, have anti-inflammatory properties due to the unsaturated double bond that
inactivates reactive oxidative species (ROS) and inhibits the interaction with NF-kB
[153, 154]. Concomitantly, human observational studies suggested that high plasma
levels of omega-6 maintained a positive correlation to IL-10, which is the antiinflammatory cytokine [155]. Meanwhile, human experimental studies reported that
feeding healthy volunteers 7 times (15g/d) the usual intake of AA for 7 weeks had no
effect on platelet aggregation, bleeding times, the balance of vasoactive metabolites,
serum lipid levels, or immune responses [156, 157]. Likewise, when habitual dietary
intake was investigated among healthy men and women, the combination of total n-6
and n-3 contributed to lowering the inflammatory biomarkers including TNF.
Moreover, when participants consumed a high level of EPA, DHA, LA, and n-6 fatty
acids did not suppress the effects of n-3 anti-inflammatory properties [158]. In Japan,
two studies confirm that a high intake AA supplement had no effect on platelet
function or any metabolic parameter [159] although it may have the ability to prevent
CVD [160]. GLA is one type of omega-6 that has been studied for a while to explain
the anti-inflammatory effects of omega-6 [161]. Moreover, some prospective cohort
studies have not found significant associations between n-6 intake and hemorrhagic
[162, 163], stroke or stroke mortality [164], and ischemic [162, 163, 165].
Fatty acid composition of the modern Western diet has changed. Typically the
ratio of n-6: n-3 in the Western diet has been estimated to be 15:1 to 16.7:1 [166,
167]. High levels of n-6 intake could escalate in vivo susceptibility to low-density
lipoprotein (LDL) oxidation that can promote vascular inflammation [168, 169]. Even
though omega 3 has anti-inflammatory effects in humans, a high ratio of n-6: n-3 may
increase pro-inflammatory cytokine production [170]. These changes might be a
cause of the increase in inflammatory diseases [171, 172].
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Until now, it’s still hard to be sure that diet may reduce IBD cases, it has been
proposed that a high incidence of IBD is related to a high ratio of n-6:n-3 [173].
Animal studies are used trinitrobenzene sulfonic acid (TNBS) rat models to
investigate the effect of n-6:n-3 with colitis [139]. Using TNBS model studies
demonstrated that a diet rich in safflower oil (n-6) rather than omega-3 rich foods
including cod liver oil and perilla oil increases colonic ulceration damage and
inflammation levels including Leukotriene B4 (LTB4)1 levels [174-176]. Moreover, it
has been proposed that consuming a diet with a high ratio of n-6:n-3 is related to the
severity and the thickness of the inflammatory infiltrate [177] and it increases
intestinal damage and inflammation during infection-induced colitis [173]. Fat-1
transgenic mice revealed that low ratio of n-6:n-3 reduces pro-inflammatory
cytokines, IL-6, and IFNγ and decreases the incidence of colitis [178]. Moreover, a
recent prospective cohort study in Denmark examined the high levels of n-6:n-3 ratio
in adipose tissue in ulcerative colitis (UC) patients (57,053 men and women). They
found that inflammation was the interacting factor between diet and disease
progressions by increasing inflammatory responses [179]. In colonic biopsies, high
levels of n-6:n-3 ratio regulate LTB4 that are pro-inflammatory lipid mediators that
have been correlated with IBD [180, 181].
In Japan, a case control study of 111 patients reported that high intakes of n-6
was associated with CD incidence [144] because n-6 increases the production of ROS
from inflammatory cells [145]. In 2003, a double-blind, randomized controlled trial
enrolled patients to assess the effect of a low ratio of n-6:n-3 and atherosclerotic
plaques progression. Fewer plaques and thin fibrous caps and signs of inflammation
were found in patients who consumed high n-3 fatty acids. However, the high n-6
1

Leukotriene B4 (LTB4) is a leukotriene involved in inflammation.
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group had more plaques and thick fibrous caps with no signs of inflammation [182].
Table 2.1 illustrates the studies that have investigated the relationships between fatty
acids and inflammatory biomarkers.
To sum up, aggregate data from animal experiments, in vitro studies, and
human observational and experimental feeding studies indicate that high n-6:n-3
ratios may lead to increased risk of contracting many diseases
Alzheimer’s-Related Genes and Its Associations with Systemic Inflammation
Recent large genome-wide association studies (GWAS) have identified many
genes/loci (CR1, BIN1, CLU, PICALM, MS4A4/MS4A6E, CD2AP, CD33, EPHA1,
and ABCA7) that are associated with late-onset Alzheimer's disease (LOAD) [183].
Recent genetic data reveal that some risks of disease initiation, progression, and
severity are linked to different gene alleles by affecting inflammation pathways. Gene
diversity plays an important role in immunity, inflammation, and inflammatory
disease [184]. For instance, Familial Cold Autoinflammatory Disease occurs as a
result of single missense heritable mutation [185,186, 187].
Alzheimer’s-Related Genes
Apolipoprotein E (APOE)
Apolipoprotein E (APOE) is a lipoprotein class that is found in chylomicron
and intermediate-density lipoproteins (IDLs). APOE is essential to regulate
triglyceride levels and metabolism and transport of cholesterol by binding to a
specific receptor on the liver and peripheral cells and by the catabolism of
triglyceride-rich lipoprotein constituents [188, 189]. Functionally, it contributes to
neuronal development, regeneration, and repair in the central nervous system (CNS)
[190, 191].
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Even though APOE is considered the strongest genetic risk factor for AD, it
still accounts for only 10–20% of LOAD susceptibility when combined with
environmental factors [192]. The results of meta-analysis have firmly established that
apolipoprotein E epsilon polymorphism leads to the generation of APOE 2, APOE 3,
and APOE 4, which are coded by three alleles ε2, ε3, and ε4 [193]. Later,
rs439401was found to be another type of APOE polymorphism that displays an
association with AD [194]. Very few studies have investigated putative associations
between APOE rs439401 and triglyceride traits [194-196].
Numerous data suggest that APOE has pro-inflammatory roles in the CNS
[197, 198]. Brain biology and neurodegeneration studies suggest that APOE genotype
ε4 has a role as an immunomodulatory agent and it has an effect on inflammatory
mediators [199-201]. Other studies have focused on understanding the role of APOE
in regulating acute inflammation [202] by increasing monocyte production of IL8 and
TNF-α in human cells [203]. APOE and amyloid plaque association have been
hypothesized to increase inflammation levels in the CNS by modifying beta-amyloid
(Abeta)-induced glial activation [197]. Animal studies found that the APOE ε4
genotype is associated with cytokines by increasing pro-inflammatory cytokines IL-6
and TNF-α in mice that express human APOE [200, 204]. It has also been
demonstrated that APOE deficiency in mice diminishes immune response, increases
macrophage levels, and causes inflammation [205, 206].
Furthermore, other features work the implication of the anti-inflammatory role
for APOE. APOE genotypes ε2/ ε2 are thought to reduce inflammation levels when
researchers mixed neuronal-glial cultures from APOE deficient mouse pups and
measured the secretion of TNFα after stimulation with lipopolysaccharide (LPS), and
when they compared the inflammatory responses of targeted-replacement mice
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expressing the human gene after intravenous administration of lipopolysaccharide
[207] [200]. Negative effects on the inflammatory responses occurred as a result of
isolating APOE ε4 from peripheral blood mononuclear cells [208].
BIN1
Bridging integrator 1 (BIN1) is located on chromosome 2q14.3. BIN1 encodes
many isoforms of nucleocytoplasmic adaptor proteins. BIN1 has many roles in the
human body such as tumor suppression, transcriptional regulation, DNA repair, and
cytoskeletal organization [209]. BIN1 isoforms have many biological functions in the
central nervous system. BIN1 may be involved in synaptic vesicle endocytosis and
may interact with endophilin, dynamin, clathrin, and synaptojanin [210]. Many mouse
genetic studies reported that BIN1 is associated with a decreased risk of chronic
inflammation in the liver, pancreas, heart, prostate [211], inflammatory bowel disease
[212] cancer [213] and AD [214]. There are several isoforms of BIN1 that are
expressed in the brain. Knockout mosaic mice show that BIN1 reduced inflammation
levels when they are aging [215]. Another study of aged mice reported the benefits
effects of having BIN1 by reducing inflammation and cancer susceptibility [216].
Moreover, it has been found that BIN1 plays a role in cancer patients by suppressing
the production of interferon-y (IFN-y), which is one kind of proinflammatory
biomarker [217].
CLU
Clusterin (CLU) is a protein that can be found in the cytosol and is secreted
under stress conditions, also known as apolipoprotein J [218]. A CLU gene may play
a role in initiating the immune system because it is one of the phospholipid transfer
proteins (PLTP), which links with apolipoprotein A-I – the major HDL protein [219].
It has several functions in neurodegenerative disorders, cell death, and tumor
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progression [220]. CLU has a dual effect on inflammation. When CLU works as an
anti-inflammatory, it enhances anti-apoptotic properties [221]. When CLU works as
pro-inflammatory, it regulates a wide variety of stimuli that may increase the
production of protein such as growth factors and cytokines [222, 223]. CLU has been
linked to several diseases such as diabetes, aging, degenerative diseases [222],
atherosclerosis [222, 224], and increased the risk of AD 8.2% [223]. It has been
hypothesized that CLU might have a protective role in neuroinflammation and AD
[224, 225].
CD2AP
CD2AP is an 80-kDa CD2 protein, which was initially replicated from a
protein that works together with the CD2’s cytoplasmic domain [226]. Extensive
studies about human podocytes reported that low expression of CD2AP is associated
with increased inflammatory biomarkers [227-230]. CD2AP plays an important role
in the transportation of proteins and lipids within cells, and inflammation, and these
are potential pathways for the development of Alzheimer’s disease. Other studies
suggest that this association might happen as a result of gene variants that contribute
to late onset AD [226]. The gene CD2AP plays an important role as a cerebral
inflammation regulator, a process that is associated with the brain being inhabited by
viruses, in a dormant state. Scientists have found that there is a high presence of
inflammatory-related genes in the brains of people suffering from Alzheimer disease.
Essentially, the genes that are associated with the risk of Alzheimer’s include CD2AP,
which is also an inflammatory gene [231].
AGTR1
Angiotensin II receptor, type 1 (AGTR1) is the main product of aldosterone
secretion [232]. It helps control blood pressure and the cardiovascular system
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capacity. AGTR1 is responsible for mediating the cardiovascular system by affecting
angiotensin II [233]. An experimental study revealed the proinflammatory effects of
AGTR1 in the lungs of chronic antigen exposure to rats [230]. There was a significant
relationship between CRP levels and AGTR1 polymorphisms that led to increased
inflammation levels in 42-year-old women recruited from a population registry [232],
a case-control community-who acquired pneumonia [258], a case-control communitywho acquired pneumonia [234], and in a twin hypertension cohort [235].
MPP7
Membrane protein palmitoylated 7 (MAGUK p55 subfamily member 7)
(MPP7) can be found in synapse adherence junctions [236]. MPP7 has been linked to
increased inflammatory bowel disease, which may lead to malignant transformation
of normal tissue [237]. A recent study found that MMP7 polymorphism probably
helps manifestations within aspects of immune/inflammatory activity that are
macrophage/monocyte-mediated [238] in ulcerative colitis [239]. The same result was
observed in human [240] and mice epithelial cells [241].
MMP8
Matrix metallopeptidase 8 (neutrophil collagenase) (MMP8) is a part of the
MPP7 family. MMP8 helps break down the extracellular matrix in normal
physiological processes such as tissue remodeling in embryonic development and
disease processes [242]. The main function for MPP8 is to degrade type I, II and III
collagens [243]. It has been proposed that the absence of MMP8 in mice has been
linked to increased lung inflammatory responses by modulating two major products
S100A8 and S100A9, which activate macrophages regulating cell damage [244].
Strong evidence suggests that having MMP8 enhances inflammatory biomarkers
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including TNF-α and IL-1β in metabolic syndrome [245], ischemic stroke [246], and
cancer [242, 247].
TOMM40
Translocase of outer mitochondrial membrane 40 homolog (yeast) (TOMM40)
is an essential protein importer in mitochondria. It forms channels to translocase the
mitochondrial outer membrane (TOM) complex [248]. TOMM40 locus is located
close in linkage disequilibrium with APOE on 19q13.2. This gene encodes an outer
mitochondrial membrane translocase involved in the transport of amyloid-β and other
proteins into mitochondria that have been involved in AD progression [249, 250].
Concomitantly, APOE-TOMM40 genotypes have been revealed to modify disease
risk and age at onset of symptoms. TOMM40 has been linked to CRP and triglyceride
levels in Australian families [251]. TOMM40 was found to have a pro-inflammatory
effect in metabolic syndrome of 85,500 participants from 14 large epidemiological
studies within the Cross Consortia Pleiotropy Group [252], and in the Candidate gene
Association Resource (CARe) study and race-combined meta-analyses that included
29,939 additional individuals of European descent from CARe, and the Women's
Health Initiative (WHI) [253].
CR1
Complement receptor 1 (CR1) can be found on leukocytes, glomerular
podocytes, splenic follicular dendritic cells, and erythrocytes [254]. It encodes a
monomeric single-pass type I membrane glycoprotein. CR1 helps to mediate and
activate cellular binding to immune complexes and particles by activating T-cells
[255]. CR1 has been associated with autoimmune and inflammatory disorders in the
pathophysiology of a several diseases as pro-inflammatory [255-258] including AD
[259-261].
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CD33
CD33 or Siglec-3 is a trans-membrane receptor expressed on cells of myeloid
lineage and sometimes can be found on lymphoid cells [262, 263]. CD33 inhibits
cellular activity because it contains immunoreceptor tyrosine-based inhibitory motifs
that activate the intracellular portion. CD33 is considered as an immunoglobulin
superfamily because it has immunoglobulin domains (one IgV and one IgC2 domain)
that affect the extracellular portion in cells [264]. Many studies have shown that
CD33 is associated with an increased risk of AD in a Caucasian population. A new
study among the Chinese Han population revealed that a higher AD risk is associated
with allele T in MS4A6A and allele C in CD33 [192, 265]. Later, inflammation was
proposed as one way that CD33 affects AD [266].
PICALM
Phosphatidylinositol Binding Clathrin Assembly Protein (PICALM) is a
clathrin assembly protein that recruits adaptor protein complex 2 (AP2) and clathrin
[267]. Even though PICALM polymorphisms are associated with the risk of
Alzheimer’s disease [268], this association is still far weaker than APP, PSEN1,
PSEN2, and APOE [267].
MS4A6A
Membrane-spanning 4-domains, subfamily A, member 6A (MS4A6A) is a
gene that encodes a member of the membrane-spanning 4A gene family [265].
Hematopoietic cells and nonlymphoid tissues are the unique expressions for MS4A6A
in human. MS4A6A has different protein isoforms due to unusual splicing [269].
Membrane-spanning 4-domains, subfamily A, member 4E (MS4A4E) is a type of the
MS4A gene family and it encodes at least four transmembrane domains C- and Nterminal cytoplasmic domains that are encoded by distinct exons. MS4A6A has an
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effect on T cell levels in humans [270] which may explain the proinflammatory
effects in northern Han Chinese [266].
ABCA7
ATP-binding cassette, sub-family A (ABC1), and member 7 (ABCA7) are
associated with the superfamily of ATP-binding cassette (ABC) transporters [271].
ABC proteins transport various molecules across extra- and intra-cellular membranes.
It consists of seven distinct subfamilies (ABC1, MRP, OABP, MDR/TAP, ALD,
GCN20, and White). The function of this protein is still unclear, however, the gene
expression is related to lipid homeostasis especially cholesterol in cells of the immune
system [272]. It has been believed that cytokine levels such as IFN-γ, IL-1β and
platelet-derived growth factor (PDGF) may decrease ABCA7 expression. However,
other cytokines such as IL-10 have been shown to increase ABCA7 expression [273,
274].
DTNA
Dystrobrevin, alpha (DTNA) is a dystrophin-associated protein complex
(DPC) and it has been identified as having different isomers when mutated [275]. This
gene was found to be involved in the formation and stability of synapses and the
clustering of nicotinic acetylcholine receptors. Studies had shown that DTNA gene
polymorphisms are related to left ventricular defects when patients had congenital
heart defects [275].
HTR2C
5-Hydroxytryptamine (serotonin) receptor 2C, G protein-coupled (HTR2C) is
a coupled receptor for 5-hydroxytryptamine and it is considered a neurotransmitter. In
certain areas of the brain, this gene inhibits dopamine and norepinephrine releases by
binding serotonin [276].
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EPHA1
EPH receptor A1 (EPHA1) is a member of the protein-tyrosine kinase family
in the ephrin receptor subfamily. EPHA1 has been found in some human cancer cell
lines and has been associated with carcinogenesis [277]. EPHA1 has been linked to
inflammation as it plays a role in apoptosis [201, 278]. It has been reported that
EPHA1 plays an important role during endothelial cell activation by enhancing
proinflammatory gene expression in mouse and human atherosclerotic plaques [279].
SORCS1
The sortilin-related VPS10 domain containing receptor 1 (SORCS1) is one of
the vacuolar proteins sorting 10 (VPS10) family members. It mediates intracellular
protein trafficking and sorting [280]. It has many functions in a developing and
maturing central nervous system, and it displays neuropeptide receptor activity [281].
SORCS 1 has been linked to AD pathogenesis by increasing Aβ production [282].
PPP3R1
Protein phosphatase 3, regulatory subunit B, and alpha (PPP3R1), calcium
dependent, have many functions such as by being a calmodulin stimulated protein
phosphatase, and a regulatory subunit of calcineurin [283]. Mutation in this gene has
been linked to increasing AD risk by affecting calcium signaling pathways [284].
MAPT/STH
STH is known as MAPT. The transcripts of MAPT can be found in the
nervous system and it is expressed differently depending on the neuron type and cell
maturation. Studies have shown that MAPT is related to many neurodegenerative
disorders such as Pick's disease, front temporal dementia, corticobasal degeneration
and progressive supranuclear palsy, and AD [285-287]. STH is considered to be like a
tau protein and is linked to many neurodegenerative disorders [288]. In 2008, a study
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conducted in China found that a polymorphism in STH may increase
neuroinflammation and abnormal phosphorylation of TAU proteins in AD patients
[289]. It has also been proposed that mutation in MAPT/STH may cause front
temporal dementia [290].
In conclusion, GWA is a great technique to discover novel susceptibility
gene/loci for AD. All of these genes (APOE, BIN1, CLU, CD2AP, AGTR1, MMP8,
MPP7, TOMM40, CR1, CD33, PICALM, MS4A6A, MS4A4E, ABCA7, DTNA,
HTR2C, EPHA1, SORCS1, PPP3R1, MAPT/STH) have been associated with AD
which may facilitate new research in human genetics and genomics with biological
insights and direct clinical benefit.
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Table 2.1: Studies reporting the relationship between fatty acids and inflammatory
biomarkers.
Published evidence between fat acids and inflammatory cytokines
Fatty acids

Statistically Not
Type

Inflammatory types

Statistically significant
significant
P-value <0.05
P-value >0.05

Pentadecanoic acid

Palmitic acid

Margaric acid

Stearic acid

Arachidic acid

Behenic acid

Lignoceric acid

Palmitoleic acid

Oleic acid

Pro-inflammatory

No references found related to pro-inflammation

Anti- inflammatory

No references found related to ant-inflammation

Pro-inflammatory

[291-299]

Anti- inflammatory

No references found related to ant- inflammation

Pro-inflammatory

No references found related to pro-inflammation

Anti- inflammatory

[302-304]

Pro-inflammatory

[294, 298, 299, 305-307]

Anti- inflammatory

[309]

Pro-inflammatory

No references found related to pro-inflammation

Anti- inflammatory

No references found related to ant-inflammation

Pro-inflammatory

[298]

Anti- inflammatory

No references found related to ant-inflammation

Pro-inflammatory

No references found related to pro-inflammation

Anti- inflammatory

No references found related to anti-inflammation

Pro-inflammatory

[299]

Anti- inflammatory

[310-314]

Pro-inflammatory

[315, 316]

Anti- inflammatory

[126, 310, 319-321]

Pro-inflammatory

No references found related to ant-inflammation

Anti- inflammatory

No references found related to pro-inflammation

Pro-inflammatory

No references found related to pro-inflammation

Anti- inflammatory

No references found related to ant-inflammation

Pro-inflammatory

No references found related to pro-inflammation

Anti- inflammatory

No references found related to anti-inflammation

Pro-inflammatory

[316]

Anti- inflammatory

[324, 325]

Pro-inflammatory

[289, 291-293, 320, 326, 327]

Anti- inflammatory

[330, 331]

Pro-inflammatory

No references found related to pro-inflammation

Anti- inflammatory

[126, 293, 320, 330-333]

SFA

SFA

[300, 301]

SFA

SFA

[300, 308]

SFA

SFA

SFA

MUFA

MUFA

MUFA

[317, 318]

Gondoic acid

Erucic acid

Nervonic acid

MUFA

MUFA

Vaccenic acidTFA
Trans

Linoleic acid (LA)

PUFA

α-Linolenic acid
(ALA)

[322, 323]

PUFA

[296, 328, 329]
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Eicosadienoic acid

PUFA

Dihomo-γ-linolenic
acid (DGLA)

PUFA

Arachidic acid
PUFA
Eicosapentaenoic
acid (EPA)

Arachidonic acid

Adrenic acid

PUFA

PUFA

PUFA

Docosapentaenoic
acid n-6

[334]

Anti- inflammatory

No references found related to ant-inflammation

Pro-inflammatory

[335]

Anti- inflammatory

[336]

Pro-inflammatory

No references found related to pro-inflammation

Anti- inflammatory

No references found related to ant-inflammation

Pro-inflammatory

No references found related to pro-inflammation

Anti- inflammatory

[126, 293, 320, 330-333]

Pro-inflammatory

[136, 292, 335, 337]

Anti- inflammatory

No references found related to anti-inflammation

Pro-inflammatory

No references found related to pro-inflammation

Anti- inflammatory

No references found related to anti-inflammation

Pro-inflammatory

No references found related to pro-inflammation

Anti- inflammatory

[340-343]

Pro-inflammatory

No references found related to pro-inflammation

Anti- inflammatory

No references found related to anti-inflammation

Pro-inflammatory

No references found related to pro-inflammation

[317]

[296, 338, 339]

[317]

PUFA

Docosapentaenoic
acid n-3

Pro-inflammatory

PUFA

Docosahexaenoic
acid (DHA)

PUFA

[121, 126, 292-294, 301, 329, 330, 335, 337,
Anti- inflammatory
344-347]
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CHAPTER 3
THE ROLE OF THE DIETARY APPROACH TO STOP HYPERTENSION (DASH)
AND MEDITERRANEAN DIETARY PATTERNS IN SYSTEMIC
INFLAMMATION
IN THE CACHE COUNTY MEMORY STUDY
Abstract
Objective: To evaluate whether healthy dietary patterns, defined by the Dietary
Approaches to Stop Hypertension (DASH) and Mediterranean dietary patterns
(MED), are associated with a reduced level of systemic inflammation as indicated by
levels of inflammatory CRP in plasma in a prospective, population-based study.
Design: Participants included 1,713 men and women ≥65 y at baseline of age
who were residents of Cache County, Utah, in 1995. Diet-adherence scores were
computed by summing across the energy-adjusted rank-order of individual food and
nutrient components and categorizing participants into quintiles (Q) of the distribution
of the diet accordance score. Multiple logistic regression models were used to
examine the risk of elevated CRP level (> 3.0mg/L) across increasing quintiles of
accordance dietary scores and individual food components that comprised each score.
Results: High adherence score to the DASH and MED dietary patterns were
similarly associated with a reduced risk of elevated CRP (odds ratio for Q5 vs Q1:
DASH (aOR= 0.74, 95% CI 0.53- 1.05; MED: aOR= 0.73 (0.52- 1.0)). This
association appeared stronger among overweight and obese participants (DASH:
aOR= 0.65 (0.41- 1.0), p-trend = 0.027; MED: aOR= 0.55 (0.35- 0.8), p-trend= 0.018)
than among normal weight (DASH aOR= 0.86 (0.52- 1.4), p-trend= 0.46; MED aOR=
0.98 (0.58- 1.6), p-trend= 0.916. Food component dietary scores associated with
reduced risk of elevated CRP included nuts and legumes (DASH), legumes (MED),
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fruits (MED), and high-fat dairy (MED) was associated with an increased risk; these
food associations were generally not observed among the low-BMI participants.
Conclusions: The DASH and Mediterranean dietary patterns may play an
important role in reducing systemic inflammation, especially in overweight and obese
elderly persons.
Introduction
Systemic inflammation is a risk factor for the development of Alzheimer
Disease (AD) [1]. AD is the most common form of dementia among aging men and
women worldwide [2]. Studies in elderly patients with mild cognitive impairment
(MCI), AD and normal elderly have suggested that measuring peripheral
inflammatory markers including tumor necrosis factor α (TNF-α) in AD patients
helped to detect early progression of both MCI and AD [3, 4]. Despite the
complicated etiology of inflammation, C-reactive protein (CRP) is one of the
strongest and most commonly reported inflammatory biomarker [5]. Concomitantly,
CRP has been linked to many diseases including metabolic syndrome, diabetes,
cardiovascular [6], and AD [7].
Dietary quality scores method have been used widely to assess the relationship
between diet adherence and CRP levels [8-10]. Two dietary quality scores of interest
are the Mediterranean diet (MED) and the Dietary Approach to Stop Hypertension
(DASH) scores. The Mediterranean diet is a traditional dietary pattern from different
countries bordering the Mediterranean Sea. MED diet is characterized by a high
consumption of fruits, vegetables, whole grains, full-fat dairy foods, meat, fish,
poultry, nuts and beans. MED diet is also limited in sugar-sweetened foods and
beverages, red meat, and added fats and includes a moderate consumption of alcohol
[11]. Mediterranean diet is usually higher in n-3 (α-linolenic acid) and lower in n-6
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(linoleic acid) which may explain the anti-inflammatory effects of MED diet. Olive
oil is the primary fat in this diet [12]. Much epidemiologic research indicates that
MED diet adherence was associated with beneficial health outcomes including
improved quality of life [13-15], reduction in mortality risk, and major chronic
disease incidence [16, 17] such as cancer, cardiovascular mortality, Parkinson’s
disease [18], and Alzheimer’s disease [14, 19-21].
The Dietary Approaches to Stop Hypertension (DASH) was developed to
lower and control hypertension by Appel and others and funded by the U.S.-based
National Heart, Lung, and Blood Institute [22]. It includes a high consumption of
fruits, vegetables, low fat and nonfat dairy, beans and nuts, with small amounts of
lean meats, fish, poultry, and grains (at least 3 servings of whole grains per day), low
intake of fats and sweets, and sodium intake should be limited to 2,300 mg each day
[22, 23]. Evidence gathered from studies conducted approximately a decade ago
indicated that the DASH diet helps lower the risk of several diseases including
hypertension [24], coronary heart disease [25], stroke [24], cancer [26], osteoporosis
[27], cognitive function [28], kidney diseases [29], bone health by reducing bone
turnover [30], and AD [21, 31]. In the current study, we examined the associations
between MED and DASH dietary adherence scores and systemic inflammation levels
as indicated by levels of inflammatory CRP, using the data from the Cache County
Memory Study (CCMS).
Methods
Study Participants and Data Collection
The Cache County Memory Study is a prospective cohort study among elderly
who were 65 years old and older in 1995 and who were permanent residents of Cache
County, Utah. This population is largely non-Hispanic White and the genetic makeup
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is mostly from Northern European ancestry. The institutional review boards of each
collaborating site at Utah State University, Duke University Medical Center, and The
Johns Hopkins University approved the protocol of the study.
On January 1, 1995, trained personnel from Center for Epidemiologic Studies
at Utah State University visited and interviewed 5,092 residents representing a 90
percent response rate in the baseline interview. The baseline interview included
information about demographic characteristics, health history, and family history of
dementia, use of medications, alcohol, tobacco, other lifestyle factors, and extensive
cognitive testing. Reassessments of this study were completed in different years with
a decline in the screening sample size: Wave 2, 1998-1999, with 3,411; Wave 3,
2002-2003, with 2,344; and Wave 4, 2005-2006, with 1,137. Details of the study
protocols have been previously published [32].
Diet Assessment
A food frequency questionnaire (FFQ), patterned after the Nurses’ Health
Study [33, 34], was used to assess usual dietary intake at the Wave 3 interview
examination [21]. Many studies have shown that FFQ is an appropriate tool for
populations of different demographic characteristics and different ages [34]. The Food
Processor Program (ESHA Research, Portland) was used for the nutrient analysis. All
nutrients from foods were adjusted for total caloric intake via the regression-residual
methods of Willett [35]. Nutrient intakes from supplements were added to energy
adjusted nutrient intake levels from food to obtain an accurate measure of total
nutrient intake.
In Wave 3, the FFQ included 150 food items with specified serving sizes
described by using usual portions (e.g., 1 orange, 1 slice of bread) of the servings
commonly consumed in this study population. For each food item, participants
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indicated their average frequency of consumption over the past year in terms of the
specified serving size by checking 1 of 9 frequency categories ranging from “almost
never, <1 per month” to “≥6 times/d.” Participants were asked to report the name
brands of some food items such as cereal and margarine. Also, participants were
asked to list any food items that were not mentioned in the FFQ and report the serving
size of that food and how many times they had it. The last part of the FFQ includes
questions about following a specific diet such as: Do you follow a special diet? How
many years do you follow it? Was the diet prescribed by a doctor? How many years
have you been following this diet? What kind of diet did you follow?
Mediterranean diet and DASH Assessment
Based on the nutrient and food components, the Mediterranean diet (MED)
and DASH diet adherence scores were computed. The Mediterranean diet contained
eight components: a high intake of vegetables, fruits, grains, fish, legumes, and a ratio
of monounsaturated fatty acids to saturated fatty acids (MUFA:SFA), low intakes of
meat and meat products, and high-fat dairy products. Alcohol consumption was not
used to define the MED diet score because of low rates of alcohols consumption in
the population. The DASH diet adherence scores were contained the following
components: a high intake of vegetables, fruits, nuts and legumes, whole grains, and a
low intake of fat from dairy products, sodium, sweetened beverages, and red and
processed meats. Both diet components were selected to represent food groups
targeted in the DASH diet [36] and the Mediterranean diet [16] as described
previously by Wengreen [21].
Participants were categorized based on their consumption of each food
component in both the Mediterranean and DASH diets including: fruits, vegetables,
whole grains, total grains, full-fat dairy foods, nuts, legumes (nuts and legumes),
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MUFA/SUFA ratio, and fish (Table 6). Based on the adopted method used by
Wengreen et al., (Table 3.1). For each component, participants were ranked based on
the distribution of food or nutrient component intake levels. Mediterranean diet
adherence and DASH scores were determined by summing across the ranked scores
of each relevant nutrient and food component. The sum score of the ranked scores of
each relevant nutrient or food component defined the diet adherence scores. The score
range for each food group is from 1-5. Therefore, higher values indicate greater
adherence to the Mediterranean diet and DASH. Positive scoring meant that
participants who consumed the lowest amount in the food group received a low rank
score of 1, and participants who consumed the highest amount in the food group
received the highest rank score. Inverse scoring study samples were arranged in the
opposite order based on their intake levels of sweetened beverages, sodium, red and
processed meat, and full fat dairy food. Negative scoring meant that the participants
who consumed the lowest amount received the highest rank score; while participants
who consumed the highest amount received a rank score of 1 [37, 38].
CRP assessment
Blood samples were collected and assayed for CRP from participants in Wave
3 at McKay Dee Hospital Laboratory, Ogden, UT by Dade Behring BNII (BN for
Behring Nephelometer) for high-sensitivity CRP (hs-CRP) in 2002.

Dade's

nephelometry method has been considered for quite some time as a gold standard for
these tests in the laboratory industry [39]. Many large reference studies refer to the
Dade BNII assay that uses particle enhanced immunonephelometry. Dade was one of
the first vendors to receive FDA approval for cardiac marker claims for their sensitive
CRP assay [40]. The method uses polystyrene particles coated with mouse
monoclonal antibodies to CRP that are agglutinated when mixed with samples
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containing CRP [41]. The intensity of the scattered light in the nephelometer depends
on the CRP content of the sample and, therefore, the CRP concentration. Typically,
expected values for healthy individuals are found to be < 3.0 mg/L, or < 0.3 mg/dL
[42]. The measuring range is determined by the lower limit of the reference curve and
depends on the concentration of the standard used. The typical limit of detection for
the method was 0.175 mg/L or 0.0175 mg/dL. The upper level of detection was
typically 1500 mg/L or 150 mg/dL. We defined elevated CRP as values >3.0 mg/L.

Statistical Analyses
SPSS version 22.0 was used for statistical analysis. The Analysis of Variance
(ANOVA) test for continuous variables and Chi-square test for categorical were used
to evaluate differences between quintiles of diet scores (Tables 3.2 and 3.3).
Logistic regression analyses were used to evaluate the risk of elevated CRP
(>3.0 mg/L) by quintiles of each dietary pattern score with quintile 1 as the reference
category while controlling the potential confounding variables. Obesity is associated
with systemic inflammation [43-45]; thus, we further examined whether the dietinflammation association was different among overweight and obese versus nonoverweight (body mass index ≥25 versus <25 kg/m2). Potential confounding variables
included in the model were gender (male, female), age (years), body mass index (BMI
weight in kilograms/ height in meters2), educational level (less than high school, high
school, college and graduate), drinking and smoking habits (never, former, current);
health variables included diabetes (no, yes), stroke (no, yes), and heart attack (no,
yes), multivitamin and minerals use (yes vs. no), APOE genotype (no e4, 1 or 2 e4).
Participants with no dementia (n= 154) were excluded from all analyses. Reported pvalues are two-sided, and type I error rate for statistical significance was 0.05.
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Results
The range of rank-order DASH and Mediterranean diet scores was 1,602 14,049 and 2,033 - 13,525, respectively. The DASH diet scores and Mediterranean
diet scores were positively correlated (r = 0.512, p-value <0.001). Participants in the
highest quintile of DASH or Mediterranean diet scores were more likely to be women,
more educated, less likely to have ever smoked or drank alcohol than were subjects in
lower quintiles of either score. Participants in the highest quintile of the DASH or
Mediterranean diet scores consumed less total fat, saturated fat, and cholesterol than
did subjects in the lowest quintile of either diet score. Moreover, participants in the
highest quintile of the DASH or Mediterranean diet scores consumed more fiber,
vitamin C, folate, and vitamin B6, than did subjects in the lowest quintile of either
diet score. The pattern of vitamin B12 intake was different between the two diet
scores; no differences were observed across quintiles of the DASH diet score (P =
0.218), but vitamin B12 intake was lower in quintiles 4 and 5 compared to the lower
quintiles of the Mediterranean diet score (P = <0.001). Subjects in the highest quintile
of either accordance score consumed more potassium, magnesium, and zinc than did
subjects in lower quintiles. Calcium intake increased across increasing quintiles of the
DASH score, but the pattern was the opposite for the MED quintiles. An increasing
quintile of the DASH diet but not Mediterranean accordance scores was associated
with decreasing sodium intake. An increasing quintile of the Mediterranean diet but
not DASH diet accordance scores was associated with increasing omega-3 and
omega-6 fatty acid intake. There was no association between DASH and MED scores
with age, APOE genotype, diabetes, or stroke. The heart attack was significantly
associated with the Mediterranean diet but not with the DASH diet. Conversely, CRP
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and multivitamin and mineral use was significant with the DASH diet but not with the
Mediterranean diet (Tables 3.2 and 3.3).
Logistic regression analyses were used to evaluate the association between
DASH and MED diet scores and elevated CRP levels (>3.0 mg/L). After controlling
for covariates, The DASH diet score and MED diet score were similarly associated
with a reduced risk of elevated CRP levels adjusted OR (aOR) and 95% confidence
intervals (CIs)) for Q5 vs Q1: DASH (aOR=0.74 [95%CI 0.53- 1.05]30); MED
(aOR=0.73 [95%CI 0.52- 1.0]). Nuts and legumes (DASH) and legumes (MED) were
associated to reduce the risk of elevated CRP (aOR=0.72 [95%CI 0.51- 1.0]) and
(aOR=0.75 [95%CI 0.54- 1.0]), respectively. Full fat dairy (MED) was associated
with increased risk of elevated CRP (aOR=1.30 [95%CI 0.99- 1.9]), shown in Table
3.4.
Because obesity is associated with inflammation, we stratified the data by
BMI to examine whether the associations between diet patterns and CRP differed in
BMI strata. Mean plasma CRP concentrations were found in overweight and obese
participants compared to non-overweight participants by using multiple logistic
regression (Table 3.5) and (Table 3.6). Among overweight and obese persons there
were significant decreases in plasma CRP across increasing DASH quintiles (aOR for
quintile 5 vs. quintile 1= 0.65 [95%CI 0.41- 1.0]), MED (aOR = 0.55 [95%CI 0.350.89]), nuts and legumes (DASH) (aOR = 0.60 [95%CI 0.38- 0.94]), legumes (MED)
(aOR = 0.59 [95%CI 0.38- 0.93]), fruits (MED) (aOR = 0.71 [95%CI 0.45- 1.1]). Full
fat dairy (MED) (aOR = 1.4 [95%CI 0.96- 2.3]) was associated with increased CRP
plasma across quintile 5 vs. quintile 1. In non-overweight and non-obese participants,
there was no association between plasma CRP and DASH and MED and their
components.
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Both MED and DASH scores were positively correlated with carbohydrate,
fiber, total sugar, monosaccharide, disaccharide, vitamin B1, and vitamin B6, vitamin
C, folate, pantothenic acid, copper, iron, magnesium, manganese, potassium, and zinc.
The scores of MED but not DASH were positively correlated with intakes of vitamin
B3, selenium, omega 3, and omega 6; the scores of DASH but not MD were
positively correlated with phosphorus and calcium. Also, all three diet indices were
negatively correlated with total fats, saturated fats, monounsaturated fats, cholesterol,
vitamin B2, and caffeine. MED but not DASH scores were negatively correlated with
intakes of total calorie intake, vitamin B12, calcium, and omega6:omega3 ratio;
sodium was the only nutrients that are correlated negatively with DASH score (Table
3.6).
While the associations between DASH and MED diet patterns and reduced
risk of elevated CRP appeared to be present only in overweight and obese persons and
not among normal weight persons, there was not a significant multiplicative
interaction between these diet patterns and CRP elevation ( p > 0.05).
Discussion
Diet may influence the risk of Alzheimer’s disease through its effects on
systemic inflammation [46]. Overeating of certain specific dietary components is an
important factor that should be considered in inflammatory processes [43, 47]. We
report a reduction in risk of having a high level of CRP among overweight and obese
elderly Utah study participants who were free of dementia in the highest versus lowest
DASH and MED quintiles. A higher consumption of nuts and legumes, included in
the DASH score, and legumes, included in the MED score, were the food items most
strongly associated with a reduced risk of elevated CRP. Other individual food items
appeared to contribute to the protective effect of both patterns particularly fruits and
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vegetables. Conversely, higher consumption of full fat dairy was associated with an
increase in CRP level.
Evidence gathered from studies conducted approximately a decade ago
indicated that obesity plays an important role in the inflammation [43, 48]. The
initiation step of inflammation in obesity starts with overeating that activates
metabolic signals in adipose tissues, causing the increased production of bioactive
molecules called adipokines [49]. Adipokines are cytokines (small proteins) that
function as hormones and growth factor and influence inflammatory cells such as
macrophages. The main function of adipokines is to regulate food intake, glucose and
fatty acid metabolism, and energy expenditure [50]. Then, low grade inflammation
causes changes in macrophages in the adipose and muscle tissue of obese individuals,
which encourages pro-inflammatory responses and disturbs the normal physiological
function [43, 51]. Over time, nutrient excess distresses the immune cell responses
from metabolic cellular signals and reinforces inflammatory pathways, which cause
unresolved chronic inflammation [43]. In normal conditions, feeding induces a low
level of inflammation, but after the nutrients are metabolized inflammation levels
diminish. Compared with lean persons, obese persons tend to consume high calorie
food causing high fat deposition in abdominal fat and fatty liver. Thus, the resolution
of inflammation become less efficient which activates adipokines activity and
increase cell death. Consequently, the production of inflammatory mediators increases
including interleukin 1β (IL-β), TNF-α, and CRP [43, 52-55]. Because of the previous
evidence regarding the relationship between obesity and inflammation, we examined
the relationship between DASH and MED dietary patterns adherence and CRP levels
among the group that we thought more vulnerable and susceptible to inflammation
that are overweight and obese participants.
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The Mediterranean diet (MED) is a modern nutritional recommendation
inspired by the way of eating traditional foods and drinks in Mediterranean olive
grove areas [56]. This diet is rich in fruits, vegetables, legumes, and complex
carbohydrates, with a moderate consumption of fish. The main source of fat is the
consumption of olive oil and a low-to-moderate amount of red wine during meals
[57]. The conceptual origins of the “Mediterranean Diet” in human studies were
expanded to reflect the typical dietary patterns followed mainly in Greece, Spain, and
Southern Italy [58]. In the early 1960s, the Seven Country Studies (SCS) was the first
to recognize the health benefits of MED diet. SCS participants were from the United
States, Japan, Italy, Greece, Netherlands, Finland, and Yugoslavia. The SCS team
found low rates in the prevalence of coronary heart disease and cancers [58].
Our findings on the association between MED adherence and CRP were partly
supported by previous human observational studies. A growing body of evidence
suggests that Mediterranean diets could serve as an anti-inflammatory dietary pattern,
which could help in fighting diseases that are related to chronic inflammation,
including cardiovascular disease, metabolic syndrome diseases [59], and cognitive
function [37]. Longitudinal studies reported a 3.2-20% reduction in CRP level among
participants that consumed high levels of MED [60-62]. A significantly lower CRP
level was found in three different populations including 180 metabolic syndrome
patients, 690 nurses from The Nurses' Health Study, and 112 participants from
PREDIMED (Prevención con Dieta Mediterránea), when comparing patients that
consumed the intervention diet (cases) with the control diet (control) [10, 63, 64].
Two more clinical trials among individuals with metabolic syndrome participants
have been conducted to estimate the prevalence of metabolic syndrome show that
high consumption and strong adherence score to a Mediterranean diet had
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significantly lowered pro-inflammatory CRP levels [65, 66]. However, other findings
from human observational studies have been inconsistent. Five studies reported no
preventive effect from strong adherence to MED diet on inflammatory biomarkers.
Two Cohort studies found that high consumption of MED diet affects inflammatory
markers TNF-α and IL-6 with no change in plasma levels of CRP [57, 67]. A study
conducted in Spain, Greece, and Sweden showed no strong or consistent association
between the Mediterranean Diet and inflammatory markers [68]. A crossover clinical
trials from Spain, Greece, and Sweden showed no strong or consistent association
between the Mediterranean Diet and inflammatory markers [69-71]. Another
population-based case-control study using data from patients with coronary artery
disease also did not reveal reduced CRP levels among these patients [72].
Even though a significant association between DASH accordance and the
sensitive biomarker CRP was found in our study, studies on the association between
DASH and CRP levels have produced mixed results. The DASH diet found in many
studies to decrease inflammation levels by decreasing blood triglycerides, systolic
blood pressure, diastolic blood pressure, colorectal cancer, insulin resistance, and
increased HDL cholesterol [73, 74] due to dietary pattern components. The DASH
diet is considered an anti-inflammatory diet for diabetes patients because it helps
reduce liver aminotransferase and fibrinogen levels [75]. King et al. and Saneei et al.
both reported a significant reduction of CRP levels when DASH was followed for
three weeks [76] and for six weeks, respectively [77]. Two crossover clinical trials
have been conducted to examine the effect of metabolic syndrome and diabetes
reported the beneficial effect of DASH adherence in these participants because of the
decrease in CRP plasma and other inflammatory markers when was DASH consumed
more [78, 79]. In contrast, Asemi et al. found that consumption of the DASH diet and
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a control diet for four weeks for randomized controlled clinical tests of 32 pregnant
women had no effect on CRP levels [80]. Similarly, an observational study did not
reveal reduced CRP levels among participants with metabolic syndrome [81].
The mechanisms by which the DASH and MED diets might affect CRP are
unknown. Nuts and legumes were the food group with the strongest anti-inflammatory
association in our study. Many health benefits have been reported for legumes on
blood lipids [82], low glycemic index [83]. Legumes include dried beans, peas,
lentils, tofu, soybeans, and green beans, all of which are sources of dietary fiber and
resistant starch, which are rich in proteins, oligosaccharides, dietary fiber, potassium,
calcium, and magnesium, polyunsaturated fatty acids, and phytochemicals. Legumes
are also good sources of L-arginine (a precursor of nitric oxide) and polyunsaturated
fatty acids, which have anti-inflammatory effects [84, 85]. Many studies did not
report an inverse association between high legume consumption and lower CRP levels
[86-88], whereas one crossover study resulted in a reduction of CRP [89]. In 2015, a
meta-analysis of eight studies with 464 participants reported that high consumption of
non-soy legumes reduced CRP levels and had a significant effect on CRP in parallel
studies [90]. Nuts are a good source of fiber, phenolic compounds and other antiinflammatories. Nuts are also rich in unsaturated fatty acids and contain sizeable
amounts of L-arginine, which is a precursor of the endogenous vasodilator nitric
oxide [91]. Nuts have been linked to reducing inflammatory biomarkers. A crosssectional study of 6,050 participants including Americans age 45–84 years report that
high consumption of nuts was associated with lower CRP levels among the MultiEthnic Study of Atherosclerosis [92]. The same result was observed in 339 men and
433 women age 55-80 years at high cardiovascular risk [91]. Few studies report an
association between the combination of nuts and legumes, the food group used in the
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DASH score, and CRP. A systemic review of cohort studies found that high
consumption of the combination of nuts and legumes helps to reduce the risk of
depression [93]. Cross-sectional data from diabetes-free female participants in the
Nurses’ Health Study of 3690 female age 30-55 concluded that nuts and legumes
replacement for unprocessed red meat reduces inflammatory biomarkers CRP but
after adjustment for BMI, the association did not demonstrate any significant
difference [94].
In the present study, we found an association between increasing of full fat
dairy, which is a negatively-scored MED component and elevated CRP levels
similarly in overweight and obese and non-overweight and obese participants. Full fat
dairy includes whole milk, chocolate milk, ice cream, cheddar and other hard cheese.
In 2010, dairy consumption was associated with improved inflammatory profile by
lowering inflammatory biomarkers [95]. In 2013, Kratz et al. reported that the
beneficial effect of high fat dairy is still unclear, however, low fat dairy, which
includes milk, yogurt, frozen yogurt, and cottage cheese, is related to many health
benefits especially in metabolic syndrome markers including diabetes and blood
pressure [96]. No previous study, to our knowledge, has reported an association
between full fat dairy and CRP level. Da Silva et al. reported a correlation between
adherences to dairy, which are composed of high and low levels of fat with CRP
levels; the data suggest that strong adherence to dairy increases CRP levels.
Concomitantly, the data reported that due to the study design, there was no causal
relationship found between dairy intake and CRP levels [97].
To our knowledge, this is the first study that examines the multiplicative
interaction between DASH and MED diet patterns and reduced risk of elevated CRP.
Thus, further studies are needed to confirm our results.
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The strength of the present population-based study is that the Cache County
Memory Study (CCMS) is a large population-based study of white non-Hispanic
elderly men and women. The Cache County Memory Study includes the repetitive
detailed assessment of anthropometric and physiological variables at mean age of 74
at baseline for the same individuals in different subsets of the cohort, which makes the
present study population unique and appropriate for investigating the impact of
DASH and MED diet adherence and related inflammatory marker CRP. Over the last
two decades, Food Frequency Questionnaires (FFQ) become a widely accepted
method to assess the usual intake and has been used widely in epidemiologic studies
[98].
However, several limitations need to be acknowledged. Cache County
Memory Study does not have a collection of blood for inflammatory markers at the
Wave 1 baseline examination that would allow a prospective study of CRP levels and
subsequent cognitive outcomes. We also used a single inflammatory marker, CRP, to
determine the plasma level of inflammatory biomarkers, but due the complexity of
systemic inflammation [94], examining multiple inflammatory biomarkers would help
to strengthen our results.
In conclusion, the results of the present study confirmed that MED and DASH
are associated with lower risk of elevated systemic inflammation as indicated by CRP
levels. This association appears to be modified by BMI, with overweight and the
obese person having a stronger association than normal weight person. These results
observed after controlling for gender, age, educational level, drinking and smoking
habits, diabetes, stroke, heart attack, multivitamin and minerals use, and APOE
genotype. MED is a formula for healthy day-to-day eating over a period, and people
have eaten it for centuries, and adherents live longer with lower rates of heart disease,

74

cancer, and dementia. DASH diet was demonstrated to lower blood pressure. DASH
also has been found to improve health by lowering cholesterol and preventing
diabetes and increasing life expectancy. Thus, there is good scientific support
recommending MED and DASH diets because both of these diets serve as antiinflammatory diets and offer health benefits that can promote substantial protection
against many conditions influenced by inflammatory biomarkers.
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Table 3.1: Food groups and nutrient scoring criteria for Mediterranean Diet (MED)
score and Dietary Approach to Stop Hypertension (DASH) score; Cache County
Memory Study (n =1713)
Food Items

Scoring
Criteria

Median (25th,
75th percentiles)

DASH Diet
Components

MED
Components

Fruits
(serv/d)

All fruits and 100% fruit
juices

Positive

2.8 (2.0, 3.8)

Yes

Yes

Vegetables
(serv/d)

All vegetables except
potatoes and legumes

Positive

2.7 (1.9, 3.8)

Yes

Yes

Negative

0.69 (0.47, 0.98)

No

Yes

Inverse

0.63 (0.38, 1.1)

Yes

No

Positive

1.5 (1.0, 2.5)

Yes

No

Positive2

0.35 (0.14, 0.86)

Yes

No

Positive2

0.34 (0.22, 0.57)

Yes

Yes

Negative

1.5 (0.89, 2.4)

No

Yes

Positive

1.3 (0.93, 2.6)

Yes

No

Inverse

0.14 (0.00, 0.500)

Yes

No

Positive

0.16 (0.09, 0.27)

No

Yes

Positive

0.11 (0.10, 0.12)

No

Yes

Inverse

2653 (2033, 3416)

Yes

No

Food Group

All meat
(serv/d)
Red and
processed
meats
(serv/d)

Whole grains
(serv/d)

Nuts (serv/d)
Legumes
(serv/d)
Full-fat dairy
(serv/d)
Low-fat
dairy (serv/d)
Sweetened
beverages
(serv/d)
Fish (serv/d)

MUFA/SUF
A ratio
Sodium
(mg/d)
1

Beef, pork, lamb,
chicken, turkey, liver,
salami, bologna, hot
dogs, bacon, sausage,
other processed meats
Beef, pork, lamb, liver,
salami, bologna, hot
dogs, bacon, sausage,
other processed meats
Dark bread or pita,
whole-grain cold
breakfast cereals,
cooked cereal, oatmeal,
popcorn, other grains
(e.g. bulgur, kasha,
couscous)
Peanuts, peanut butter,
other nuts
Dried beans, peas,
lentils, tofu, soybeans,
green beans
Whole milk, chocolate
milk, ice cream, cheddar
and other hard cheese
Skim or low-fat milk,
yogurt, cottage or ricotta
cheese
Sweetened beverages,
including soda pop,
punch, and other
sweetened beverages
Dark meat fish, other
white meat fish
Ratio of total
monounsaturated fatty
acids/total saturated fatty
acids
Sum of sodium content
of all foods

Positive scoring in Wave 3 of the CCMS: participant consuming the lowest amount received a rank
score of 1, participant with highest amount received rank score of 1713; negative scoring: participant
consuming the lowest amount received a rank score of 1713, participant with the highest amount
received rank score
of 1.
2
Nuts and legumes combined for DASH-style diet pattern score.
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Table 3.2: Participant characteristics by quintiles of the 8-component DASH diet
score in the Cache County Study on Memory.
Quintiles and ranges of DASH scores
Characteristic

Quintile 1

Quintile 2

Quintile 3

Quintile 4

Quintile 5

p-

(n= 365)

(n= 365)

(n= 366)

(n= 364)

(n= 366)

value1

1602- 5693

5694- 6815

6816- 7778

7779- 8927

8928- 14,049

5993± 1619

6675± 1577

7325± 1544

7675± 1536

8866± 1697

<0.001

4.9± 7.3

4.7± 6.5

4.3± 6.0

4.1± 6.0

4.0± 6.6

0.033

<0.001

Mediterranean
scores 2
Mean CRP
(mg/L) 2
Gender (%)
-

Male

27.1

22.4

16.2

18.1

16.2

-

Female

15.1

18.4

22.2

21.0

23.3

73.1± 5.5

72.5± 5.7

72.5± 5.1

72.5± 5.2

73.4± 5.4

Age (y) 2
(kg/m) 2

0.157
<0.001

Mean BMI
25.9± 4.6

27.1± 4.7

26.3± 3.9

26.5± 4.2

25.6± 4.0

17.8

20.5

17.9

15.3

14.7

<0.001

22.7

20.9

18.7

19.5

18.2

0.004

17.4

20.1

20.6

20.1

21.8

18.5

20.0

20.1

20.1

20.8

18.6

20.7

18.1

19.1

23.1

0.434

18.2

24.2

16.2

19.9

21.5

0.181

26.6

21.6

18.7

15.1

18.1

0.210

22.7

22.7

16.4

22.3

16.0

0.104

2023± 692

1877± 664

1788± 634

1853± 591

2005± 570

<0.001

79.4± 11.0

75.8± 12.8

73.0± 11

69.1± 10.9

66.0± 12.6

<0.001

81.8± 19.7

83.9± 19.2

83.2± 18.5

86.9± 16.0

85.1± 17.6

0.014

74.9± 14.9

More than high
school education
(%)
MVM use (%)
Ever smoke
(%)3
Ever alcohol
(%)

3

<0.001

0.018

At least one
APOE e4 allele
(%)
Diagnosed with
diabetes (%)
Diagnosed with
stroke (%)
Diagnosed with
heart attack (%)
Dietary intake2:
Energy (kcal)
Fat (g)

4

Carbohydrate (g)4
Protein (g)

4

75.3± 13.7

76.1± 13.4

74.8± 12.5

74.8± 13.3

0.340

Saturated fats (g)4
Monounsaturated
fats (g)4
Polyunsaturated

27± 5.8

25.1± 5.6

24.1±5.0

22.6± 4.8

20.7± 5.3

25.9± 5.6

25.7± 6.7

25± 5.5

23.5± 5.2

23.3± 5.8

<0.001
<0.001

(g)4

11.2± 3.4

11.5± 3.6

11.2± 3.2

11± 3.4

11.5± 3.6

0.321

0.10± 0.18

0.11± 0.02

0.11± 0.02

0.11±0.02

0.12± 0.02

<0.001

1.1± 0.44

1.0±0.43

1.1± 0.42

1.0± 0.44

1.1± 0.59

0.256

Ratio MUFAs to
SFSAs
Omega-3 fatty
acids(g) 4
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Omega-6 fatty
acids (g)4

9.2± 3.2

9.5± 3.4

9.3± 2.9

9.0± 3.1

9.6± 3.4

0.332

Cholesterol (mg)4

333± 194

294± 141

276± 97

255± 947

236± 123

<0.001

15.7± 4.1

17± 4.4

19.8± 4.3

21.5± 4.2

24.8± 6.8

<0.001

106± 49.8

117± 48.8

134± 47

144± 52.4

167± 62.6

<0.001

364± 91

397± 92

414± 86

451± 109

471± 109

<0.001

1.6± 0.45

1.8± 0.41

1.8± 0.40

2.0± 0.45

2.0± 0.47

5.1± 2.3

5.6± 2.9

5.4± 2.2

6.0±5.3

5.1± 2.2

0.003

3019± 456

2901±532

2774± 509

3050±472

2523± 469

0.023

813± 261

927± 305

968± 263

1055± 298

1057± 313

<0.001

2637± 508

2902± 434

3095± 448

3287± 456

3588± 538

<0.001

253± 45

287± 43

304± 36

326± 39

357± 48

<0.001

10± 2.7

10.6±2.9

10.7± 2.7

11.2± 3.1

11.1± 2.9

<0.001

Fiber (g)

4

Vitamin C (mg)

4

Folate (µg) 4

<0.001

Vitamin B-6
(mg)

4

Vitamin B-12
(µg)4
Sodium (mg)4
Calcium (mg)

4

Potassium (mg)

4

Magnesium (mg)
Zinc (mg)
1

4

4

p-values were obtained by using the Chi-square test for categorical variables and Analysis of Variance
(ANOVA) for continuous variables. DASH, Dietary Approaches to Stop Hypertension; MVM, multivitaminmineral supplement; BMI, Body Mass Index, CRP, C-reactive protein.
2
Means ± standard deviation (SD).
3
An ever smoker was defined as a subject who reported ever regularly smoking; an ever drinker was defined
as a subject who reported ever regularly drinking alcohol.
4
Energy-adjusted nutrient intakes per day.
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Table 3.3 Participant characteristics by quintiles of the 8-component Mediterranean
diet score in the Cache County Study on Memory.
Quintiles and ranges of MED scores

Characteristic
DASH score2
Mean CRP
(mg/L)2

Quintile 1

Quintile 2

Quintile 3

Quintile 4

Quintile 5

p-

(n= 365)

(n= 365)

(n= 366)

(n= 364)

(n= 366)

value1

2033- 5684

5685-6795

6796- 7818

7819- 8856

8857- 13,525

6400± 1920

6939± 1668

7261± 1668

7638± 1771

8175± 1767

<0.001

4.8± 7.5

4.5± 5.6

4.3± 6.7

4.4± 5.8

3.9± 6.7

0.069

<0.001

Gender %
-

Male

187 (27.1)

140 (20.3)

125 (18.1)

121 (17.5)

118 (17.1)

-

Female

152 (14.9)

198 (20.9)

214 (20.9)

225 (22.0)

233 (22.8)

76.5± 5.4

72.6± 5.3

73.1± 5.7

73.0± 5.6

72.8± 5.1

0.606

26.5± 4.4

26.5± 3.9

26.6± 4.3

26.4± 4.3

26.0± 4.1

0.178

18.6

17.9

19.0

20.1

24.3

0.004

21.7

19.6

19.9

19.1

19.8

0.239

18.0

20.9

19.4

20.1

21.5

<0.001

18.8

20.3

20.2

20.3

20.4

<0.001

19.6

20.2

20.8

20.0

19.4

0.235

19.9

20.4

20.0

20.5

20.0

0.787

20.2

19.8

19.6

20.3

20.1

0.486

19.5

15.2

18.0

29.3

18.0

0.002

2030± 670

1903± 624

1850± 636

1858± 624

1911± 620

Fat (g)4

80± 11.8

75± 10.9

72± 11.3

70± 11.7

64± 11.6

<0.001

Carbohydrate (g)4

235± 29

247± 27

251± 27

260± 28

273± 29

<0.001

74.3± 14.4

75.5± 13.3

76.4± 13.9

75.5± 13.5

76.1± 12.8

0.402

29± 5.5

25± 4.4

23± 4.6

22± 4.0

18± 4.3

<0.001

27± 6.1

25± 5.8

24± 5.4

23± 5.6

22± 5.3

<0.001

10± 3.3

10± 3.7

11± 3.4

11± 3.3

12± 3.4

<0.001

0.1± 0.01

0.1± 0.01

0.11± 0.01

0.12± 0.02

0.13± 0.02

<0.001

0.95± 0.38

0.99± 0.43

1.1± 0.42

1.1± 0.43

1.3± 0.58

Age (y) 2
Mean BMI (kg/m)
2

More than high
school education
(%)
MVM use (%)
Ever smoke (%)

3

Ever alcohol (%)3
At least one APOE
e4 allele (%)
Diagnosed with
diabetes (%)
Diagnosed with
stroke (%)
Diagnosed with
heart attack (%)
Dietary intake3
Energy (kcal)

0.002

Protein (g) 4
Saturated fats (g)4
Monounsaturated
fats (g)4
Polyunsaturated (g)4
Ratio MUFAs to
SFSAs
Omega-3 fatty
acids(g)

Omega-6 fatty acids
(g)

<0.001

4

8.4± 3.1

9.1± 3.5

9.4± 3.1

9.7± 3.1

10± 3.05
<0.001

4

Cholesterol (mg)4
Fiber (g)

4

311± 160

297± 128

289± 165

266± 113

228± 97

<0.001

15± 3.7

18± 3.6

19± 4.1

21± 3.9

25± 6.8

<0.001
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Vitamin C (mg) 4

100± 47.9

122± 49.3

128± 46.8

147± 48.4

171± 61.6

<0.001

Folate (µg) 4

349± 88

395± 89.7

416± 87.2

445± 91.9

494± 108

<0.001

Vitamin B-6 (mg)4

1.6± 0.44

1.8± 0.41

1.8± 0.44

1.9± 0.41

2.1± 0.45

<0.001

Vitamin B-12 (µg) 4

5.7± 2.8

5.5± 2.2

5.7± 5.3

5.3± 2.3

4.9± 2.3

<0.021

2694± 569

2830± 506

2860± 533

2827± 520

3045± 471

0.421

1046± 349

1013± 297

951± 298

913± 278

902± 257

<0.001

2780± 530

3000± 507

3052±530

3235± 499

3466± 582

<0.001

Magnesium (mg)4

271± 50

293± 43

299± 47

319± 46

347± 56

<0.001

Zinc (mg)4

10.4± 2.7

10.7± 2.6

10.8± 3.2

10.8± 2.8

11.1± 3.03

0.135

Sodium (mg)4
Calcium (mg)

4

Potassium (mg) 4

1

p-values were obtained by using the Chi-square test for categorical variables and Analysis of Variance
(ANOVA) for continuous variables. DASH, Dietary Approaches to Stop Hypertension; MVM, multivitaminmineral supplement; BMI, Body Mass Index, CRP, C-reactive protein.
2
Means ± standard deviation (SD).
3
An ever smoker was defined as a subject who reported ever regularly smoking; an ever drinker was defined
as a subject who reported ever regularly drinking alcohol.
4
Energy-adjusted nutrient intakes per day.
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Table 3.4: Odds ratio of clinically relevant elevation of CRP (> 3.00 mg/L) by
quintile of the DASH diet score, Mediterranean diet score, and their respective food
items in the Cache County Memory (n = 1713).
Quintile of accordance score or food group

Quintile 1

p-linear
trend
Quintile 2

Quintile 3

Quintile 4

Quintile 5

DASH and components (multivariable adjusted)1
DASH

1.00 [reference]

0.98 (0.70- 1.3)

0.96 (0.68- 1.3)

0.78 (0.55- 1.0)

0.74 (0.531.05)

0.036

Whole grain

1.00 [reference]

1.10 (0.82- 1.5)

0.89 (0.64- 1.2)

0.74 (0.53- 1.0)

1.00 (0.74- 1.4)

0.348

Nuts and
legumes

1.00 [reference]

0.99 (0.71- 1.3)

0.86 (0.62- 1.2)

0.84 (0.60- 1.1)

0.72 (0.51- 1.0)

0.039

Fruits

1.00 [reference]

1.20 (0.88- 1.7)

0.98 (0.70- 1.3)

1.00 (0.71- 1.4)

0.89 (0.63- 1.2)

0.249

Vegetables

1.00 [reference]

0.81 (0.58- 1.2)

0.76 (0.55- 1.0)

0.70 (0.50- .97)

0.84 (0.60- 1.1)

0.197

Red and
processed
meat

1.00 [reference]

1.20 (0.86- 1.6)

1.00 (0.72- 1.4)

1.30 (0.98- 1.9)

1.20 (0.89- 1.7)

0.136

Low-fat
dairy

1.00 [reference]

1.00 (0.75- 1.4)

0.88 (0.63- 1.2)

1.20 (0.89- 1.6)

1.00 (0.77- 1.5)

0.366

Sweetened
beverages

1.00 [reference]

0.66 (0.48- 0.9)

0.70 (0.50- 97)

0.78 (0.56- 1.0)

0.89 (0.64- 1.2)

0.801

Sodium

1.00 [reference]

1.00 (0.74- 1.4)

1.20 (0.89- 1.4)

1.10 (0.79- 1.5)

1.10 (0.85- 1.6)

0.284

1.00 (0.72- 1.4)

0.73 (0.52- 1.0)

1.00 (0.74- 1.4)

0.73 (0.52- 1.0)

0.131

0.94 (0.68- 1.3)

0.81 (0.58- 1.1)

1.00 (0.76- 1.4)

0.91 (0.65- 1.2)

0.864

0.96 (0.69- 1.3)

0.74 (0.53- 1.0)

0.78 (0.56- 1.1)

0.75 (0.54- 1.0)

0.048

1.30 (0.98- 1.9)

0.91 (0.65- 1.2)

1.00 (0.76- 1.5)

0.88 (0.63- 1.2)

0.204

0.81 (0.58- 1.1)

0.80 (0.57- 1.1)

0.77 (0.55- 1.0)

0.86 (0.61- 1.2)

0.368

1.00 (0.73- 1.4)

1.00 (0.72- 1.3)

0.97 (0.70- 1.3)

0.93 (0.67- 1.3)

0.651

0.94 (0.67- 1.3)

1.10 (0.81- 1.6)

1.40 (0.99- 1.9)

1.30 (0.99- 1.9)

0.006

0.72 (0.52- 1.0)

0.88 (0.63- 1.2)

0.84 (0.60- 1.1)

1.00 (0.75- 1.4)

0.488

0.70 (0.50- 0.9)

0.94 (0.67- 1.3)

0.91 (0.65- 1.2)

0.55 (0.54- 1.0)

0.514

Mediterranean and components (multivariable adjusted) 1
MED
1.00 [reference]
All grains
1.00 [reference]
Legumes

1.00 [reference]

Fruits
1.00 [reference]
Vegetables

1.00 [reference]

Meat and
meat
products

1.00 [reference]

Full fat
dairy

1.00 [reference]

Fish
Ratio of
MUFAs to
SFA
1

1.00 [reference]
1.00 [reference]

The multivariable model included the following covariates: age, sex, BMI, education, APOE, history of
drinking and smoking, and history of diabetes, heart attack, and stroke.
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Table 3.5: Odds ratio of clinically relevant elevation of CRP (> 3.00 mg/L) by
quintile of the DASH diet score, Mediterranean diet score, and their respective food
items in the Cache County Memory (n= 914): overweight and obese participants
(BMI ≥25) only.
Quintile of accordance score or food group
Quintile 1

Quintile 2

Quintile 3

Quintile 4

Quintile 5

p-linear
trend

DASH and components (multivariable adjusted) 2
DASH

1.00 [reference]

1.05 (0.68- 1.6)

0.81 (0.68-1.2)

0.76 (0.49- 1.2)

0.65 (0.41-1.0)

0.027

Whole grain

1.00 [reference]

1.00 (0.772- 1.4)

0.84 (0.61-1.1)

0.72 (0.52- 1.0)

0.99 (0.72- 1.3)

0.383

Nuts and
legumes

1.00 [reference]

0.88 (0.57- 1.3)

0.74 (0.48-1.1)

0.55 (0.35- .88)

0.60 (0.38 - .94)

0.004

Fruits

1.00 [reference]

1.20 (0.80- 1.9)

0.94 (0.61-1.4)

0.79 (0.51- 1.2)

0.77 (0.49- 1.2)

0.067

Vegetables

1.00 [reference]

0.75 (0.48- 1.1)

0.61 (0.39-.97)

0.66 (0.42- 1.0)

0.68 (0.43- 1.0)

0.101

Red and
processed
meat

1.00 [reference]

1.40 (0.93- 2.3)

1.10 (0.73- 1.8)

1.50 (0.95- 2.4)

1.30 (0.84- 2.1)

0.329

Low-fat dairy

1.00 [reference]

0.96 (0.62- 1.5)

0.75 (0.47-1.2)

1.20 (0.81- 2.0)

0.98 (0.62- 1.5)

0.070

Sweetened
beverages

1.00 [reference]

0.65 (0.42- 1.0)

0.19 (0.50-1.2)

0.61 (0.61- 1.4)

0.70 (0.46- 1.0)

0.505

Sodium

1.00 [reference]

1.10 (0.71- 1.8)

1.20 (0.76- 1.9)

1.30 (0.86- 2.2)

1.20 (0.75- 1.9)

0.306

Mediterranean and components (multivariable adjusted) 1
Mediterranean

1.00 [reference]

0.78 (0.50- 1.2)

0.62 (0.40-.97)

0.73 (0.47- 1.1)

0.55 (0.35-0.89)

0.018

All grains

1.00 [reference]

0.89 (0.57- 1.3)

0.72 (0.46 1.1)

1.00 (0.66- 1.5)

0.78 (0.50- 1.1)

0.488

Legumes

1.00 [reference]

0.87 (0.56- 1.3)

0.75 (0.48-1.1)

0.74 (0.47- 1.1)

0.59 (0.38-0.93)

0.021

Fruits

1.00 [reference]

1.30 (0.86- 2.0)

0.85 (0.55-1.3)

0.89 (0.57- 1.4)

0.71 (0.45- 1.1)

Vegetables

1.00 [reference]

0.74 (0.48- 1.1)

0.65 (0.42-1.0)

0.74 (0.46- 1.1)

0.66 (0.42- 1.0)

0.131

Meat and
meat products

1.00 [reference]

0.86 (0.54- 1.3)

0.81 (0.52-1.2)

0.79 (0.50- 1.2)

0.86 (0.55- 1.3)

0.509

Full fat dairy

1.00 [reference]

0.94 (0.60- 1.4)

0.97 (0.61-1.5)

1.30 (0.85- 2.1)

1.40 (0.96- 2.3)

0.020

Fish

1.00 [reference]

0.83 (0.54- 1.3)

0.73 (0.46-1.1)

0.80 (0.52- 1.2)

0.90 (0.58- 1.4)

0.677

Ratio of
MUFAs to
SFA

1.00 [reference]

0.73 (0.47- 1.1)

0.76 (0.49-1.1)

0.88 (0.56- 1.3)

0.63 (0.40- 1.0)

0.172

1

0.049

The multivariable model included the following covariates: age, sex, education, BMI, APOE, history of drinking
and smoking, and history of diabetes, heart attack, and stroke.
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Table 3.6: Odds ratio of clinically relevant elevation of CRP (> 3.00 mg/L) by
quintile of the DASH diet score, Mediterranean diet score, and their respective food
items in the Cache County Memory (n = 914): non-overweight and non-obese
participants (BMI <25) only.
Quintile of accordance score or food group

Quintile 1

Quintile 2

DASH and components (multivariable adjusted)

Quintile 3

Quintile 4

Quintile 5

plinea
r
trend

1

DASH

1.00
[reference]

0.886 (0.51- 1.5)

1.10 (0.71-1.9)

0.808 (0.47- 1.3)

0.856 (0.52-1.4)

0.46

Whole grain

1.00
[reference]

1.20 (0.75- 2.0)

0.778 (0.46-1.3)

0.776 (0.46- 1.3)

1.05 (0.64- 1.7)

0.54

Nuts and
legumes

1.00
[reference]

1.16 (0.68- 1.9)

1.08 (0.65-1.8)

1.30 (0.84- 2.2)

1.30 (0.57 – 1.6)

0.83

Fruits

1.00
[reference]

1.20 (0.76- 2.1)

1.05 (0.62-1.8)

1.30 (0.82- 2.3)

1.05 (0.63- 1.7)

0.81

0.718 (0.43- 1.2)

0.925 (0.56- 1.5)

0.702 (0.41- 1.1)

0.990 (0.60- 1.6)

0.95

0.995 (0.60- 1.6)

0.844 (0.50- 1.3)

1.30 (0.82- 2.1)

1.20 (0.74- 1.9)

0.24

Low-fat dairy

1.00
[reference]
1.00
[reference]
1.00
[reference]

1.22 (0.73- 2.02)

1.07 (0.65-1.7)

1.20 (0.76- 2.0)

1.27 (0.76- 2.1)

0.37

Sweetened
beverages

1.00
[reference]

0.690 (0.42- 1.1)

0.58 (0.35-.96)

0.588 (0.35- 0.98)

1.20 (0.73- 1.9)

0.85

Sodium

1.00
[reference]

0.916 (0.55- 1.5)

1.30 (0.85- 2.1)

0.767 (0.46- 1.2)

1.20 (0.74- 1.9)

0.71

Vegetables
Red and
processed meat

Mediterranean and components (multivariable adjusted) 1
Mediterranean

1.00
[reference]

1.30 (0.80- 2.3)

0.878 (0.51-1.4)

1.40 (0.90- 2.4)

0.980 (0.58-1.6)

0.91

All grains

1.00
[reference]

0.968 (0.58- 1.6)

0.886 (0.52 1.4)

1.00 (0.62- 1.8)

1.07 (0.61- 1.7)

0.67

Legumes

1.00
[reference]
1.00
[reference]
1.00
[reference]
1.00
[reference]
1.00
[reference]
1.00
[reference]
1.00
[reference]

1.20 (0.72- 2.01)

0.681 (0.40-1.1)

0.832 (0.49- 1.3)

1.00 (0.60- 1.6)

0.52

1.4 (0.85- 2.4)

0.985 (0.58-1.6)

1.36 (0.808- 2.3)

1.10 (0.66- 1.8)

0.82

0.866 (0.52- 1.4)

1.05 (0.63- 1.7)

0.806 (0.48- 1.3)

1.12 (0.68- 1.8)

0.78

1.26 (0.78- 2.0)

1.20 (0.77- 2.0)

1.20 (0.77- 2.0)

1.02 (0.60- 1.7)

0.86

0.928 (0.55- 1.5)

1.44 (0.67-2.3)

1.50 (0.94- 2.6)

1.50 (0.80- 2.2)

0.05

0.601 (0.35- 1.0)

1.09 (0.66-1.8)

0.915 (0.55- 1.5)

1.26 (0.77- 2.0)

0.13

0.689 (0.40- 1.1)

1.20 (0.77- 2.0)

0.976 (0.58- 1.6)

0.95 (0.58- 1.5)

0..69

Fruits
Vegetables
Meat and meat
products
Full fat dairy
Fish
Ratio of
MUFAs to SFA

1

The multivariable model included the following covariates: age, sex, education, BMI, APOE, history of
drinking and smoking, and history of diabetes, heart attack, and stroke.
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Table 3.7: Spearman rank order correlation coefficients of the CRP and
Mediterranean Diet (MED) and the Dietary Approaches to Stop Hypertension
(DASH) scores with nutritional factors; Cache County Memory Study.
Nutrients
Total calorie intake
Protein
Carbohydrate
Fiber
Total sugar
Monosaccharide
Disaccharide
Total fats
Saturated fats
Monounsaturated
fats
Polyunsaturated
Cholesterol
Thiamine (B1)
Riboflavin (B2)
Niacin (B3)
Pyridoxine (B6)
Cobalamin (B12)
Ascorbic acid ©
Folate
Pantothenic acid
Calcium
Copper
Iron
Magnesium
Manganese
Phosphorus
Potassium
Selenium
Sodium
Zinc
Omega 3
Omega 6
Omega6:omega3
Alcohol
Caffeine

Correlation with MED
(p-values)
-0.071** (0.003)
0.026 (0.278)
0.421** (0.010)
0.639** (<0.001)
0.076** (0.004)
0.409** (<0.001)
0.272** (<0.001)
-0.424** (<0.001)
-0.612** (<0.001)

Correlation with DASH
(p-values)
0.000 (0.992)
0.014 (0.591)
0.063** (0.018)
0.589** (<0.001)
0.134** (<0.001)
0.488** (<0.001)
0.248** (<0.001)
-0.397** (<0.001)
-0.397** (<0.001)

Correlation with CRP
(p-values)
-0.015 (0.516)
0.049* (0.049)
-0.026 (0.298)
-0.063* (0.010**)
0.015 (0.556)
-0.030 (0.220)
0.006 (0.821)
-0.004 (0.870)
0.014 (0.579)

-0.279** (<0.001)

-0.182** (<0.001)

-0.015 (0.553)

0.193** (<0.001)
-0.228** (<0.001)
0.333** (<0.001)
-0.104** (<0.001)
0.263** (<0.001)
0.363** (<0.001)
-0.123** (<0.001)
0.435** (<0.001)
0.483** (<0.001)
0.113** (<0.001)
-0.179** (<0.001)
0.486** (<0.001)
0.355** (<0.001)
0.482** (<0.001)
0.561** (<0.001)
-0.029 (0.266)
0.413** (<0.001)
0.189** (<0.001)
0.028 (0.282)
0.052* (0.048)
0.268** (<0.001)
0.192** (<0.001)
-0.126** (<0.001)
0.096** (<0.001)
-0.107** (<0.001)

-0.003 (0.791)
-0.260** (<0.001)
0.292** (<0.001)
0.241** (<0.001)
0.044 (0.132)
0.324** (<0.001)
0.031 (0.218)
0.397** (<0.001)
0.387** (<0.001)
0.324** (<0.001)
0.318** (<0.001)
0.409** (<0.001)
0.208** (<0.001)
0.699** (<0.001)
0.576** (<0.001)
0.355** (<0.001)
0.598** (<0.001)
0.020(0.458)
-0.338** (<0.001)
0.139** (<0.001)
0.032 (0.462)
0.008 (0.757)
-0.040 (0.095)
0.018(0.498)
-0.172** (<0.001)

0.061* (0.013)
0.073** (0.003)
-0.018 (0.473)
0.018 (0.458)
-0.026 (0.300)
-0.015 (0.381)
-0.022 (0.226)
0.030 (0.681)
-0.035 (0.151)
0.026 (0.295)
-0.011 (0.464)
-0.020 (0.418)
-0.033 (0.177)
-0.026 (0.293)
-0.048 (0.051)
0.046 (0.062)
0.009 (0.713)
0.046 (0.063)
0.018 (0.459)
0.010 (0.671)
-0.048 (0.054)
-0.064** (0.010)
0.046 (0.395)
0.004 (0.861)
0.046 (0.063)

* Correlation is significant at the 0.05 level (2-tailed).
** Correlation is significant at the 0.01 level (2-tailed).
Note: Nutrients in which correlations are different between DASH, the Mediterranean Diet (MED), and Creactive protein (CRP).
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CHAPTER 4
ERYTHROCYTE MEMBRANE FATTY ACID COMPOSITION AND SYSTEMIC
INFLAMMATION IN THE CACHE COUNTY MEMORY STUDY
Abstract
Objective: To evaluate whether erythrocyte membrane fatty acids composition
(EMFAs) are associated with elevated plasma inflammatory C- reactive protein (CRP)
levels.
Design: 1844 men and women aged ≥65 years and older at the baseline
participated in the Cache County Memory Study (CCMS) and who resident of Cache
County, Utah. Fatty acid (FA) composition was measured in serum fatty acid methyl
esters and were examined in relation to high-sensitivity C-reactive protein.
Multivariable logistic regression models were used to estimate the risk of CRP
elevation (> 3.0mg/L) by increasing tertiles of EMFA, with control for potential
confounding factors.
Results: Risk of elevated CRP was increased in tertile 3 vs. tertile 1 of
palmitoleic acid, and nervonic acids, both monounsaturated fatty acids (MUFA),
(aOR=1.7 [95%CI 1.3-2.2], aOR=1.3 [95%CI 1.0-1.6], respectively), and dihomo-ylinolenic acid (DGLA), doco-sapentaenoic acid (DPA-6), docosahexaenoic acid
(DHA), all polyunsaturated fatty acids (PUFA), (aOR=1.5 [95%CI 1.2-1.9], aOR=1.3
[95%CI 1.0- 1.6], aOR=1.2 [95%CI 1.0- 1.6]), respectively. Conversely, risk of CRP
elevation was reduced in tertile 3 vs. tertile 1 of margaric acid, stearic acid, and
arachidic acid, all saturated fatty acids (SFA), (aOR=0.67 [95%CI 0.53- 0.89],
aOR=0.78 [95%CI 0.60- 0.99], and aOR=0.69 [95%CI 0.53- 0.88]), respectively.
These associations appeared stronger among women compared to men.
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Conclusions: Several erythrocyte membrane fatty acids were associated with
plasma CRP level, a marker of systemic inflammation. Unexpectedly, all associations
with reduced CRP level were among SFAs and all associations with increased CRP
level were among MUFAs and PUFAs.
Introduction
Alzheimer’s disease (AD) is a result of a neurodegenerative disease that
affects memory and thinking skills [1]. The prevalence of AD increases with age [1]
and the number of people with AD are growing due to physical inactivity, social
isolation, cardiovascular disease, diabetes, and diet [2]. Neuro- and vascular
inflammation may participate in the pathogenesis of AD [3] and markers of systemic
inflammation have been associated with AD [4, 5].
The underlying cause of systemic inflammation is unclear, but one
contributing factor may be dietary fatty acids (FAs) [6, 7]. Serum and plasma fatty
acid composition have been used as a biomarker of dietary fat quality [8-10]. FAs
may contribute to pro-inflammatory and anti-inflammatory mechanisms [11]. This
concept noticeably changes the understanding of the role of high intake of FAs in the
western diet and inflammation [12].
FA composition has been studied extensively in experimental, observational,
and human health studies [13-17]. FA composition of plasma also affects endogenous
elongation and desaturation catalyzed by several enzymes [18]. Omega-3 fatty acids
(n-3) and omega-6 FAs (n-6) make up a families of polyunsaturated fatty (PUFA)
acids that are essential in small quantities for health benefits because humans do not
have the mechanisms to synthesize them [19, 20]. While omega- 3 FAs come from
fish oils and flaxseed, canola, soy, perilla, and walnut oils [21], omega-6 FAs are
mainly found in vegetable oils including palm, soybean, rapeseed, and sunflower [22].
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Docosahexaenoic acid (DHA), a long chain omega-3 FA, is one of the major FAs in
the brain and has been hypothesized as anti-inflammatory. Animal and human trials
studies have shown that DHA is associated with decreased CRP concentration [23-25]
and other inflammatory biomarkers [26-36]. Concomitantly, omega-6 fatty acid
consumption is still a controversial issue, because human observational and
experimental studies suggest that n-6 fatty acids have both pro-inflammatory [37, 38]
and anti-inflammatory [39, 40] effects.
Given the increased interest in research in this area, FA composition of the
diet among elderly will be the focus of much discussion and debate. In the present
study, we examined the associations between erythrocyte membrane fatty acid
composition and systemic inflammation levels as indicated by level of inflammatory
CRP levels, using the data from the Cache County Memory Study (CCMS), also
taking several potential confounding variables into account.
Materials and Methods
Study participants
The Cache County Memory Study (CCMS) is a prospective cohort study with
participants aged ≥65 years and older at the baseline who were a resident of Cache
County, Utah. This population is largely non-Hispanic White, and the genetic makeup
is mostly from Northern European ancestry. The baseline interview included
information about demographic characteristics, health history, and family history of
dementia, use of medications, alcohol, tobacco, other lifestyle factors, and extensive
cognitive testing. Reassessments of participants were completed in subsequent years
with sample size at the Wave 2 examination in 1998-1999, of 3,411; Wave 3 in 20022003 with 2,344; and Wave 4 in 2005-2006 with 1,137. In Wave 3, a non-fasting
venous blood sample, diet, and cognitive data were collected from 2252 participants.
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Exclusions included 108 participants who did not complete a dietary assessment and
62 who did not provide a blood sample. Moreover, 203 participants were eliminated
from the analyses because the percent contribution of fatty acids in their erythrocyte
membranes could not be determined, and an additional 7 were excluded because they
provided implausible dietary intakes of <500 or >5000 kcal per day. The final sample
size was 1987. Participants provided signed consent to participate. The institutional
review boards of each collaborating site at Utah State University, Duke University
Medical Center, and The Johns Hopkins University approved the protocol of the
study. Details of the study protocols have been previously published [41].
Fatty acid assessment
Blood samples were drawn from the arm and were collected during the third
examination Wave in 2002. Erythrocytes (red blood cells, RBCs) were analyzed by
using the gas chromatography (GC) method. RBCs mixed with deionized water to
direct transesterification after the sample was thawed, and then centrifuged at 10,000
x g for 5 minutes [42]. The resulting product was mixed with 1.9 ml of a solution
containing 1.7 ml methanol, 100 ul acetyl chloride, and 100 ul internal standards. The
tubes were capped and then heated to 100 ul for 60 minutes. After cooling the tubes,
0.75 ml of hexane was added and the tubes were vortexed for 30 seconds. A
Shimadzu GC-2010 with a flame ionization detector was used to analyze fatty acid
methyl esters [43]. The amount of analyzed EMFA was expressed as a percentage.
The 23 EMFAs assayed are listed in Table 4.2.
CRP assessment
Non-fasting blood samples were collected and assayed for high- sensitivity Creactive protein (hs-CRP) from 2185 participants in Wave 3 at McKay Dee
Laboratory Hospital, Ogden, UT. A Dade Behring BNII (BN for Behring
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Nephelometer) was used for measurement, considered as a gold standard for these
tests in the laboratory industry [44]. Many large reference studies refer to the Dade
BNII assay that uses particle enhanced immunonephelometry. Dade was one of the
first vendors to receive FDA approval for cardiac marker claims for their sensitive
CRP assay [45]. The method uses polystyrene particles coated with mouse
monoclonal antibodies to CRP that are agglutinated when mixed with samples
containing CRP [46]. The intensity of the scattered light in the nephelometer depends
on the CRP content of the sample and, therefore, the CRP concentration. Typically,
expected values for healthy individuals are found to be < 3.0 mg/L, or < 0.3 mg/dL
[45]. The actually measuring range is determined by the lower limit of the reference
curve and depends on the concentration of the standard used. The typical limit of
detection for the method was 0.175 mg/L or 0.0175 mg/dL. The upper level of
detection was typically 1150 mg/L or 150 mg/dL. We clinically defined elevated CRP
as values >3.0 mg/L [45].
Statistical Analyses
Baseline characteristics were analyzed and presented by CRP levels. We
reported selected sociodemographic variables, medical, and behavior characteristic of
the participants. Percent composition of EMFAs was categorized into tertiles of the
cohort’s distribution of each EMFA.
Analysis of Variance (ANOVA) was used to test whether there were
statistically significant differences between the means of EMFAs in elevated vs.
normal CRP levels. Potential confounding variables including body mass index (BMI)
(kg/m2, continuous), smoking (never, former, current), age in years (65-74, 75-84,
85+), education levels (less than high school, more than high school), and gender
(male, female) were evaluated. We estimated the odds ratio (ORs) and 95% confident
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intervals (CIs) for CRP elevation by increasing tertiles of EMFA levels using logistic
regression models while controlling for potential covariates. Gender was found in
previous studies to be associated with habitual intake of fatty acids [47, 48] and it also
appeared to differ the ability to synthesize fatty acids [49, 50], thus models for
adjusted odds ratios included gender as a covariate and analyses were stratified by
gender to examine effect modification by gender. Participants with no dementia (n =
154) were excluded from all analysis. Statistical analysis was performed using
software package SPSS version 22. Reported p-values are two-sided, and the type I
error rate for statistical significance was 0.05.
Results
Demographic characteristics are presented in Table 4.1. The average age was
73 ± 5.5 years. Elevated CRP levels were found more often in women, the less
educated, current smokers, and those with a history of stroke and was associated with
higher BMI. Apolipoprotein (APOE) ε4 allele was associated with lower CRP levels.
Table 4.2 shows the relative percentage of the measured 23 EMFAs. Saturated
fatty acids (SFAs) accounted for 47% of all identified fatty acids, trans-fat (TFA)
accounted 0.43%, and monounsaturated fatty acid (MUFA) accounted 8.3%, and
PUFAs accounted for 16.5%; the PUFAs included 4.98% omega-6 and 3.46% from
omega-3. All EMFAs accounted for 78.39%, and the remaining 18.8% was accounted
for plasmalogen phospholipids that are comportment of the red blood cell membrane.
In the one-way ANOVA analyses of mean CRP by tertile (T) of EMFAs
(Table 4.3), higher mean CRP was associated with tertile 3 (T3) vs. tertile 1 (T1) of
palmitic (p= 0.053), palmitoleic acid (p= <0.001), eicosadienoic acid (p= <0.005),
dihomo-y-linolenic acid (DGLA) (p= <0.009), and docosapentaenoic acid (DPA-6)
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(p= <0.002). Lower mean CRP levels were found with T3 vs. T1 of margaric acid (p=
<0.001), arachidic acid (p= 0.001), and linoleic (p=0.05).
Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to
estimate the relative risk for elevated plasma CRP across the EMFA tertiles, are
shown in Table 4.4. In a multiple logistic regression analysis that controlled for BMI,
smoking, age, education, and gender shown in Table 4.4, the estimated relative risk
(adjusted OR (aOR) and 95% confidence intervals (CIs)) for having elevated CRP
levels in T3 vs. T1 of total EMFA level was increased for palmitoleic acid (aOR=1.7
[95%CI 1.3-2.2]), nervonic acid (aOR=1.3 [95%CI 1.0-1.6]), DGLA (aOR=1.5
[95%CI 1.2-1.9]), DPA-6 (aOR=0.1.3 [95%CI 1.0- 1.6]), and Docosahexaenoic acid
(DHA) (aOR=1.2 [95%CI 1.0- 1.6]). In contrast, the estimated relative risk for having
elevated CRP levels was decreased in T3 vs. T1 of margaric acid (aOR=0.67 [95%CI
0.53- 0.89]), stearic acid (aOR=0.78 [95%CI 0.60- 0.99]), and arachidic acid
(aOR=0.69 [95%CI 0.53- 0.88]).
When the data were stratified by gender, palmitic acid, palmitoleic acid, and
DGLA were more strongly associated with increased risk of elevated CRP risk among
women (aOR=1.5 [95%CI 1.1-2.1]), (aOR=1.9 [95%CI 1.3- 2.7]), and (aOR=1.5
[95%CI 1.1-2.2]), respectively, compared to men. Inversely, margaric acid and stearic
acid were more strongly associated with reduced risk of elevated CRP in women
(aOR=0.57 [95%CI 0.42- 0.80]) and (aOR=0.67 [95%CI 0.48- 0.93]), respectively,
than among men. Lastly, arachidic acid was associated with decreased risk of
elevation CRP (aOR=0.66 [95%CI 0.44- 0.97]) in both men and (aOR=0.67 [95%CI
0.49- 0.93]) in women.
While the associations between erythrocytes fatty acids and risk of elevated
CRP appeared to be stronger in women and not among men, there was not a
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significant multiplicative interaction between these erythrocytes fatty acids and CRP
elevation ( p > 0.05).
Discussion
This study provides evidence that erythrocyte membrane fatty acids
composition influence the risk of systemic inflammation among participants in the
CCMS. Higher levels of palmitoleic acid and nervonic acid both MUFAs, and
dihomo-y-linolenic acid, DPA-6, and DHA, all PUFAs, were associated with
increased risk of elevation of CRP. Increased levels of margaric acid, stearic acid, and
arachidic acid, all saturated FAs, were associated with a lower risk of CRP elevation.
None of the other erythrocyte membrane FAs were significantly associated with CRP.
These associations were found to be stronger for women vs. men. High level of
arachidic acid an SFA was associated with a reduced the risk of elevated CRP among
both men and women.
The results of a higher composition of erythrocyte membrane saturated fatty
acids and lower CRP risk are consistent with other studies of margaric acid [51-53],
but to our knowledge, no other study has examined the association between arachidic
acid and inflammatory biomarkers. Until now, the mechanisms of margaric acid as an
anti-inflammatory have not been well understood [51], and one observational study
reported that the proportion of margaric acid was correlated negatively with
inflammatory biomarkers in men and women [52]. Similarly, Wang and Fernandes
demonstrated that margaric acid was associated with lower CRP levels among morbid
obese patients [51] and adolescents [54].
Findings from studies testing for the association between inflammatory
biomarkers and stearic acid have also been inconsistent. In human feeding trials, high
levels of stearic acid up-regulates interleukin-6 (IL-6) [55, 56], which is the primary
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regulatory agent for CRP [57, 58]. In relevant human tissue culture studies, it was
found that high level of stearic acid increased intercellular adhesion molecule (ICAM1) expression, which activates inflammation pathways [59]. Similarly, thioglycollateelicited mouse peritoneal macrophages (MPMs) were collected from knockout mice
and showed that a high level of stearic acid up regulates pro-inflammatory signals
causing ER stress–mediated apoptosis [60]. With this in mind, many potentially
therapeutic and anti-inflammatory effects have also been proposed for stearic acid.
Stearic acid attenuated cholestasis-induced liver injury in rats and had an antiinflammatory effect by reducing Alpha-smooth muscle actin (alpha-SMA); alphaSMA is the actin isoform that predominates in vascular smooth-muscle cells and plays
an important role in fibrogenesis [61],which produces fibrogenic cytokine leading to a
transforming of growth factor beta-1 (TGF-β1) production [62]. Moreover, a
copolymer of fatty acids, composed of oleic acid, palmitic acid and stearic acid, called
Ara 3000 beta reduced osteoarthritis symptoms due to the FAs anti-inflammatory
effects in human [63] and dogs [64].
Findings from studies associating palmitoleic acid and inflammation have also
been inconsistent. Previously, a serum FA pattern with high palmitoleic acid was
linked to elevated CRP among Swedish elderly [65]. Two clinical trials reported that
palmitoleic acid composition elevated inflammatory biomarkers [66] leading to an
increase in the risk of metabolic syndrome [66]. The same result was found when diet
and a low-density lipoprotein (LDL) receptor genotype were examined on
macrophage foam cell formation within the peritoneal cavities of mice [67]. In a
human adipocyte cell culture, palmitoleic acid induced pro-inflammatory effect by
activating a Toll-like receptor-4/nuclear factor-kB (TLR-4/NF-kB) pathway [68]. In
contrast, a prospective cohort study of 86 ambulatory patients and 45 healthy subjects
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reported that palmitoleic acid was not associated with inflammation [69]. Until now,
no study to our knowledge has investigated the effect of monounsaturated nervonic
acid on plasma CRP level or any other inflammatory biomarkers.
Our results are not consistent with the reported anti-inflammatory effect of
DGLA which is an omega-6 FA [39, 40, 70]. Metabolic studies reported that gammalinolenic acid (GLA) fatty acids convert to dihomo-γ-linolenic acid (DGLA) by
competing with arachidonic acid (AA) to express an anti-inflammatory effect in cells
by inhibiting enzymes that come from the breakdown of AA accumulation in cells
[71, 72]. This inhibition reduces prostaglandin cyclooxygenase-2 (COX-2),
lipoxygenase (LOX), and leukotrienes [73] causing a reduction of inflammatory
molecules [74, 75] in lung function, autoimmune conditions, cardiovascular disease,
and diabetes [71, 72].
Our results confirmed the limited evidence that investigated Docosapentaenoic
acid n6 (DPA-6) fatty acids [76, 77]. In rats, a high administration of DHA lowered
the conversion of DPA-6 to arachidonic acid (AA) [77].
There is literature on using plasma and erythrocyte levels to reflect the
measured dietary intake of fatty acids [43, 78, 79]. Due to the different structure and
function properties of plasma and erythrocyte membrane, it is not surprising that level
and the relevant composition of the FA is different between these two compartments
of the blood [80]. Plasma measurement is considered the most immediate biomarker
for each individual fatty acid [81, 82] because it reflects the dietary intake of the
previous hours (triglyceride) or the past few days (cholesterol ester and phospholipid
fatty acids). Erythrocyte measures of fatty acids are of interest for fatty acid analysis
[82]. The half-life of erythrocytes has been estimated to be 120 days, which is much
longer than that of plasma lipoproteins. Thus, erythrocytes reflect fat intake over
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longer term [83, 84]. Sun et al. reported moderate-to-strong correlations between the
dietary intake of n-3 fatty acids from marine origin and trans fatty acids and their
levels in erythrocytes and plasma and the correlations with dietary intakes were
stronger for erythrocytes than for plasma [85]. Because of these differences in long
term stability FA analysis of erythrocytes is more suitable to test the association
between long term FAs intake and inflammatory biomarkers [27, 86].
Regarding fatty acid composition in human subjects, Petersson et al. [65]
reviewed compilation of a studies on total plasma fatty acid composition in the
elderly, and among the fatty acids analyzed, linoleic acid, oleic acid, and palmitic acid
had the highest proportions, respectively. In the present study, palmitic acid and
stearic acid had the highest proportions, respectively. Other studies with elderly
showed a similar pattern compared to the results found in the current work, with high
amounts of SFA and low amount of PUFA [87, 88] in the erythrocyte membrane.
The association between plasma CRP levels and DHA composition is unusual
and requires further investigation. The literature on the association between DHA and
high risk of CRP bring mixed results. Over the last decade, many biochemical and
observational studies have suggested that DHA works as anti-inflammatory, which is
not in line with our results [89-92]. Many observational studies reported that high
consumption of omega-3 including DHA did not affect CRP levels among type 2
diabetics, healthy individuals, and elderly [93-97].

Recently, a study of double

blinded randomized trial of 2425 patients found that there was no effect of high
consumption of EPA-DHA on CRP levels [98]. Ours is the first study to our
knowledge that showed evidence of increased CRP risk among elderly participants
who have higher levels of erythrocyte DHA. Biochemical studies have suggested that
FAs compete for the same set of enzymes to form a long chain of PUFA derivatives
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[13, 18, 99, 100]. Despite this finding, more studies are needed to confirm and explain
the association between total DHA fatty acid composition and CRP levels,
particularly in the elderly.
In our analysis, we observed CRP levels were higher in women compared with
men. Piéroni et al. reported that CRP values were higher among women than men
when they measured CRP levels in healthy adults in Paris [101] and Rifai and Ridker
reported the same results when they measured CRP levels in healthy men and women
in the United States [102]. The relationship between gender and erythrocyte
membrane fatty acids needs further work, but it appears that erythrocyte membrane
fatty acids have a greater effect on CRP levels in women compared to men.
To our knowledge, this is the first study that examines the multiplicative interaction between erythrocyte fatty acids and risk of elevated CRP. Thus, further studies
are needed to confirm our results.
Our study has several key strengths: the study is population-based of the
elderly and relatively robust against selection bias because of higher participation
rates. EMFA assays also reflect the combination of dietary factors, metabolic and
genetic effects. CRP was used to assess low grade systemic inflammation because a
large amount of work using CRP has been done over the last two decades to assess
inflammation levels in humans. Thus, our results are more valuable and reliable thru
the use of CRP levels and a large number of study participants. The results of our
analysis must be considered in light of its limitations chiefly that the analysis was
cross-sectional as the Cache County Memory Study did not have a collection of blood
for CRP at the Wave 1 baseline examination that would allow for a prospective study
of CRP levels and subsequent outcomes.
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In this Cache County cohort of elderly participants, increasing levels of
palmitoleic acid and nervonic acid, both MUFAs, and dihomo-y-linolenic acid,
docosapentaenoic acid n6, docosahexaenoic acid, all PUFAs, were associated with
elevates CRP. Conversely, increasing levels of margaric acid, stearic acid, and
arachidic acid, all SFAs, were related to decreased CRP. The relationship between
CRP and another FA was not significant even after controlling the covariates.
In summary, our results suggest that the higher SFA composition of EMFAs
including margaric, stearic, and arachidic fatty acids are anti-inflammatory.
Concomitantly, our finding suggests that higher levels of the MUFAs palmitoleic and
nervonic and the PUFAs DGLA, DPA-6 and DHA are pro-inflammatory. Further
prospective and experimental studies should be conducted to gain a better
understanding of the controversies regarding dietary intake of FAs, cell membrane FA
composition and systemic inflammation.
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Table 4.1: Demographic characteristics by level of C- reactive protein (CRP) in the
Cache County Study on Memory, Health and Aging in Wave 3 (N= 2031).
Characteristic

Plasma CRP composition (mg/L)
<3.0 (mg/L)
>3.0 (mg/L)

p-value1

Gender
-

Male (%)

63.5

36.5

-

Female (%)

54.9

45.1

<0.001

-

Less than high school education (%)

54.9

61.8

-

More than high school education (%)

45.1

38.2

Age in years (SD)2

73.0± 5.4

73.1± 5.5

0.480

Body mass index (kg/m2) (SD) 2

25.9± 4.0

27.2± 4.4

<0.001

Current smoke (%)3

1.4

2.9

0.042

Current alcohol (%)3

4.4

3.7

0.442

At least one APOE e4 allele (%)

35.8

26.2

<0.001

Diagnosed with diabetes (%)

17.4

20.0

0.078

Diagnosed with stroke (%)

7.3

10.1

0.018

Diagnosed with heart attack (%)

14.4

16.0

0.178

0.001

p-values were obtained by using the Chi-square test for CRP (low vs. high) for categorical variables and
One-way analysis of variance (ANOVA) for continuous variables.
1

2
3

Means ± standard deviation (SD).

A current smoker was defined as a subject who reported currently smoking; a current drinker was defined
as a subject who reported currently drinking alcohol.
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Table 4.2: Median erythrocyte membrane fatty acid (FA) (range) percent composition in serum in the Cache County Memory Study (n=
1835).
RBC FAs1

Type2

Pentadecanoic acid

SFA

Palmitic acid

SFA

Margaric acid

SFA

Molecular Formula
C15H30O2

C:D3
15:0

C16H32O2

16:0

C17H34O2

17:0

C18H36O2

18:0

Percent concentration
0.14 (0.04- 0.59)
23.3 (7.75- 36.21)
0.40 (0.12- 1.9)

Food Sources

References

Cow milk

[103]

Meat, including poultry, beef and game meats

[104]

Cow milk

[105]

Meat, poultry, fish, grain products, and milk/
Stearic acid

SFA

Arachidic acid

SFA

Behenic acid
Lignoceric acid

C20H40O2

20:0

SFA

C22H44O2

22:0

SFA

C24H48O2

24:0

MUFA

C16H30O2

16:1

MUFA

C18H34O2

19.6 (6.3- 33.3)

0.31 (0.08- 1.32)
1.1 (0.06- 3.9)
2.6 (0.11- 6.8)

[56]
milk products, cocoa butter, lard, and butter
Peanut oil (1.1%–1.7%) and corn oil

[106]

Peanut oil and peanut butter

[107]

Peanut oil

[106]

Animal oils, vegetable oils, marine oils,
Palmitoleic acid

(Omega 7)

0.11 (0.01- 0.59)

[108]
macadamia oil, and sea buckthorn oil
Vegetable oils such as olive, canola and

Oleic acid (%)
Gondoic acid
(Omega 9)
Erucic acid
(Omega 9)
Nervonic acid

MUFA
MUFA
MUFA

18:1

C20H38O2

20:1

C22H42O2

22:1

C24H46O2

24:1

0.42 (0.07- 1.72)

3.4 (0.09- 6.7)
2.8 (0.23- 4.2)
1.3 (0.28- 3.9)

[109]
sunflower, nut oils, meat, poultry, and cheese
Plant oils and nuts

[110]

Wallflower seed and mustered oil

[111]

Salmon, yellow mustard seed, and flaxseed

[112]
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Vaccenic acid

TFA

C18H34O2

18:1

PUFA

C18H32O2

18:2

PUFA

C18H30O2

PUFA

C20H36O2

20:2

C18H30O2

20:3

C20H32O2

20:4

PUFA

C20H30O2

20:5

PUFA

C22H36O2

22:4

PUFA

C22 H34 O 2

22:5

PUFA

C22 H34 O 2

22:5

PUFA

C22H32O2

22:6

0.43 (0.07- 0.89)

Meat and dairy fat such as milk, and buttr

[113]

Vegetable oils such as flaxseed (linseed) oil,
1104Linoleic acid

4.7 (1.17- 8.0)

[114]
canola (rapeseed) oil, and soybean oil.
Fish oils, flaxseed oil, and in canola, soy, perilla,

a-Linolenic acid
(ALA)
Eicosadienoic acid
(Omega 6)
Dihomo-y-linolenic
acid (DGLA)
(Omega 6)
Arachidonic acid
Eicosapentaenoic acid
(EPA)
(Omega 3)
Adrenic acid
(Omega 6)
Docosapentaenoic
acid n3 (DPA-3)
(Omega 3)
Docosapentaenoic
acid n6 (DPA-6)
(Omega 6)
Docosahexaenoic acid
(DHA)
(Omega 3)

PUFA

0.06 (0.01- 0.37)

0.11 (0.02- 0.63)
0.62 (0.14- 1.41)
6.6 (1.57- 10.17)
0.18 (0.03- 1.2)
1.4 (0.43- 2.3)

[21]
and walnut oils
Poultry, nuts, and cereals

[115]

Animal-source foods, such as meat, egg, fish.

[116]

Chicken, eggs, and beef

[117]

Fish oil, cod liver, herring, mackerel, and sardine

[118]

Poultry, nuts, cereals, and whole grain breads

[115]

Bearded
1.0 (0.17- 2.0)

0.28 (0.05- 0.76)

1.6 (0.22- 5.3)

seal

Native),

fish

oil,
[119]

menhaden, salmon, and sardine
Fish and fish oils

[119]

Fish oils, eggs and meats

[118]

FA are presented as percentage of FA analyzed.
SFA, saturated fatty acids; MUFA, monounsaturated fatty acids; TFA, trans fatty acids; PUFA, polyunsaturated fatty acids.
3
Number of carbon atoms: number of double bonds.
2

(Alaska
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PUFA
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Table 4.3: Mean of plasma biomarker concentration of C-reactive protein (CRP)
across tertiles of erythrocyte membrane fatty acid in the Cache County Memory
Study.
Mean plasma CRP concentration (mg/L) 2
by tertiles (T1-T3) of erythrocyte membrane fatty
acid
T1
T2
T3

RBC Fatty acids

Type1

Pentadecanoic acid

SFA

4.8± 7.2

4.8± 7.2

4.2± 7.6

0.125

Palmitic acid

SFA

4.6± 7.3

4.2± 6.9

5.1± 8.2

0.053

Margaric acid

SFA

5.2± 7.6

4.5± 6.9

4.1± 7.9

<0.001

Stearic acid

SFA

4.8± 7.4

4.7± 7.3

4.2± 7.7

0.105

Arachidic acid

SFA

4.8± 7.0

5.0± 8.4

4.0± 6.9

0.001

Behenic acid

SFA

4.6± 7.0

4.9± 8.4

4.2± 6.9

0.244

Lignoceric acid

SFA

4.6± 8.0

4.9± 7.2

4.3± 7.3

0.103

Palmitoleic acid

MUFA

4.2± 8.2

4.4± 6.5

5.1± 7.7

<0.001

Oleic acid

MUFA

4.7± 7.1

4.5± 7.3

4.5± 8.1

0.184

Gondoic acid

MUFA

4.4± 6.5

4.8± 8.2

4.6± 7.7

0.266

Erucic acid

MUFA

4.1± 6.3

4.8± 8.3

4.9± 7.7

0.052

Nervonic acid

MUFA

4.4± 8.0

4.2± 5.6

5.1± 8.5

0.149

Vaccenic acid

TFA

4.5± 7.3

4.7± 7.6

4.6± 7.6

0.426

Linoleic acid

PUFA

5.1± 8.3

4.4± 8.1

4.2± 5.7

0.050

a-Linolenic acid (ALA)

PUFA

4.7± 8.0

4.8± 8.2

4.2± 6.1

0.791

Eicosadienoic acid

PUFA

4.9± 8.1

3.8± 6.0

5.1± 8.2

0.005

Dihomo-y-linolenic acid (DGLA)

PUFA

4.6± 8.2

4.5± 7.2

4.7± 6.9

0.009

Arachidonic acid

PUFA

3.9± 5.3

4.9± 9.0

4.9± 7.6

0.127

Eicosapentaenoic acid (EPA)

PUFA

5.3± 9.3

4.4± 6.5

4.1± 6.2

0.900

Adrenic acid

PUFA

4.1± 6.3

4.8± 7.6

4.9± 8.3

0.357

Docosapentaenoic acid (DPA-3)

PUFA

5.0± 8.0

4.4± 6.8

4.3± 7.6

0.090

Docosapentaenoic acid (DPA-6)

PUFA

4.3± 7.3

4.2± 6.7

5.3± 8.0

0.002

Docosahexaenoic acid (DHA)

PUFA

4.7± 8.6

4.7± 7.6

4.3± 6.0

0.386

SFA, saturated fatty acids; MUFA, monounsaturated fatty acids; TFA, trans fatty acids; PUFA,
polyunsaturated fatty acids.
2 Means± standard deviation (SD)
3
p-values were obtained by using Analysis of Variance (ANOVA)

p-value3
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Table 4.4: Odds ratio of clinically relevant elevation of CRP (> 3.00 mg/L) by tertiles
of erythrocyte membrane fatty acid in the Cache County Memory (n= 1844).
RBC Fatty acids

Type1

T1

T2

T3

P-linear
trend2

Pentadecanoic acid

SFA

1.00 [reference]

1.2 (0.97- 1.5)

1.0 (0.85- 1.4)

0.497

Palmitic acid

SFA

1.00 [reference]

0.90 (0.70- 1.1)

1.2 (0.95- 1.6)

0.121

Margaric acid

SFA

1.00 [reference]

0.92 (0.73- 1.2)

0.68 (0.53- 0.89)

0.004

Stearic acid

SFA

1.00 [reference]

0.90 (0.72- 1.1)

0.78 (0.60- 0.99)

0.040

Arachidic acid

SFA

1.00 [reference]

0.89 (0.70- 1.1)

0.69 (0.53- 0.88)

0.002

Behenic acid

SFA

1.00 [reference]

1.0 (0.81- 1.3)

0.89 (0.70- 1.1)

0.294

Lignoceric acid

SFA

1.00 [reference]

1.2 (0.98- 1.6)

1.0 (0.81- 1.3)

0.840

Palmitoleic acid

MUFA

1.00 [reference]

1.3 (0.98- 1.6)

1.7 (1.3- 2.2)

<0.001

Oleic acid

MUFA

1.00 [reference]

0.98 (0.77- 1.2)

0.80 (0.63- 1.0)

0.089

Gondoic acid

MUFA

1.00 [reference]

1.0 (0.79- 1.2)

0.90 (0.70- 1.1)

0.414

Erucic acid

MUFA

1.00 [reference]

1.1 (0.85- 1.3)

1.0 (0.82- 1.3)

0.748

Nervonic acid

MUFA

1.00 [reference]

1.1 (0.86- 1.4)

1.3 (1.0- 1.6)

0.038

Vaccenic acid

TFA

1.00 [reference]

1.1 (0.89- 1.4)

1.1 (0.83- 1.3)

0.606

Linoleic acid

PUFA

1.00 [reference]

0.80 (0.63- 1.0)

1.0 (0.81- 1.3)

0.695

a-Linolenic acid (ALA)

PUFA

1.00 [reference]

1.1 (0.90- 1.5)

1.1 (0.87- 1.4)

0.415

Eicosadienoic acid

PUFA

1.00 [reference]

0.83 (0.65- 1.0)

1.1 (0.86- 1.3)

0.435

Dihomo-y-linolenic acid (DGLA)

PUFA

1.00 [reference]

1.3 (0.99- 1.6)

1.5 (1.2- 1.9)

0.001

Arachidonic acid

PUFA

1.00 [reference]

1.1 (0.84- 1.3)

1.0 (0.79- 1.2)

0.984

Eicosapentaenoic acid (EPA)

PUFA

1.00 [reference]

1.2 (0.96- 1.5)

1.1 (0.85- 1.4)

0.510

Adrenic acid

PUFA

1.00 [reference]

1.1 (0.89- 1.4)

0.98 (0.76- 1.2)

0.818

Docosapentaenoic acid n3 (DPA-3)

PUFA

1.00 [reference]

0.90 (0.70- 1.1)

0.95 (0.75- 1.2)

0.681

Docosapentaenoic acid n6 (DPA-6)

PUFA

1.00 [reference]

0.99 (0.77- 1.2)

1.3 (1.0- 1.6)

0.026

Docosahexaenoic acid (DHA)

PUFA

1.00 [reference]

1.4 (1.1- 1.8)

1.2 (1.0- 1.6)

0.039
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Total n-3 fatty acids3

PUFA

1.00 [reference]

1.16 (0.91- 1.5)

1.06 (0.84- 1.4)

0.605

Total n-6 fatty acids3

PUFA

1.00 [reference]

0.90 (0.70- 1.1)

1.02 (0.80- 1.30)

0.810

Total n-6/ n-3 fatty acids

PUFA

1.00 [reference]

0.95 (0.74- 1.2)

1.06 (0.82- 1.4)

0.640

1

SFA, saturated fatty acids; MUFA, monounsaturated fatty acids; TFA, trans fatty acids; PUFA,
polyunsaturated fatty acids.
2

Values are 95% Confidence Interval in parentheses (all such values). Adjusted variables in multivariate
models included body mass index (kg/m2, continuous), smoking (never, former, current), age, in years (6574, 75-84, 85+), education levels (less than high school, high school, more than high school), and gender
(male, female).
3

Total n-3 fatty acids included ALA, EPA, DPA-3, and DHA; Total n-6 fatty acids included linoleic acid,
eicosadienoic acid, DGLA, adrenic, and DPA-6.
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Table 4.5: Odds ratio of clinically relevant elevation of CRP (> 3.00 mg/L) by tertiles of erythrocyte membrane fatty acid in the Cache
County Memory stratified by gender.
Male
RBC Fatty acids

Female

Type1
T1
SFA

Palmitic acid

SFA

Margaric acid

SFA

Stearic acid

SFA

Arachidic acid

SFA

Behenic acid

SFA

Lignoceric acid

SFA

Palmitoleic acid

MUFA

Oleic acid

MUFA

Gondoic acid

MUFA

Erucic acid

MUFA

Nervonic acid

MUFA

Vaccenic acid

TFA

Linoleic acid

PUFA

a-Linolenic acid (ALA)

PUFA

Eicosadienoic acid

PUFA

Dihomo-y-linolenic acid
(DGLA)

PUFA

Arachidonic acid

PUFA

Eicosapentaenoic acid (EPA)

PUFA

Adrenic acid

PUFA

1.00
[reference]
1.00
[reference]
1.00
[reference]
1.00
[reference]
1.00
[reference]
1.00
[reference]
1.00
[reference]
1.00
[reference]
1.00
[reference]
1.00
[reference]
1.00
[reference]
1.00
[reference]
1.00
[reference]
1.00
[reference]
1.00
[reference]
1.00
[reference]
1.00
[reference]
1.00
[reference]
1.00
[reference]
1.00
[reference]

T3

0.93 (0.63- 1.3)

1.00 (0.70- 1.4)

0.209

0.66 (0.45- 0.95)

0.88 (0.61- 1.2)

0.459

1.30 (0.85- 1.8)

0.91 (0.61- 1.3)

0.557

1.10 (0.72- 1.5)

0.92 (0.62- 1.3)

0.631

0.76 (0.52- 1.1)

0.66 (0.44- 0.97)

0.035

0.90 (0.62- 1.3)

0.89 (0.62- 1.3)

0.571

1.00 (0.69- 1.5)

0.97 (0.67- 1.4)

0.883

1.20 (0.83- 1.7)

1.30 (0.92- 2.0)

0.101

0.95 (0.65- 1.3)

0.78 (0.53- 1.1)

0.222

0.93 (0.64- 1.3)

0.99 (0.68- 1.4)

0.980

1.10 (0.72- 1.5)

1.30 (0.90- 1.9)

0.140

0.79 (0.54- 1.2)

1.10 (0.79- 1.6)

0.480

1.10 (0.76- 1.6)

1.00 (0.70- 1.4)

0.893

0.78 (0.52- 1.1)

1.10 (0.71- 1.5)

0.701

1.30 (0.95- 1.9)

1.10 (0.76- 1.6)

0.488

0.57 (0.38- 0.84)

0.95 (0.65- 1.3)

0.791

1.20 (0.83- 1.7)

1.30 (0.91- 1.9)

0.128

1.10 (0.73- 1.5)

1.20 (0.83- 1.7)

0.307

1. 20 (0.96- 1.5)

1.10 (0.85- 1.4)

0.510

1.10 (0.75- 1.6)

1.10 (0.76- 1.6)

0.566

T1
1.00
[reference]
1.00
[reference]
1.00
[reference]
1.00
[reference]
1.00
[reference]
1.00
[reference]
1.00
[reference]
1.00
[reference]
1.00
[reference]
1.00
[reference]
1.00
[reference]
1.00
[reference]
1.00
[reference]
1.00
[reference]
1.00
[reference]
1.00
[reference]
1.00
[reference]
1.00
[reference]
1.00
[reference]
1.00
[reference]

T2

T3

P-linear
trend2

1.40 (1.0- 2.0)

1.10 (0.79- 1.5)

0.520

1.10 (0.81- 1.5)

1.50 (1.1- 2.1)

0.015

0.78 (0.57- 1.0)

0.57 (0.42- 0.80)

0.001

0.82 (0.60- 1.1)

0.67 (0.48- 0.93)

0.019

0.98 (0.71- 1.3)

0.67 (0.49- 0.93)

0.021

1.10 (0.80- 1.5)

0.85 (0.61- 1.2)

0.375

1.40 (1.0- 1.9)

1.00(0.76- 1.4)

0.717

1.30 (0.96- 1.9)

1.90 (1.3- 2.7)

<0.001

0.98 (0.71- 1.3)

0.83 (0.60- 1.1)

0.270

1.10 (0.79- 1.5)

0.84 (0.61- 1.1)

0.300

1.10 (0.79- 1.5)

0.89 (0.64- 1.2)

0.461

1.30 (0.98- 1.8)

1.40 (1.0- 1.9)

0.042

1.10 (0.81- 1.5)

1.00 (0.77- 1.4)

0.672

0.82 (0.60- 1.1)

1.10 (0.76- 1.4)

0.774

1.00 (0.71- 1.3)

1.10 (0.79- 1.5)

0.554

1.10 (0.79- 1.5)

1.30 (0.90- 1.7)

0.169

1.20 (0.92- 1.7)

1.50 (1.1- 2.2)

0.005

1.10 (0.77- 1.4)

0.90 (0.64- 1.2)

0.453

1.10 (0.79- 1.5)

0.554

1.00 (0.71- 1.3)
1.10 (0.82- 1.5)

0.88 (0.63- 1.2)

0.471

109

Pentadecanoic acid

T2

P-linear
trend2
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Docosapentaenoic acid n3
(DPA-3)
Docosapentaenoic acid n6
(DPA-6)

1

PUFA
PUFA

Docosahexaenoic acid (DHA)

PUFA

Total n-3 fatty acids3

PUFA

Total n-6 fatty acids3

PUFA

Total n-6/ n-3 fatty acids

PUFA

1.00
[reference]
1.00
[reference]
1.00
[reference]
1.00
[reference]
1.00
[reference]
1.00
[reference]

0.79 (0.52- 1.1)

1.10 (0.77- 1.6)

0.422

0.93 (0.63- 1.3)

1.40 (0.97- 2.1)

0.077

1.30 (0.95- 2.0)

1.20 (0.85- 1.8)

0.235

1.2 (0.78- 1.7)

1.2 (0.81- 1.7)

0.391

1.1 (0.75- 1.6)

1.06 (0.72- 1.5)

0.760

0.93 (0.62- 1.4)

1.1 (0.72- 1.5)

0.757

1.00
[reference]
1.00
[reference]
1.00
[reference]
1.00
[reference]
1.00
[reference]
1.00
[reference]

0.95 (0.69- 1.2)

0.79 (0.57- 1.1)

0.169

1.10 (0.76- 1.4)

1.20 (0.91- 1.7)

0.156

1.40 (1.0- 2.1)

1.30 (0.95- 1.8)

0.118

1.14 (0.83- 1.6)

0.98 (0.71- 1.4)

0.938

0.78 (0.56- 1.1)

1.02 (0.74- 1.4)

0.867

0.98 (0.70- 1.4)

1.1 (0.77- 1.5)

0.661

SFA, saturated fatty acids; MUFA, monounsaturated fatty acids; TFA, trans fatty acids; PUFA, polyunsaturated fatty acids.

2

Values are 95% Confidence Interval in parentheses (all such values). Adjusted variables in multivariate models included body mass index (kg/m2, continuous), smoking
(never, former, current), age, in years (65-74, 75-84, 85+), education levels (less than high school, high school, more than high school), and gender (male, female).
3

Total n-3 fatty acids included ALA, EPA, DPA-3, and DHA; Total n-6 fatty acids included linoleic acid, eicosadienoic acid, DGLA, adrenic, and DPA-6.

110

111

Table 4.6: Spearman rank order correlation coefficients of the dietary intake of total fats, saturated fatty acids, monounsaturated fatty
acids, polyunsaturated fatty acids, omega 3, omega 6, omega6:omega3 ratio, CRP and with erythrocyte membrane fatty acid in the Cache
County Memory Study.
Correlation with
total fats
(p-values)

Correlation with
SFA (p-values)

Correlation with
MUFA (p-values)

Correlation with
PUFA (p-values)

Correlation with
Omega 3 (pvalues)

Correlation with
Omega 6 (pvalues)

Correlation with
Omega6:omega3
(p-values)

Correlation with
CRP
(p-values)

0.029 (0.267)

0.176** (<0.001)

0.023 (0.362)

-0.192** (<0.001)

-0.049 (0.057)

-0.206** (<0.001)

-0.123** (<0.001)

-0.031 (0.190)

Palmitic acid

-0.071** (0.006)

-0.025 (0.339)

-0.069** (0.007)

-0.069** (0.008)

-0.020 (0.427)

-0.068 (0.008)

-0.069** (0.008)

0.053* (0.023)

Margaric acid

0.000 (0.985)

0.016 (0.525)

-0.020 (0.449)

-0.070** (0.007)

-0.033 (0.197)

0.087** (0.001)

-0.059* (0.024)

0.118** (<0.001)

-0.056* (0.029)

0.035 (0.170)

0.042 (0.101)

0.025 (0.331)

0.016 (0.537)

0.014 (0.595)

0.024 (0.367)

-0.041 (0.080)

Arachidic acid

0.022 (0.398)

0.011 (0.669)

0.011 (0.667)

0.006 (0.821)

0.029 (0.254)

-0.001 (0.969)

-0.017 (503)

-0.080** (0.001)

Behenic acid

0.050 (0.054)

0.046 (0.074)

0.032 (0.218)

0.006 (0.811)

0.011 (0.673)

0.004 (0.865)

-0.007 (0.786)

-0.043 (0.063)

Lignoceric acid

0.036** (0.157)

0.017 (0.501)

0.036 (0.157)

0.020 (0.439)

0.014 (0.597)

0.017 (0.517)

-0.009 (0.742)

-0.013 (0.567)

-0.175** (<0.001)

-0.067** (0.009)

-0.159 (<0.001)

-0.208** (<0.001)

-0.059** (0.023)

-0.198 (<0.001)

-0.088** (0.001)

0.146** (<0.001)

0.044 (0.085)

0.016 (0.539)

0.005 (0.839)

0.070** (0.006)

0.018 (0.484)

0.066* (0.010)

0.039 (0.133)

-0.059* (0.012)

-0.061* (0.017)

-0.042 (0.107)

0.078** (0.002)

-0.077** (0.003)

-0.027 (0.293)

-0.072** (0.005)

-0.021 (0.424)

-0.025 (0.282)

Erucic acid

0.032 (0.215)

0.014 (0.583)

0.039 (0.134)

0.039 (0.132)

-0.018 (0.486)

0.045 (0.080)

0.041 (0.112)

0.049* (0.035)

Nervonic acid

-0.026 (0.320)

-0.070** (0.007)

-0.015 (0.558)

0.022 (0.385)

0.025 (0.332)

0.023 (0.377)

-0.020 (0.454)

0.035 (0.135)

-0.063* (0.015)

-0.081** (0.002)

-0.059* (0.022)

0.025 (0.341)

0.021 (0.416)

0.016 (0.531)

-0.023 (0.368)

Erythrocyte membrane fatty
acid
Saturated fatty acids
Pentadecanoic acid

Stearic acid

Monounsaturated fatty acids
Palmitoleic acid
Oleic acid
Gondoic acid

Monounsaturated fatty acids trans
Vaccenic acid

0.013 (0.572)
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Polyunsaturated fatty acids
Linoleic acid

0.120** (<0.001)

0.024 (0.349)

0.099** (<0.001)

0.150** (<0.001)

0.036 (0.163)

0.152** (<0.001)

0.086** (0.001)

-0.033** (0.157)

a-Linolenic acid (ALA)

-0.062* (0.017)

-0.114** (<0.001)

-0.082 (0.001)

0.035 (0.177)

0.072** (0.005)

0.046 (0.075)

-0.019 (0.456)

-0.004 (0.867)

Eicosadienoic acid

-0.025 (0.338)

-0.169** (<0.001)

-0.042 (0.102)

0.179** (<0.001)

0.179** (<0.001)

0.071** (0.006)

0.183** (<0.001)

0.002 (0.993)

Dihomo-y-linolenic acid
(DGLA)

-0.055* (0.032)

-0.026 (0.311)

-0.031 (0.232)

-0.055* (0.033)

-0.047 (0.068)

-0.052* (0.044)

0.078** (0.003)

0.093** (<0.001)

0.027 (0.294)

0.006 (0.810)

0.031 (0.226)

0.043 (0.094)

-0.023 (0.381)

0.047 (0.067)

0.050 (0.053)

0.044 (0.061)

Eicosapentaenoic acid
(EPA)

-0.123** (<0.001)

-0.099** (<0.001)

-0.090** (<0.001)

-0.075** (0.004)

0.116** (<0.001)

-0.097 (<0.001)

-0.183** (<0.001)

0.018 (0.434)

Adrenic acid

0.108** (<0.001)

0.080** (0.002)

0.091 (<0.001)

0.072** (0.005)

-0.065** (0.011)

-0.069 (0.011)

0.069** (0.007)

0.023 (0.318)

-0.038 (0.141)

-0.029 (0.262)

-0.024 (0.347)

-0.011 (0.660)

0.063* (0.014)

-0.026 (0.322)

-0.067* (0.010)

-0.060* (0.010)

0.084** (0.001)

0.128** (<0.001)

0.081 (0.002)

-0.028 (0.282)

0.122** (<0.001)

-0.017 (0.514)

-0.085** (0.001)

0.079* (0.001)

-0.146** (<0.001)

-0.193** (<0.001)

-0.108** (<0.001)

0.023 (0.377)

0.142** (<0.001)

0.007 (0.780)

-0.150** (<0.001)

0.022 (0.348)

Arachidonic acid

Docosapentaenoic acid
(DPA-3)
Docosapentaenoic acid
(DPA-6)
Docosahexaenoic acid
(DHA)

* Correlation is significant at the 0.05 level (2-tailed).
** Correlation is significant at the 0.01 level (2-tailed).
Note: Nutrients in which correlations are different between Saturated fats (SFA), Monounsaturated (MUFA), Polyunsaturated (PUFA), and C-reactive protein (CRP).
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CHAPTER 5
THE ROLE OF ALZHEIMER'S- RELATED GENES IN SYSTEMIC
INFLAMMATION IN THE CACHE COUNTY MEMORY STUDY
Abstract
Objective: To evaluate whether Alzheimer’s Disease (AD)-related genes,
identified in previous genome-wide association studies, are associated with elevated
levels of inflammatory C-reactive protein (CRP) in a prospective, population-based
study.
Design: We analyzed data from dementia-free participants in the Cache County
Memory Study (CCMS). In a total of 2031 men and women ≥ 65 years of age at the
baseline, we examined the association between polymorphisms of 20 AD-related genes
and biomarker of systemic inflammation.
Results: After controlling multiple covariates, risk of elevated CRP was increased
in minor allele homozygotes vs. major allele homozygotes for APOE rs439401 (aOR=
1.4 [95%CI 1.4- 1.7]) and TOMM40 rs157580 (aOR= 1.2 [95%CI 0.96- 1.46]). In
contrast, risk of CRP elevation was reduced in minor allele homozygotes for MMP8
rs1892886 (aOR = 0.78 [95%CI 0.64- 0.90]). These and other associations appeared
stronger among male than women; risk of elevated CRP in males was increased in minor
allele homozygotes for APOE rs439401 (aOR= 1.6 [95%CI 1.1- 2.1]) and TOMM40
rs157580 (aOR= 1.5 [95%CI 1.1- 2.1]) and reduced for MMP8 rs1892886 (aOR = 0.64
[95%CI 0.46- 0.89]), CR1 rs665401 (aOR = 0.60 [95%CI 0.42- 0.84]), CR1 rs3818361
(aOR= 0.43 [95%CI 0.28- 0.66]), and CR1 rs4844609 (aOR = 0.38 [95%CI 0.19- 0.80]).
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Conclusions: The AD associated genes APOE, TOMM40, CR1, and MMP8 are
associated with altered CRP levels, a marker of systemic inflammation and these
associations appear stronger for men compared to women.
Introduction
Alzheimer’s disease (AD) is the sixth leading cause of death in the United States
[1]. It is the most common form of dementia. In 2015, Alzheimer’s disease affected 5.3
million Americans, and it affects 44 million worldwide. Alzheimer's prevalence is 1 in 9
older Americans [1]. Inflammation plays a key role in the pathogenesis of AD [2].
Scientific knowledge is far from complete regarding the relationship between
inflammatory biomarkers and AD. However, scientific advances recently have been
noticeably changing the understanding of the role of high levels of inflammatory
biomarker C-reactive protein (CRP) in AD patients and other chronic diseases [3, 4].
CRP is a plasma protein synthesized by the liver in response to cytokines including
interleukin-1 (IL-1), interleukin-6 (IL-6), and tumor necrosis factor α (TNF-α)[5]. A
growing number of cross-sectional studies reported that high level of CRP was found in
AD patients when they were compared to controls [6-8]. Concomitantly, several
observational studies have provided convincing evidence that the low-grade
inflammatory process that is indicated by high levels of CRP in older adults correlates
with AD risk [9, 10].
Recent large genome-wide association studies (GWAS) have identified many
genes/loci that are associated with late-onset Alzheimer's disease (LOAD) including
BIN1, CLU, PICALM, MS4A6A, CD33, MS4A4E, CD2AP, CR1, ABCA7, AGTR1,
APOE, TOMM40, DTNA, HTR2C, EPHA1, MMP8, MPP7, SORCS1, PPP3R1, and
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MAPT/STH [11]. Genetic data reveal that some risks of disease initiation, progression,
and severity are linked to different alleles of genes by affecting inflammation pathways.
Genetic diversity plays an important role in immunity, inflammation, and inflammatory
disease [12].
Genes affecting the risk of systemic inflammation have gathered increasing
attention from geneticists and epidemiologists interested in related inflammatory diseases
including Alzheimer’s disease [13]. APOE (chromosome 19q12-13.2) is known to have a
key role in determining the risk of AD. APOE has many polymorphisms including
epsilon (ε2, ε3, and ε4), rs439401, and rs4420638 [14]. Functionally, APOE
polymorphisms contribute to neuronal development, regeneration, and repair in the
central nervous system (CNS) [13, 15]. APOE also plays a major role in the cholesterol
and triglyceride metabolism [16-18]. Most studies have reported that ε2 and ε4 have an
opposing biological effect on lipid metabolism [19-21].
In regards of inflammation, APOE ε4 genotype is still a controversial issue,
because much scientific evidence suggests that APOE ε4 works as a pro-inflammatory
that induces the production of inflammatory biomarkers via several mechanisms [22-29].
Concomitantly, in the scientific literature, there are a few studies that suggest the benefits
arising from the having a copy of APOE ε4 because it works as an anti-inflammatory [30,
31].
In the current study, the Cache County Memory Study (CCMS) was used to
examine the influence of APOE-epsilon genotypes and SNPs in 20 genes previously
associated with AD with plasma CRP levels. The hypotheses of this study are divided
into primary hypotheses and exploratory hypotheses (Table 5.1). Primary hypotheses,
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which are based on previously published reports, include genes that are associated with
either increased or decreased levels of inflammatory biomarkers. Exploratory hypotheses
included genes that are associated with Alzheimer's disease, but not known to be
associated with inflammation.

Materials and Methods
Study participants
This investigation used data from the Cache County Memory Study, a prospective
cohort study among elderly who were 65 years old and older at the baseline in 1995 and
who were permanent residents of Cache County, Utah. This population is largely nonHispanic White (5,092 residents), and the genetic makeup is mostly from Northern
European ancestry. The institutional review boards of each collaborating site at Utah
State University, Duke University Medical Center, and The Johns Hopkins University
approved the protocol of the study. Participants were interviewed about demographic
characteristics, health history, and family history of dementia, use of medications,
alcohol, tobacco, other lifestyle factors, and extensive cognitive testing. Re-examination
of the study participants was completed three more times in subsequent years. Details of
the study protocols have been previously published [32].
CRP assessment
In 2002, fasting blood samples were obtained and assayed for CRP from 2185
participants in Wave 3 at McKay Dee Laboratory Hospital, Ogden, UT. Dade's
nephelometry method has been considered for quite some time as a gold standard for
these tests in the laboratory industry [33]. Many large reference studies refer to the Dade
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BNII assay that uses particle enhanced immunonephelometry to detect high-sensitivity
CRP (hs-CRP). Dade was one of the first vendors to receive FDA approval for cardiac
marker claims for their sensitive CRP assay [34, 35]. Typically, expected values for
healthy individuals are found to be less than 3.00 mg/L, or 0.3 mg/dL [36]. The
measuring range is determined by the lower limit of the reference curve and depends on
the concentration of the standard used. The typical limit of detection for the method was
0.175 mg/L or 0.0175 mg/dL. The upper level of detection was typically 1150mg/L or
150 mg/dL. We defined elevated CRP as values >3.0 mg/L [34].
Genotyping
At the baseline of the CCMS, DNA buccal samples were obtained from 4,654
participants to genotype APOE at Duke University School of Medicine. Later, a mixture
of 2,974 DNA buccal and blood samples were genotyped for 20 non-APOE LOAD risk
alleles at Brigham Young University by Dr. Kauwe using custom TaqMan assays [37,
38]. The genotype assays included BIN1, CLU, CD33, PICALM, MS4A6A, MS4A4E,
CD2AP, APOE, ABCA7, AGTR1, DTNA, HTR2C, MMP8, MPP7, EPHI1, SORCS1,
TOMM40, PPP3R1, CR1, and MAPT/STH.
Statistical Analyses
Descriptive analyses were conducted to examine the association between CRP
and other factors, such as gender (male, female), age (years), body mass index (BMI
weight in kilograms/ height in meters2), educational level (less than high school, and
more than high school), drinking and smoking habits (never, former, current); health
variables included diabetes (no, yes), stroke (no, yes), and heart attack (no, yes), APOE
genotype (no e4, 1 or 2 e4), and cholesterol (mg, continues).
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The epsilon polymorphism in the APOE gene was defined by six- levels (ε3/ ε2,
ε2/ ε3, ε2/ ε4, ε3/ ε3, ε3/ ε4, and, ε4/ ε4). Chi-square analyses of contingency tables of
CRP levels (low:< 3.00 mg/L, high:> 3.0 mg/L) by genotype categories were performed
to evaluate associations. Analysis of Variance (ANOVA) was used to test for differences
between the mean of CRP across levels of genotypes. We also tested the associations
between APOE- epsilon genotypes and APOE rs439401, TOMM40 rs1160985.
AD-related genotypes define three-level categorical variables (major allele
homozygote, heterozygote, minor allele homozygote). The three-level genotype variables
were used in additive genetic models to test for an effect of 0, 1, or 2 alleles. Analysis of
Variance (ANOVA) was used to test for differences between the mean of CRP across
levels of genotypes. Potential confounding variables including BMI, smoking, age,
diabetes, stroke, heart attack, and gender were evaluated. Logistic regression models
were used to estimate the risk of CRP elevation (> 3.0 mg/L) by genotype level. The
major allele homozygote was used as a reference in these models to estimate the odds
ratio (ORs) and 95% confident intervals (CIs) for CRP elevation (coded 0, 1). All tests
were performed first with gender as covariates, and then models were stratified by
gender. This stratification provides a means of comparing CRP- genotype association
between males and females [39], thus making it possible to observe the differences.
Participants with dementia (n= 154) were excluded from all analysis. Statistical analyses
were conducted using SPSS, version 22.
Results
Baseline demographic characteristics of the study participants are shown in Table
5.2. Participants with a high level of CRP were more likely to be women, less educated
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and had higher BMI. High CRP levels were also associated with current smoking. Those
in the higher vs. lower CRP level reported more strokes (10.1 vs. 7.3 percent) and the
prevalence of diabetes was slightly higher in the high CRP group.
The genotype distribution of the APOE-epsilon genotypes and the mean plasma
CRP level for APOE-epsilon genotype and the percent of normal and elevated CRP by
genotype group are presented in Table 5.3. A Chi-square test for association between
APOE-epsilon genotypes and CRP levels revealed that mean CRP level was significantly
different between APOE-epsilon genotypes (p= <0.001). Lower mean CRP was observed
among APOE-epsilon genotype ε2/ ε2 and ε4/ε4, and the highest mean CRP was
observed among ε2/ ε4 allele genotype.
A Chi-square test for association was conducted between APOE-epsilon

genotypes and APOE and TOMM40 polymorphisms. There was a statistically significant
association between gene APOE-epsilon genotypes and APOE rs439401, TOMM40
rs157580, and TOMM40 rs157580, (χ2 (5) = 33.8, p = <0.001), (χ2 (10) = 400, p =
<0.001), and (χ2 (10) = 454, p = <0.001), respectively (Table 5.4).
The genotype distribution of AD-related genes appears in Table 5.5. Mean plasma
of CRP by the AD-related genotypes are presented in Table 5.6. Mean CRP levels were
significantly different between APOE rs439401 and TOMM40 rs157580 genotypes (P=
<0.001, P= <0.001, P= 0.002), respectively. Higher mean plasma CRP concentrations
were found in the minor allele heterozygotes and homozygotes compared to the major
allele homozygotes for both APOE and TOMM40.
The results of the logistic regression models that estimated the relative risk of
having an elevated plasma CRP are shown in Table 5.7. The models presented were
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adjusted for gender, age, education, BMI, smoking, alcohol intake, diabetes, stroke,
myocardial infarction. The adjusted multivariate logistic analysis of 20 AD-related genes
found that individuals compared to major allele as the reference category had increased
the risk of elevated CRP level for minor allele homozygotes; adjusted OR (aOR) and
95% confidence intervals (CIs)); APOE rs439401(aOR = 1.4 [95%CI 1.1- 1.7]),
TOMM40 rs157580 (aOR= 1.2 [95%CI 0.96- 1.46]). In contrast, individuals compared to
major allele homozygote as the reference category had decreased the risk of elevated
CRP levels for minor allele homozygotes MMP8 rs1892886 (aOR = 0.78 [95%CI 0.640.9]). No associations between others genes and CRP elevation were observed levels was
observed.
When the data were stratified by gender, we found that mean CRP levels were
strongly associated with APOE-epsilon genotype in both. Lower mean plasma CRP
concentrations were found in major allele homozygotes compared to minor allele
heterozygotes and homozygotes in SNPs APOE rs439401 in both men and women.
TOMM40 rs157580 genotype was associated with CRP in males but not in females.
Higher mean plasma CRP concentration was found in the major allele homozygote
compared to minor allele heterozygotes and homozygotes in MMP8 and HTR2C for
males and MS4A6A in females (Table 5.9 and Table 5.10).
The results of the logistic regression analyses for the relative risk of having an
elevated plasma CRP stratified by gender are shown in Table 5.11. The adjusted
multivariate logistic analysis of 20 AD-related genes found that individuals compared to
major allele homozygotes as the reference category, increased risk of elevated CRP level
for minor allele homozygotes for males were: APOE rs439401(aOR = 1.6 [95%CI 1.1-
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2.1]) and TOMM40 rs157580 (aOR= 1.5 [95%CI 1.07- 2.1]). Decreased risk of elevated
CRP for minor allele homozygotes in males was found for MMP8 rs1892886 (aOR =
0.64 [95%CI 0.46- 0.89]), CR1 rs665401 (aOR = 0.59 [95%CI 0.42- 0.84]), CR1
rs3818361 (aOR = 0.43 [95%CI 0.28- 0.66]), and CR1 rs4844609 (aOR = 0.38 [95%CI
0.19- 0.80]). These associations were not observed in women.
While the associations between AD-related genes and risk of elevated CRP
appeared to be present only in men and not among women, there was not a significant
multiplicative interaction between most AD-related genes and CRP elevation (p > 0.05).
Only TOMM40 rs157580, CR1 rs665401, CR1 rs3818361, and CR1 rs4844609 were
significant with the multiplicative interaction between most AD-related genes and CRP
elevation (p= 0.0418, 0.005, 0.002, 0.0193), respectively.
Discussion
The present study found that APOE-epsilon genotypes influence the risk of
systemic inflammation but in an unexpected direction the ε4/ε4 genotype, associated with
the highest risk of AD, had among the lowest mean CRP compared to other APOE
genotype. Plasma CRP differed in a similar pattern across APOE-epsilon genotypes in
both genders. When major allele homozygotes were compared to minor allele
homozygotes, the risk of elevation CRP increased in those who have APOE rs439401 and
TOMM40 rs157580. In contrast, the risks of elevation CRP decrease in those who have
minor allele homozygotes MMP8 rs1892886, CR1 rs665401, CR1 rs3818361, and CR1
rs4844609. These associations were found to be stronger in men vs. women.
Several prospective studies have demonstrated that CRP is an independent predictor
of future risk for AD, and it may aid in identifying subjects at high risk [6-9, 40]. The
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observation of elevated CRP in subjects with AD has led to extensive studies on the role
of inflammatory reactions in the pathogenesis of AD [9, 10, 41].
The link between plasma CRP and the common allelic variants ε2, ε3, and ε4 of
the APOE gene has been observed in some earlier studies. Five studies of APOE [34, 99102] showed that APOE-epsilon genotypes had no effect on inflammatory biomarkers.
Other studies were consistent with our current results. Angelopoulos et al., and Haan et
al., examined the association between APOE ε3/ε4 in healthy elderly Latinos. They found
that ε3/ε4 reduced CRP levels among participants [42, 43]. In Japanese Americans, CRP
levels were found to be low in ε4/ε4 and ε3/ε4 participants, but not with ε/ε2 genotype
[44]. Moreover, a data from the Czech part of the HAPIEE (Health, Alcohol, and
Psychosocial factors In Eastern Europe) study reported that ε3/ε4 and ε4/ε4 was
associated with reduced CRP levels among 2,886 males and 3,344 females [45]. This
pattern of association is consistent with other studies that indicated ε4 carriers have lower
levels of plasma CRP in the elderly and different patient groups [29, 46-52]. APOE ε4
were associated with higher CRP levels, the sensitive inflammatory biomarker and
predictor of Alzheimer disease [53], only one study of young participants stratified by
gender and they found that APOE ε4 was associated with lower mean CRP, but only for
men not for women [54].
The present result that is consistent with the most previously published studies
highlighted the contradiction regarding the relationship between APOE genotypes, CRP,
and AD. Until now the mechanism has been unknown for how APOE isoforms affect
inflammation and risk of AD but it has been suggested that each APOE isoform has been
implicated in different modulation mechanisms in regards to inflammatory responses
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(apoE2 > apoE3 > apoE4) [55]. Some studies suggest anti-inflammatory benefits arising
from having genotypes of APOE ε2/ ε3 [24, 56-61], ε3/ ε4 [43, 62], ε4 [29, 46-52], ε4/ ε4
[19, 29, 49-52, 63-66] which suggest that this association may be influenced by different
independent mechanism. Other studies suggest the pro-inflammatory effect of APOE ε4
[22-28]. Over the last decades, high level of CRP has been used widely to estimate the
risk of several chronic diseases including cancer [67], type 2 diabetes [68], coronary
artery disease risk, damage from a heart attack [69], inflammatory bowel disease [70],
some forms of arthritis [71], pelvic inflammatory disease [72], lupus [71], and AD [73].
Moreover, individuals with APOE ε4 genotype are at increased risk of cardiovascular
disease, end stage renal disease [74], and AD [75]. Genetic data also revealed that high
levels of CRP are related to gene polymorphisms by increasing the risk of some disease
such as cardiovascular disease rather than inflammatory status, which may explain the
limited effects of the environmental factors [45, 76]. Thus, further experimental studies
are needed to explain this conflict evidence that came from only observational studies.
No previous study, to our knowledge, has examined associations between
rs439401 in APOE and rs157580 in TOMM40 with inflammatory biomarkers in males.
On the other hand, The Women’s Health Initiative (WHI) study of 8,280 African
American reported [77] and 7,570 African Americans (AA) from the Candidate Gene
Association Resource (CARe) study [78] reported that CRP is significantly associated
with APOE rs157580 and TOMM40 rs439401 loci. The biologic mechanism of the
relationship between these polymorphisms and CRP is not clear [45]. Both TOMM40 and
APOE are located on chromosome 19 [79]. AD pathology in multiple brain regions have
been associated with SNPs in APOE and TOMM40 genes [80]. Even though the effect of
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length variation between TOMM40 and APOE has been reported [79, 81], there are no
studies conducted, to our knowledge, that have analyzed the interaction effect of
rs157580 and rs439401 polymorphisms on CRP levels, thus more studies are needed to
explore and explain the effect of the interaction between APOE rs157580 and TOMM40
rs439401 on CRP levels as a dependent variable, particularly among elderly.
No previous study, to our knowledge, has examined associations between
rs6656401, rs3818361, and rs4844609 in CR1, rs1892886 in MMP8, and CRP levels in
men. The mechanisms underlying inflammation and the immunological network leading
to AD are not well known. Genes including BIN1 [82, 83], and AGTR1 [84] have been
linked to inflammation as both pro-inflammatory and anti-inflammatory. In the scientific
literature, there are a few studies that reported BIN1 [85-90] and CLU [91-94] as antiinflammatory. Other evidence suggests that CD2AP [95-98], AGTR1 [99-101], MMP8
[102-106], MMP7 [107-111], TOMM40 [28, 112], CR1 , CD33 [113], and MS4A6A
[113] work as a pro-inflammatory that induces the production of inflammatory
biomarkers via several mechanisms. Three studies of CLU studies [114-116] reported that
these genes have no effect on inflammatory biomarkers.
To our knowledge, this is the first study that explores the multiplicative interaction
between AD-related genes and the risk of elevated CRP. Thus, further studies are needed
to confirm our results.
Our study has several key strengths, including a large sample size for determining
the association between APOE-epsilon genotypes and 20 Alzheimer’s Disease-related
genes and CRP levels in both males and females. Participants in our sample were
Caucasians, and populations with other genetic background may have different
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associations. The results of our analysis must be considered in light of its limitations.
CRP is a single measure of systemic inflammation that is a complex process, and further
studies of additional inflammatory biomarkers would be useful [117].
In conclusion, our finding supports the hypothesis that among Caucasian males, the
presence of minor alleles of APOE (C/C) rs439401 and TOMM40 (A/A) rs157580 may
be a risk factor to increase inflammation in elderly. Conversely, the minor allele of
MMP8 (T/T) rs1892886, CR1 (G/G) rs6656401, CR1 (A/A) rs3818361, and CR1 (A/A)
rs4844609 is associated with decreased risk of CRP elevation in Caucasian males. More
mechanistic studies or using other inflammatory biomarkers are needed to show how
genetic polymorphisms affect systemic inflammation, which has long term effects on the
development of Alzheimer’s.
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Table 5.1: Studies reporting on the relationship between Alzheimer’s- associated genes
and inflammatory biomarkers.
Published evidence between AD genes and inflammatory biomarkers 1
Statistically Not
Genes

Inflammatory type

Statistically significant
significant
p-value <0.05
p-value >0.05

Primary hypotheses2:
Pro-inflammatory
ε4/ ε4

[22-28]

Anti-inflammatory
ε2, ε3

[24, 56-61]

Anti-inflammatory
APOE1

[43, 62]

[40, 118-121]

ε3/ ε4
Anti-inflammatory
[29, 46-52]
ε4
Anti-inflammatory
[29, 49-52, 63-65]
ε4/ ε4
Pro-inflammatory

No references found related to pro-inflammation

----------------------------

Anti-inflammatory

[85-90]

----------------------------

Pro-inflammatory

No references found related to anti-inflammation

Anti-inflammatory

[91-94]

Pro-inflammatory

[95-98]

Anti-inflammatory

No references found related to anti-inflammation

Pro-inflammatory

[99-101]

Anti-inflammatory

No references found related to anti-inflammation

Pro-inflammatory

[103-106]

Anti-inflammatory

No references found related to anti-inflammation

Pro-inflammatory

[102, 107-111]

Anti-inflammatory

No references found related to anti-inflammation

Pro-inflammatory

[28, 112]

Anti-inflammatory

No references found related to anti-inflammation

Pro-inflammatory

[122-124]

Anti-inflammatory

No references found related to anti-inflammation

BIN11

CLU1

[114-116]

CD2AP1

AGTR11

MMP81

MPP71

TOMM401

CR11

----------------------------

----------------------------

----------------------------

----------------------------

----------------------------

----------------------------
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Exploratory hypotheses3:
Pro-inflammatory

[113]

Anti-inflammatory

No references found related to anti-inflammation

Pro-inflammatory

No references found related to pro-inflammation

Anti-inflammatory

No references found related to anti-inflammation

Pro-inflammatory

[113]

Anti-inflammatory

No references found related to anti-inflammation

Pro-inflammatory

No references found related to pro-inflammation

Anti-inflammatory

No references found related to anti-inflammation

Pro-inflammatory

No references found related to pro-inflammation

Anti-inflammatory

No references found related to anti-inflammation

Pro-inflammatory

No references found related to pro-inflammation

Anti-inflammatory

No references found related to anti-inflammation

Pro-inflammatory

No references found related to pro-inflammation

Anti-inflammatory

No references found related to anti-inflammation

Pro-inflammatory

No references found related to pro-inflammation

Anti-inflammatory

No references found related to anti-inflammation

Pro-inflammatory

No references found related to pro-inflammation

Anti-inflammatory

No references found related to anti-inflammation

Pro-inflammatory

No references found related to pro-inflammation

Anti-inflammatory

No references found related to anti-inflammation

Pro-inflammatory

No references found related to pro-inflammation

Anti-inflammatory

No references found related to anti-inflammation

CD332

PICALM2

MS4A6A2

MS4A4E

----------------------------

-------------------------------------------------------

2

ABCA72

DTNA2

HTR2C

----------------------------

----------------------------

----------------------------

2

EPHI12

SORCS12

PPP3R12

MAPT/STH

----------------------------

----------------------------

----------------------------

----------------------------

2

----------------------------

1

Note: Studies were identified in PubMed and Scopus using the following combinations of search terms: (“SNPs
number” or “ gene names” ) and (“genotype” or “gene” or “polymorphisms”) and (“crp” or “c-reactive protein”).
2

Genes hypothesized to be associated with systemic inflammation based on literature review.

3

Genes without strong evidence of association with systemic inflammation.
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Table 5.2: Demographic characteristics by levels of C- reactive protein (CRP) in the
Cache County Study on Memory, Health and Aging in Wave 3 (N= 2031).
Levels of plasma CRP concentration (mg/L)
Characteristic

p-value1
<3.0 (mg/L)

>3.0 (mg/L)

Gender
-

Male (%)

63.5

36.5

-

Female (%)

54.9

45.1

<0.001

-

Less than high school education (%)

54.9

61.8

-

More than high school education (%)

45.1

38.2

73.0± 5.4

73.1± 5.5

0.480

25.9± 4.0

27.2± 4.4

<0.001

1.4

2.9

0.042

4.4

3.7

0.442

35.8

26.2

<0.001

17.4

20.0

0.078

7.3

10.1

0.018

14.4

16.0

0.178

Age in years (SD)2
2

Body mass index (kg/m ) (SD)
Current smoke (%)

2

3

Current alcohol (%)

3

At least one APOE e4 allele (%)
Diagnosed with diabetes (%)
Diagnosed with stroke (%)
Diagnosed with heart attack (%)

0.002

p-values were obtained by using the Chi-square test for CRP (low vs. high) for categorical variables and
Analysis of Variance (ANOVA) for continuous variables.
1

2
3

Means± standard deviation (SD).

A current smoker was defined as a subject who reported currently smoking; a current drinker was defined as a
subject who reported currently drinking alcohol.
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Table 5.3: Genotype distributions and mean levels of C-reactive protein (CRP) by APOE
polymorphisms genotypes and CRP Levels in the Cache County Memory Study (CCMS).
CRP levels
Gene ID

1

Genotype

%

<3.0 (mg/L)

≥3.0 (mg/L)

n (%)

n (%)

Mean CRP3

ε2/ ε2

0.7

9 (64.3)

5 (35.7)

2.8± 2.61

ε2/ ε3

14.4

135 (46.2)

157 (53.8)

5.6± 8.2

ε2/ ε4

4.2

54 (63.5)

31 (36.5)

6.4± 13.0

ε3/ ε3

52.7

615 (57.6)

453 (42.4)

4.6± 7.3

ε3/ ε4

25.5

335 (64.8)

182 (35.2)

3.8± 6.3

ε4/ ε4

2.4

37 (75.5)

12 (24.5)

3.0± 6.6

<0.001

Epsilon

1

p-value2

<0.001

APOE-epsilon genotypes defined by variants in APOE SNPs rs429358 and rs7412.
p-values were obtained by using the chi-square test for CRP (low vs. high) for categorical variables.
3
Means± standard deviation (SD).
4
p-values were obtained by using Analysis of Variance (ANOVA).
2

p-value4
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Table 5.4: Cross-tabulations of APOE-epsilon genotype and APOE and TOMM40
polymorphisms in the Cache County Memory Study (CCMS).
APOE rs4394011
Gene ID

Genotype

R/R

1

C/R

1

C/C

TOMM40 rs1160985
1

2

R/R

2

C/R

2

C/C

2

TOMM40 rs157580
pvalue2

R/R2

C/R2

C/C2

n
(%)

n
(%)

n
(%)

n
(%)

n
(%)

n
(%)

n
(%)

n
(%)

n
(%)

ε2/ ε2

0.8

0.0

0.0

0.4

0.4

0.1

0.1

0.3

0.3

ε2/ ε3

7.1

6.1

0.2

4.5

6.2

3.2

3.3

6.1

3.8

ε2/ ε4

3.2

0.3

0.0

2.0

1.4

0.0

1.3

2.1

0.2

Epsilon

1

pvalue2

<0.001

<0.001

pvalue2

<0.001

ε3/ ε3

15.1

26.5

14.5

14.2

26.9

13.7

16.8

27.0

12.3

ε3/ ε4

12.4

10.7

0.7

11.8

12.1

0.6

12.8

10.6

0.8

ε4/ ε4

2.2

0.1

0.0

2.4

0.1

0.0

2.1

0.1

0.0

R is the major allele and C is the minor allele.
p-values were obtained by using the chi-square test for APOE-epsilon genotype and AD-related genes.
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Table 5.5: Genotype distributions of the Alzheimer’s associated genes in the Cache
County Memory Study (CCMS).
Elevated CRP (≥ 3.0) by

Gene ID

APOE
BIN1
CLU
CD2AP
AGTR1
MMP8
MPP7
TOMM40

SNP

Full name gene

C/R1
%

C/C1
%

Apolipoprotein

193
8

35.4

50.1

14.5

rs744353

Bridging integrator 1

1810

50.2

40.3

9.5

rs11136000

Clusterin

1959

37.2

48.8

13.9

rs9349407

CD2-associated protein

1975

53.1

39.1

7.8

rs2131127

Angiotensin II receptor, type 1

1931

42.5

44.8

12.7

rs1892886

Matrix metallopeptidase 8

1913

56.9

36.6

6.4

rs1457177

Membrane protein, palmitoylated 7

1961

85.2

14.4

0.4

rs1160985

Translocase of outer mitochondrial
membrane 40 homolog

1782

33.7

50.2

16.1

1959

32.1

49.8

18.0

1974

68.4

28.8

2.7

1331

67.3

29.5

3.1

1956

95.0

4.8

0.2

1981

44.1

43.5

12.3

1979

38.3

46.9

15

rs6656401
rs3818361

Complement receptor 1

rs4844609
CD33

R/R1
%
rs439401

rs157580
CR1

genotype

n

rs3865444

Siglec-3

rs3851179

Phosphatidylinositol
Clathrin Assembly Protein

rs610932

Membrane-spanning 4-domains,
subfamily A, member 6A/

1936

33.5

47

19.5

rs670139

Membrane-spanning 4-domains,
subfamily A, member 4E

1580

35.9

47.9

16.1

ABCA7

rs3752246

ATP-binding cassette, sub-family A
(ABC1),

1976

66.3

30.3

3.4

DTNA

rs4458079

Dystrobrevin, alpha

1963

78.7

19.2

2.1

HTR2C

rs6318

5-hydroxytryptamine
(serotonin)
receptor 2C, G protein-coupled

1962

74.7

16.5

8.8

EPHA1

rs11767557

EPH receptor A1

1967

65.4

30.2

4.4

PICALM

MS4A6A

MS4A4E

Binding
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SORCS1
PPP3R1

MAPT/STH
1

rs7093634

Sortilin-related
VPS10
containing receptor 1

rs1868402

rs3785883

domain

1854

38.0

49.2

12.7

Protein phosphatase 3, regulatory
subunit B, and alpha

1961

48.9

41.8

9.3

Microtubule-associated protein tau
and saitohin

1966

67.6

28.9

3.5

R is the major allele and C is the minor allele.
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Table 5.6: Mean levels of C-reactive protein (CRP) by genotype of Alzheimer’s
associated genes in the Cache County Memory Study.
Mean CRP1
Gene ID

p-value3

SNP
2

2

R/R

C/R

C/C

2

Primary hypotheses
APOE

rs439401

4.3± 7.6

4.8± 7.6

4.9± 7.8

<0.001

BIN1

rs744353

4.6± 7.7

4.6 ± 7.8

4.1± 8.4

0.750

CLU

rs11136000

4.3± 6.4

4.7± 8.2

5.0± 7.53

0.492

CD2AP

rs9349407

4.4± 7.0

4.9± 8.4

4.5± 7.2

0.890

AGTR1

rs2131127

4.7± 7.8

4.5± 7.3

4.7± 8.6

0.448

MMP8

rs1892886

4.9± 7.6

4.3± 7.3

4.3 ± 9.9

0.078

MPP7

rs1457177

4.7± 7.8

4.3± 7.0

2.5± 2.3

0.238

TOMM40

rs1160985

4.0± 4.9

4.8± 8.4

4.6± 7.7

0.868

TOMM40

rs157580

3.9± 6.1

5.1± 8.7

4.8± 7.1

0.002

CR1

rs6656401

4.7± 7.8

4.6± 7.4

4.1± 6.7

0.682

CR1

rs3818361

4.9± 7.7

4.8± 7.3

4.3± 7.2

0.670

CR1

rs4844609

5.0± 2.5

3.7± 5.8

4.6± 7.7

0.155

Exploratory hypotheses
CD33

rs3865444

5.0± 8.9

4.2± 5.9

5.1± 8.0

0.642

PICALM

rs3851179

4.7± 8.3

4.8± 8.3

4.8± 4.8

0.967

MS4A6A

rs610932

4.3± 7.1

4.8± 8.1

4.8± 7.7

0.107

MS4A4E

rs670139

4.6± 7.0

4.7± 8.5

4.1± 6.1

0.176

ABCA7

rs3752246

4.6± 7.6

4.5± 7.5

4.6± 6.4

0.834

DTNA

rs4458079

4.6± 7.3

4.8± 9.1

4.7± 4.7

0.493

HTR2C

rs6318

4.5± 7.1

4.9± 8.9

4.5± 8.1

0.222
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EPHA1

rs11767557

4.6± 7.5

4.8± 8.2

.3.3± 3.1

0.532

SORCS1

rs7093634

4.4± 6.9

4.9± 8.1

4.2± 8.5

0.170

PPP3R1

rs1868402

4.4± 6.7

4.9± 8.8

4.9± 7.2

0.828

MAPT/STH

rs3785883

5.1± 6.5

4.1± 5.5

4.8± 8.5

0.467

Means± standard deviation (SD).
R is the major allele and C is the minor allele.
3
P values were obtained by using Analysis of Variance (ANOVA).
1
2
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Table 5.7: Estimated effects of Alzheimer’s associated genes of plasma biomarker
concentration C-reactive protein (CRP) levels (high vs. low) from conditional logistic
regression in the Cache County Memory Study.
Genes

Genotype

SNP
1

R/R
1.00
[reference]

C/R

1

p- value2
1

C/C

1.3 (1.01- 1.8)

1.4 (1.1- 1.7)

1.06 (0.746-

1.06 (0.869-

1.5)

1.3)

APOE

rs439401

BIN1

rs744353

1.00
[reference]

CLU

rs11136000

1.00
[reference]

0.99 (0.73- 1.3)

CD2AP

rs9349407

1.00
[reference]

0.93 (0.65- 1.3)

AGTR1

rs2131127

1.00
[reference]

1.2 (0.89- 1.6)

MMP8

rs1892886

1.00
[reference]

0.77 (0.52- 1.1)

MPP7

rs1457177

1.00
[reference]

0.63 (0.15- 2.5)

TOMM40

rs1160985

1.00
[reference]

0.96 (0.71- 1.3)

TOMM40

rs157580

1.00
[reference]

1.5 (1.10- 1.9)

CR1

rs6656401

1.00
[reference]

0.82(.475- 1.4)

CR1

rs3818361

1.00
[reference]

0.89 (0.47- 1.7)

CR1

rs4844609

1.00
[reference]

No observation

CD33

rs3865444

1.00
[reference]

0.98 (0.72- 1.3)

PICALM

rs3851179

1.00
[reference]

MS4A6A

rs610932

1.00
[reference]

0.87 (0.711.0)
0.98 (0.801.1)
1.10 (0.901.3)
0.78 (0.640.9)
0.93 (0.711.2)
0.95 (0.781.2)
1.2 (0.961.46)
0.89 (.73- 1.1)
0.81 (0.631.04)
0.80 (0.53-1.2
)
0.96 (0.791.1)

1.03 (0.773-

1.00 (0.819-

1.3)

1.2)

1.09 (0.833-

1.03 (0.834-

1.4)

1.2)

0.004
0.552

0.584

0.717

0.199

0.020

0.473

0.813

0.008
0.224
0.152

0.616

0.802

0.861

0.537
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1

MS4A4E

rs670139

1.00
[reference]

0.89 (0.65- 1.2)

ABCA7

rs3752246

1.00
[reference]

0.88 (0.53- 1.4)

DTNA

rs4458079

1.00
[reference]

1.6 (0.81- 3.5)

HTR2C

rs6318

1.00
[reference]

EPHA1

rs11767557

1.00
[reference]

SORCS1

rs7093634

1.00
[reference]

PPP3R1

rs1868402

1.00
[reference]

1.3 (0.927- 1.8)

MAPT/STH

rs3785883

1.00
[reference]

1.1 (0.64- 1.9)

0.94 (0.751.1)
1.05 (0.861.2)
0.92 (0.731.1)

1.09 (0.781-

0.95 (0.72-

1.5)

1.2)

0.96 (0.60- 1.5)

0.87 (0.711.0)

1.07 (0.790-

1.12 (0.911-

1.4)

1.3)
1.1 (0.9251.3)
1.0 (0.8211.2)

0.451

0.919

0.858

0.793

0.322

0.426

0.081

0.779

R is the major allele and C is the minor allele.
Values are 95% Confidence Interval in parentheses (all such values). Adjusted variables in multivariate models
included body mass index (kg/m2, continuous), smoking (never, former, current), Age, in years (65-74, 75-84,
85+), diabetes (No, Yes), Stroke (No, Yes), Heart attack (yes or no), cholesterol (mg, continues), and gender
(male, female).
2
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Table 5.8: Demographic Characteristics by C- reactive protein (CRP) and stratified by
gender in the Cache County Study on Memory, Health and Aging in Wave 3.
Plasma CRP concentration (mg/L)
n%
Male (n= 840)
Female (n= 1191)
Characteristic
<3.0
(mg/L)

p≥3.0 (mg/L)

value1

-

Less than high school (%)

33.5

66.5

-

More than high school (%)

40.5

59.5

72.1± 5.0

73.3± 5.6

0.033

26.0± 3.7

26.7± 4.0

0.017

1.9

5.4

0.002

6.6

5.4

36.6

Age in years (SD)2
Body mass index (kg/m 2)
(SD )

2

Current smoke (%)3
Current alcohol (%)

3

0.026

p<3.0
(mg/L)

≥3.0 (mg/L)

52.5

47.5

57.1

42.9

73.5±

value1
0.001

72.8± 5.4

0.002

26.6± 5.2

0.000

0.9

1.5

0.580

0.95

2.7

2.7

0.883

23.7

0.000

35.1

27.7

0.004

19.7

20.7

0.420

15.6

19.7

0.036

7.3

8.8

0.261

7.3

10.8

0.024

17.1

23.1

0.021

12.2

11.9

0.470

5.8
24.4±
4.5

At least one APOE e4 allele
(%)
Diagnosed with diabetes
(%)
Diagnosed with stroke (%)
Diagnosed with heart attack
(%)

1

P values were obtained by using the chi-square test for CRP (low vs. high) for categorical variables and
Spearman rank correlation for continues variables.
2
Means ± standard deviation (SD).
3

A current smoker was defined as a subject who reported currently smoking; a current drinker was defined
as a subject who reported currently drinking alcohol.

145

Table 5.9: Mean levels of C-reactive protein (CRP) by genotype of APOE gene
stratified by gender in the Cache County Memory Study.
Male
Gene ID

SNPs

N

Mean CRP1
(mg/L)

2

p-value2

N

Mean CRP1
(mg/L)

ε2/ ε2

2

1.7± 0.63

12

3.0± 2.7

ε2/ ε3

134

5.5± 8.7

158

5.7± 7.8

ε2/ ε4

32

5.7± 14.5

53

6.9± 12.2

ε3/ ε3

435

4.2± 6.9

633

4.9± 7.6

ε3/ ε4

210

3.6± 6.3

307

4.0± 6.3

ε4/ ε4

25

1.6± 1.2

24

4.4± 9.3

Epsilon

1

Female

<0.001

Means± standard deviation (SD).
P values were obtained by using Analysis of Variance (ANOVA).

p-value2

0.006
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Table 5.10: Mean levels of C-reactive protein (CRP) by genotype of Alzheimer’s associated genes stratified by gender in the Cache
County Memory Study.
Mean CRP1
Genes

SNP

Mean CRP1
p-value3

Male
R/R2

C/R2

C/C2

3.9± 7.7

4.3± 6.8

5.1± 8.9

p-value3

Female
R/R2

C/R2

C/C2

0.003

4.5± 7.6

5.2± 8.1

4.8± 6.9

0.040

5.8± 9.1

5.4± 8.7

4.4± 6.7

0.292

Primary hypotheses
APOE

rs439401

BIN1

rs744353

3.8± 4.9

4.4± 9.3

4.8± 10.4

0.547

CLU

rs11136000

3.6± 4.6

4.2± 8.2

5.0± 11.4

0.921

5.1± 6.9

4.9± 8.2

4.7± 7.2

0.423

CD2AP

rs9349407

3.7± 5.3

5.4± 12.2

5.3± 11.9

0.787

5.0± 7.8

4.9± 7.8

4.5± 5.5

0.956

AGTR1

rs2131127

4.4± 8.3

4.8± 11.2

3.5± 3.6

0.549

4.9± 7.2

4.8± 7.3

5.2± 10.2

0.823

MMP8

rs1892886

5.1± 9.3

4.1± 10.2

2.6± 3.3

0.005

5.4± 12.5

4.6± 7.4

5.0± 7.0

0.926

MPP7

rs1457177

4.6± 9.9

3.8± 4.9

2.4± 1.9

0.949

5.0± 7.7

4.4± 7.2

2.7± 2.6

0.069

TOMM40

rs1160985

4.2± 8.2

4.7± 10.6

4.2± 8.4

0.642

4.4± 4.8

5.0± 8.6

4.9± 7.4

0.997

4.1± 5.2

5.5± 9.5

4.6± 5.2

0.153

TOMM40

rs157580

3.7± 7.5

4.9± 10.6

5.1± 9.4

0.011

CR1

rs6656401

4.6± 9.6

4.3± 8.7

4.1± 8.5

0.242

5.0± 8.4

4.6± 6.0

4.1± 4.2

0.765

4.6± 9.9
3.4± 7.2

0.221

5.1± 8.3

5.0± 6.5

4.1± 4.5

0.638

0.105

6.2± 1.9

3.9± 4.2

4.9± 7.8

0.545

CR1

rs3818361

4.7± 8.1

4.9± 12.7

CR1

rs4844609

4.5± 9.3

4.6± 9.4

Exploratory hypotheses
CD33

rs3865444

5.1± 11.8

4.0± 6.6

4.2± 8.1

0.720

5.2± 8.7

4.4± 6.5

5.3± 7.2

0.220

PICALM

rs3851179

3.5± 5.7

4.3± 7.6

5.1± 12.0

0.424

4.2± 4.2

4.9± 7.1

5.0± 9.1

0.919

MS4A6A

rs610932

5.9± 14.8

4.1± 7.2

4.3± 7.8

0.397

4.8± 5.9

5.3± 8.4

4.5± 7.4

0.014

MS4A4E

rs670139

4.4± 6.8

4.2± 8.5

5.1± 11.9

0.151

4.6± 8.4

5.0± 8.2

4.7± 6.5

0.106

4.3± 5.1

5.0± 7.7

4.8± 7.7

4.8± 6.9

5.4± 10.3

4.3± 5.1

0.313
0.818

ABCA7

rs3752246

5.0± 7.6

3.9± 7.7

4.7± 9.9

0.645

DTNA

rs4458079

4.4± 8.4

4.9± 12.4

5.9± 4.4

0.232
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HTR2C

rs6318

4.7± 8.8

0.38± 0.13

EPHA1

rs11767557

5.0± 11.0

3.8± 5.2

SORCS1

rs7093634

3.4± 6.3

4.8± 8.9

PPP3R1

rs1868402

4.8± 8.2

4.9± 10.0

MAPT/STH

rs3785883

4.6± 9.3

4.4± 10.3

4.0± 6.7

0.002

3.9± 4.3

4.0± 9.0

4.9± 7.4

0.691

2.5± 2.5
4.6± 10.9

0.133

4.5± 5.9

5.7± 10.4

3.7± 3.3

0.833

0.262

5.5± 11.7

5.0± 7.4

4.6± 6.5

0.424

4.2± 9.0

0.956

5.0± 6.3

5.0± 8.3

4.8± 7.3

0.895

3.9± 5.9

0.969

5.1± 8.5

4.2± 5.0

5.8± 6.6

0.344

Means± standard deviation (SD).
R is the major allele and C is the minor allele.
3
P values were obtained by using Analysis of Variance (ANOVA).
1
2
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Table 5.11: Estimated effects of Alzheimer’s associated genes on plasma biomarker concentration C-reactive protein (CRP)
levels (high vs. low) from conditional logistic regression stratified by gender in the Cache County Memory Study.
Male
Genes

Female

SNP
R/R

1

C/R

1

C/C

1

p- value2

R/R

1

C/R

1

C/C

1

p- value2

APOE

rs439401

1.00 [reference]

1.9 (1.2- 3.1)

1.6 (1.1- 2.1)

0.001

1.00 [reference]

1.0 (0.74- 1.6)

1.3 (1.00- 1.7)

0.259

BIN1

rs744353

1.00 [reference]

1.2 (0.71- 2.3)

1.1 (0.80- 1.5)

0.337

1.00 [reference]

0.99 (0.63- 1.5)

1.07 (0.82- 1.4)

0.791

CLU

rs11136000

1.00 [reference]

0.95 (0.58- 1.5)

0.87 (0.63- 1.2)

0.658

1.00 [reference]

1.01 (0.68- 1.5)

0.86 (0.66- 1.1)

0.717

CD2AP

rs9349407

1.00 [reference]

0.82 (0.46- 1.4)

0.84 (0.62- 1.1)

0.281

1.00 [reference]

1.04 (0.66- 1.6)

1.06 (0.82- 1.3)

0.668

AGTR1

rs2131127

1.00 [reference]

1.4 (0.87- 2.4)

1.17 (0.85- 1.6)

0.123

1.00 [reference]

1.06 (0.72- 1.5)

1.06 (0.81- 1.3)

0.654

MMP8

rs1892886

1.00 [reference]

0.62 (0.35- 1.2)

0.64 (0.46- 0.89)

0.014

1.00 [reference]

0.82 (0.50- 1.3)

0.89 (0.68- 1.1)

0.304

MPP7

rs1457177

1.00 [reference]

0.54 (0.56- 5.2)

1.2 (0.79- 1.8)

0.540

1.00 [reference]

0.69 (0.11- 4.2)

0.79 (0.56- 1.11)

0.171

TOMM40

rs1160985

1.00 [reference]

0.80 (0.50- 1.2)

1.04 (0.73- 1.4)

0.479

1.00 [reference]

1.1 (0.75- 1.6)

0.92 (0.70- 1.2)

0.748

TOMM40

rs157580

1.00 [reference]

1.9 (1.2- 3.0)

1.5 (1.1- 2.1)

0.002

1.00 [reference]

1.2 (0.85- 1.7)

0.99 (0.75- 1.3)

0.372

CR1

rs6656401

1.00 [reference]

0.50 (0.17- 1.09)

0.60 (0.42- 0.87)

0.001

1.00 [reference]

1.4 (0.67- 3.0)

1.2 (0.91- 1.6)

0.129

CR1

rs3818361

1.00 [reference]

0.54 (0.18- 1.6)

0.43 (0.28- 0.66)

<0.001

1.00 [reference]

1.3 (0.60- 3.2)

1.2 (0.92- 1.7)

0.120

CR1

rs4844609

1.00 [reference]

No observation

0.38 (0.19- 0.79)

0.009

1.00 [reference]

No observation

1.2 (0.71- 2.1)

0.160

CD33

rs3865444

1.00 [reference]

0.74 (0.46- 1.2)

1.03 (0.75- 1.4)

0.414

1.00 [reference]

1.11 (0.74- 1.6)

0.92 (0.71- 1.1)

0.905

PICALM

rs3851179

1.00 [reference]

0.87 (0.51- 1.2)

1.04 (0.75- 1.4)

0.698

1.00 [reference]

1.1 (0.78- 1.6)

0.97 (0.75- 1.2)

0.638

MS4A6A

rs610932

1.00 [reference]

1.04 (0.69- 1.5)

0.85 (0.61- 1.1)

0.990

1.00 [reference]

1.12 (0.79- 1.6)

1.17 (0.89- 1.5)

0.398
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MS4A4E

rs670139

1.00 [reference]

1.2 (0.75- 1.9)

0.82 (0.57- 1.1)

0.712

1.00 [reference]

0.70 (0.46- 1.06)

1.01 (0.74- 1.3)

0.167

ABCA7

rs3752246

1.00 [reference]

1.11 (0.54- 2.2)

0.97 (0.70- 1.3)

0.943

1.00 [reference]

0.69 (0.334- 1.4)

1.1 (0.84- 1.4)

0.980

DTNA

rs4458079

1.00 [reference]

2.25 (0.61- 8.3)

0.66 (0.45- 0.95)

0.192

1.00 [reference]

1.4 (0.578- 3.5)

1.18 (0.87- 1.6)

0.193

HTR2C

rs6318

1.00 [reference]

1.2 (0.83- 1.7)

No observation

0.360

1.00 [reference]

0.72 (0.346- 1.4)

0.95 (0.72- 1.2)

0.467

EPHA1

rs11767557

1.00 [reference]

0.56 (0.24- 1.3)

0.92 (0.66- 1.2)

0.242

1.00 [reference]

1.1 (0.655- 2.0)

0.86 (0.66- 1.1)

0.653

SORCS1

rs7093634

1.00 [reference]

0.99 (0.61- 1.6)

1.1 (0.823- 1.5)

0.778

1.00 [reference]

1.13 (0.751- 1.7)

1.12 (0.86- 1.4)

0.416

PPP3R1

rs1868402

1.00 [reference]

1.20 (0.68- 2.1)

1.06 (0.78- 1.4)

0.499

1.00 [reference]

1.3 (0.86- 2.1)

1.1 (0.91- 1.5)

0.103

MAPT/ST
H

rs3785883

1.00 [reference]

1.01 (0.46- 2.2)

1.1 (0.86-0 .1.6)

0.403

1.00 [reference]

1.3 (0.598- 2.9)

0.89 (0.68- 1.1)

0.760

1

R is the major allele and C is the minor allele.

2

Values are 95% Confidence Interval in parentheses (all such values). Adjusted variables in multivariate models included body mass index (kg/m2, continuous),
smoking (never, former, current), age, in years (65-74, 75-84, 85+), diabetes (No, Yes), stroke (No, Yes), heart attack (yes or no), cholesterol (mg, continues),
and gender (male, female
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CHAPTER 6
SUMMARY, CONCLUSIONS, AND FUTURE DIRECTIONS

Summary
The overall objective of this dissertation was to determine the extent to which
dietary factors, erythrocyte membrane fatty acids, and genes are independently associated
with C-reactive protein (CRP) concentration among elderly residents of Cache County,
Utah. Evidence for the role of inflammation in AD is limited. Epidemiologic and genetic
evidence suggest that inflammatory biomarkers are involved in the pathogenesis of AD
by

releasing

inflammatory

mediators

such

as

cytokines,

chemokines,

and

neurotransmitters [1]. There is strong evidence of an etiologic role of both genetic and
environmental factors with inflammation. Diet and erythrocyte membrane fatty acids
(EMFAs), which are considered environmental factors, may influence the risk of AD and
through its effects on systemic inflammation [2]. Concomitantly, genes associated with
AD may influence AD risk via their effects on inflammation [3].
The results of this dissertation support the roles of nutrition and genes in systemic
inflammation as indicated by CRP. Our dietary pattern analysis confirmed the importance
of the elderly diet in the etiology of inflammation, which may lower AD risk. Among
elderly individuals whose diets highly resembled the ideal high adherence of Dietary
Approach to Stop Hypertension (DASH) diet and Mediterranean dietary (MED) patterns,
there was a lowered risk of having high CRP levels. Interestingly, a greater reduction in
the risk of CRP was found with high accordance of both DASH and MED among
overweight and obese compared to normal weight participants.
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Eight of the erythrocyte membrane fatty acid concentrations were associated with
the inflammatory biomarker CRP. When comparing higher levels of palmitoleic acid and
nervonic acids, both monounsaturated fatty acids (MUFAs), dihomo-y-linolenic acid
(DGLA),

docosapentaenoic

acid

(DPA-6),

docosahexaenoic

acid

(DHA),

all

polyunsaturated fatty acids (PUFAs) with lower levels, risk of elevated plasma CRP was
lower among the CCMS participants. Conversely, higher levels of margaric acid, stearic
acid, and arachidic acid, all saturated fatty acids (SFAs), were associated with a lower
risk of elevated CRP. Among those with higher EMFA high levels of pentadecanoic acid,
palmitic acid, behenic acid, lignoceric acid, oleic acid, gondoic acid, erucic acid, vaccenic
acid,

linoleic

acid,

a-linolenic

acid,

eicosadienoic

acid,

arachidonic

acid,

eicosapentaenoic acid, adrenic acid, docosapentaenoic acid n3, there was no discernable
effect on CRP levels.
In our study, we also found an association with APOE-epsilon genotypes and four
SNPs of AD-related genes on CRP inflammatory biomarker. APOE-epsilon genotypes
were associated with CRP levels among elderly men and women. When data were
stratified by gender, major allele of APOE (C/C) rs439401, TOMM40 (A/A) rs157580,
and minor allele of MMP8 (T/T) rs1892886, CR1 (A/A) rs6656401, rs3818361, and
rs4844609 lowered the risk of elevated CRP among elderly men. Among those with
BIN1, CLU, CD2AP, AGTR1, MS4A6A/ MS4A4E, MPP7, ABCA7, CD33, PICALM,
DTNA, HTR2C, EPHI1, SORCS1, PPP3R1, and MAPT/STH, there was no significant
effect on CRP levels.
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Limitations and Future Directions
The dissertation described here provides evidence of the roles that dietary
patterns, defined by DASH and MED adherence, erythrocyte membrane fatty acids
composition, and AD-related genes, have on the risk of systemic inflammation CRP
levels after adjusting for potential confounders. There are some limitations that must be
discussed and addressed in future work. Cache County Memory Study does not have a
collection of blood for inflammatory biomarkers at the Wave 1 baseline examination that
would allow a prospective study of CRP levels and subsequent outcomes. We also used a
single inflammatory marker CRP to determine the serum level of inflammatory
biomarkers, but it has been proposed that systemic inflammatory markers change over
time [4], so examining multiple inflammatory biomarkers would help to strengthen our
results.
The following recommendations are also offered for related research on systemic
inflammation biomarker CRP:
1. Replication studies are needed to confirm the effect of a DASH diet and MED on
systemic inflammation by lowering CRP level among elderly in different populations.
2. Further prospective studies examining erythrocyte membrane fatty acids, including
palmitoleic acid, dihomo-y-linolenic acid (DGLA), docosapentaenoic acid (DPA-6),
docosahexaenoic acid (DHA), nervonic fatty, margaric acid, stearic acid, pentadecanoic
acid, palmitic acid, behenic acid, lignoceric acid, oleic acid, gondoic acid, erucic acid,
vaccenic acid, linoleic acid, a-linolenic acid, eicosadienoic acid, arachidonic acid,
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eicosapentaenoic acid, adrenic acid, docosapentaenoic acid n3, and arachidic acid,
inflammation, and other disease would strengthen the present findings.
3. We examined the association of erythrocyte membrane fatty acid concentration and
plasma CRP level in depth, but further examination of the associations between food
sources for each fatty acid with EMFA concentration and CRP would be valuable
additions regarding these associations.
4. Genotypic imputations, study of additional variants from gene sequencing, and study
of gene-nutrient interaction to increase our understanding of systemic inflammation and
to further assess the consistency of evidence in terms of both significance and direction of
effects observed in our study.
5. Our hypothesis-driven genetic study only assessed individual SNPs and did not take
into account correlation among SNPs or genes.
6. Further studies are needed to explore and explain the effects of the interactions
between APOE rs157580 and TOMM40 rs439401 on CRP level as a dependent variable,
particularly among elderly individuals.
Public Health Significance
Although more research is needed to characterize the relationship between elderly
nutrition and the risk of systemic inflammation, healthy elderly diets with adherence to a
DASH diet or MED are safe and feasible interventions that may reduce the risk of AD
among the elderly by reducing CRP and other inflammatory biomarkers. Fatty acid
consumption is still a controversial issue. Thus, more scientists and clinicians need to join
in the efforts to understand the impact of FAs on health outcomes.
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The discovery of the effects of AD-related genes on CRP may provide clinicians
specific targets for more effective intervention strategies. For example, in our study, we
observed that the presence of major allele APOE rs439401 and TOMM40 rs157580 and
minor allele of MMP8 rs1892886, CR1 rs6656401, rs3818361, and rs4844609 decrease
the risk of having elevated CRP levels. Men with the minor allele of APOE rs439401
and TOMM40 rs157580, and major allele of MMP8 rs1892886, CR1 rs6656401,
rs3818361, and rs4844609 can be targeted for more aggressive treatment to reduce their
CRP levels, which may lower the chance of having AD later in their life.
Reduction in the prevalence of AD could have tremendous importance. The
results of this dissertation may help identify factors important to AD etiology and, in turn,
provide valuable targets for preventive intervention. Until now, there is no cure for AD;
individuals with AD require medical care to maintain quality of life, maximize function
in daily activities, foster a safe environment, and enhance cognition, mood, and behavior.
The costs incurred in caring for elderly with AD not only include multi-disciplinary
clinical care, but also involves emotional disturbance and social and employment
exclusion for affected individuals. Reducing the risk of AD would lessen considerable
financial and emotional burdens for families and society.
Conclusions
In conclusion, this dissertation presents additional insight into the possible dietary
patterns, erythrocyte membrane fatty acids composition, and AD-related genes associated
with systemic inflammation. The findings indicate that adherence to dietary pattern
DASH and MED influence the risk of systemic inflammation. While saturated
erythrocyte membrane fatty acids composition may be anti-inflammatory, MUFAs and
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PUFAs may increase the risk of systemic inflammation. Additionally, the results support
the hypotheses that AD-related gene alleles affect systemic inflammation.
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